BARIATRIC SURGERY	CARDIOLOGY	CARDIOTHORACIC SURGERIES இருதய நோய் அறுவை சிகிச்சை	DERMATOLOGY	E N T காது மூக்கு தொண்டை சிகிச்சை	EMERGENCY ROOM PROCEDURES	ENDOCRINE SURGERY
ENDOCRINOLOGY உட்சுரப்பி சிகிச்சை	FOLLOW-UP	GASTROENTEROLOGY	GENERAL MEDICINE பொது மருத்துவ சிகிச்சை	GENERAL SURGERY பொது அறுவை சிகிச்சை	GENITOURINARY SURGERY இருபாலார் சிறுநீரக நோய் சிகிச்சை	GYNAECOLOGY OBSTETRIC SURGERY இரத்தவகை சிகிச்சை
HEMATOLOGY இரத்தவகை சிகிச்சை	HEPATOLOGY கல்லீரல் நோய் சிகிச்சை	INFECTIOUS DISEASES - GENERAL MEDICINE	INTERVENTIONAL CARDIOLOGY இடையீடு இருதயவியல்	INTERVENTIONAL RADIOLOGY இடையீடு கதிர்வீச்சு இருதய சிகிச்சை	MEDICAL GASTROENTROLOGY	MEDICAL ONCOLOGY புற்றுநோய் மருத்துவ சிகிச்சை
NEONATOLOGY பச்சிளம் குழந்தைகள் சிகிச்சை	NEPHROLOGY	NEUROLOGY நரம்பியல் சிகிச்சை	NEUROSURGERY நரம்பியல் அறுவை சிகிச்சை	OFMS வாய் வழி மற்றும் தாடை அறுவை சிகிச்சை	OPHTHALMOLOGY SURGERIES கண் நோய் அறுவை சிகிச்சை	ORTHOPEDICS எலும்பியல் காயம்
PAEDIATRIC INTENSIVE CARE குழந்தைகளுக்கான தீவிர சிகிச்சை	PAEDIATRIC SURGERIES குழந்தைகளுக்கான அறுவை சிகிச்சை	PAEDIATRICS குழந்தை மருத்துவம்	PAIN & PALLIATION கடைநிலை மருத்துவம்	PLASTIC SURGERY ஒட்டுறுப்பு அறுவை சிகிச்சை	PMR	POLYTRAUMA
PSYCHIATRY மனநல மருத்துவம்	PULMONLOGY நுரையீரல் நோய்	RADIATION ONCOLOGY கதிர்வீச்சு புற்றுநோய்	REHABILITATION	RESERVED	RHEUMATOLOGY முடக்கு வாதம்	SPINE
SURGICAL GASTRO ENTEROLOGY இரையகக் குடலியவியல்	SURGICAL ONCOLOGY புற்றுநோய் அறுவைசிகிச்சை	THORACIC MEDICINE	VASCULAR SURGERIES நாளஞ்சார் அறுவை சிகிச்சைகள்

SNO	Package Name	Category	A1	A2	A3	A4	A5	A6	S1	S2
130	CMU0106 : BREAST CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
131	CMU0106 -a : BREAST CANCER - COMBINED REGIMEN AC & T	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
132	CMU0106 -a-I : BREAST CANCER - DOSE DENSE AC (ADRIAMYCIN/CYCLOPHOSPHAMIDE) ; (DAY 1 - DOXORUBICIN 60MG/M2 IV, CYCLOPHOSPHAMIDE 600MG/M2 IV) ; REPEAT CYCLE - EVERY 14 DAYS FOR 4 CYCLES; FOLLOWED BY PACLITAXEL FOR 4 CYCLES	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
133	CMU0106 -a-II : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 175MG/M2) REPEAT CYCLE - EVERY 14 DAYS FOR 4 CYCLES	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
134	CMU0106 -a-III : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 175MG/M2) REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLES	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
135	CMU0106 -a-IV : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 80MG/M2) REPEAT CYCLE - WEEKLY FOR 12 CYCLES	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
136	CMU0106 -b : BREAST CANCER - TC (DOECTAXEL & CYCLOPHOSPHAMIDE) ; DAY 1 - DOCETAXEL 75MG/M2 IV, CYCLOPHOSPHAMIDE 600MG/M2 IV ; REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLES	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
137	CMU0106 -c : BREAST CANCER - CMF (CYCLOPHOSPHAMIDE/METHOTREXATE/FLUOROURACIL) - (INCLUDES DAY 1 & DAY 8) ; DAYS 1-14 - CYCLOPHOSPHAMIDE 100MG/M2 ORALLY ; DAYS 1 AND 8 - METHOTREXATE 40MG/M2 IV ; DAYS 1 AND 8 - 5-FLUOROURACIL 600MG/M2 IV. ; REPEAT CYCLE - EVERY 28 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	2900	2900	2900	2900	2900	2900	2900	2900
138	CMU0106 -d : BREAST CANCER - EC (EPIRUBICIN/CYCLOPHOSPHAMIDE) ; DAY 1 - EPIRUBICIN 100MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 830MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 8 CYCLES	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
139	CMU0106 -e : BREAST CANCER - FEC + T	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
140	CMU0106 -e-I : BREAST CANCER - FEC/CEF FOLLOWED BY T (FLUOROURACIL/EPIRUBICIN/CYCLOPHOSPHAMIDE) - FOLLOWED BY DOCETAXEL OR FOLLOWED BY WEEKLY PACLITAXEL) ; DAY 1 - 5-FLUOROURACIL 500MG/M2 IV ; DAY 1 - EPIRUBICIN 100MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
141	CMU0106 -e-II : BREAST CANCER - DOCETAXEL - (PRECEEDED BY FEC/CEF ) ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 3 CYCLES	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
142	CMU0106 -e-III : BREAST CANCER - PACLITAXEL - WEEKLY - (PRECEEDED BY FEC/CEF ) ; PACLITAXEL 100MG/M2 IV ; REPEAT CYCLE - ONCE WEEKLY FOR 8 WEEKS	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
143	CMU0106 -f : BREAST CANCER - FAC + T	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
144	CMU0106 -f-I : BREAST CANCER - FAC FOLLOWED BY T (FLUOROURACIL/ADRIAMYCIN/CYCLOPHOSPHAMIDE) - FOLLOWED BY WEEKLY PACLITAXEL ; 5-FLUOROURACIL 500MG/M2 IV DAYS 1 AND 8 OR 1 AND 4 - ; DAY 1 - DOXORUBICIN 50MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	3400	3400	3400	3400	3400	3400	3400	3400
145	CMU0106 -f-II : BREAST CANCER - PACLITAXEL - WEEKLY - PRECEEDED BY FAC ; PACLITAXEL 80MG/M2 IV ; REPEAT CYCLE WEEKLY FOR 12 WEEKS.	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
146	CMU0106 -g : BREAST CANCER - TAC (DOCETAXEL/ADRIAMYCIN/CYCLOPHOSPHAMIDE) ; DAY 1 - DOXORUBICIN 60MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES,	MEDICAL ONCOLOGY	5900	5900	5900	5900	5900	5900	5900	5900
147	CMU0106 -h : BREAST CANCER - AC FOLLOWED BY T + TRASTUZUMAB	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
148	CMU0106 -h-I : BREAST CANCER - AC - FOLLOWED BY PACLITAXEL + TRASTUZUMAB +/- PERTUZUMAB ; DAY 1 - DOXORUBICIN 60MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLE	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
149	CMU0106 -h-II : BREAST CANCER - PACLITAXEL (PRECEEDED BY AC) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; PACLITAXEL 80MG/M2 IV. ; REPEAT CYCLE WEEKLY FOR 12 WEEKS.	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
150	CMU0106 -h-III : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; REPEAT CYCLE EVERY 21 DAYS TO COMPLETE 1 YEAR. ; (TO BE APPROVED WITH PACLITAXEL CYCLE 1, 4, 7, 10 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
151	CMU0106 -h-IV : BREAST CANCER - TRASTUZUMAB 4MG (FOLLOWED BY TRASTUZUMAB 2MG SUBSEQUENT WEEKS) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 4MG/KG IV WITH FIRST DOSE OF PACLITAXEL. ; (FIRST DOSE - ONLY TO BE APPROVED WITH PACLITAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
152	CMU0106 -h-V : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 2MG/KG IV WEEKLY TILL ONE YEAR FROM DAY 1 OF AC. ; (TO BE APPROVED WITH PACLITAXEL CYCLES 2 - 12 AND STANDALONE FOR THE UPTO 1 YEAR EVERY WEEK)	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
153	CMU0106 -i : BREAST CANCER - TCH	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
154	CMU0106 -i-I : BREAST CANCER - TC (DOCETAXEL/CARBOPLATIN) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 75MG/M2 IV; CARBOPLATIN AUC 6MG PER MIN/ML IV. ; EVERY 21 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
155	CMU0106 -i-II : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH TC PACKAGE) ; TRASTUZUMAB 6MG/KG IV ; REPEAT CYCLE EVERY 21 DAYS TO COMPLETE 1 YEAR. ; (TO BE APPROVED WITH TC CYCLE 1 TO 6 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 18 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
156	CMU0106 -i-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH TC PACKAGE) ; DAY 1 - TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH TC CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
157	CMU0106 -i-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES - WEEKLY) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 17 WEEEKS MAY OVERLAP WITH TC CYCLES 2 - 6. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
158	CMU0106 -j : BREAST CANCER - AC FOLLOWED BY DOCETAXEL + TRASTUZUMAB	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
159	CMU0106 -j-I : BREAST CANCER - AC - FOLLOWED BY DOCETAXEL + TRASTUZUMAB ; DAY 1 - DOXORUBICIN 60MG/M2 IV; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES,	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
160	CMU0106 -j-II : BREAST CANCER - DOCETAXEL (PRECEEDED BY AC) + TRASTUZUMAB ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES	MEDICAL ONCOLOGY	5700	5700	5700	5700	5700	5700	5700	5700
161	CMU0106 -j-III : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH DOCETAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; REPEAT EVERY 21 DAYS TILL 1 YEAR ; (TO BE APPROVED WITH DOCETAXEL CYCLE 1 TO 4 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) OR FROM 13 TH WEEK AFTER COMPLETION OF 12 WEEKS OF WEEKLY TRASTUZUMAB - UPTO 1 YEAR EVERY 21 DAYS)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
162	CMU0106 -j-IV : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH DOCETAXEL PACKAGE) ; TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH DOCETAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
163	CMU0106 -j-V : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 11 WEEEKS MAY OVERLAP WITH DOCETAXEL CYCLES 2 - 4. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR)	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
164	CMU0106 -k : BREAST CANCER - DOCETAXEL + CYCLOPHOSPHAMIDE + TRASTUZUMAB	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
165	CMU0106 -k-I : BREAST CANCER - DOCETAXEL + CYCLOPHOSPHAMIDE - WITH TRASTUZUMAB ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 75MG/M2 IV; CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES,	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
166	CMU0106 -k-II : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH DOCETAXEL + CYCLOPHOSPHAMIDE PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; (TO BE APPROVED WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLE 1 TO 4 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 12 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
167	CMU0106 -k-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH DOCETAXEL + CYCLOPHOSPHAMIDE PACKAGE) ; TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
168	CMU0106 -k-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 11 WEEEKS MAY OVERLAP WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLES 2 - 4. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR)	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
169	CMU0106 -L : BREAST CANCER - PACLITAXEL + TRASTUZUMAB	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
170	CMU0106 -L-I : BREAST CANCER - PACLITAXEL - (WITH TRASTUZUMAB) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; PACLITAXEL 80MG/M2 IV. ; REPEAT CYCLE WEEKLY FOR 12 WEEKS.	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
171	CMU0106 -L-II : BREAST CANCER - TRASTUZUMAB (6MG) ; TRASTUZUMAB 6MG/KG IV ; REPEAT EVERY 21 DAYS ; (TO BE APPROVED AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 12 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
172	CMU0106 -L-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; TRASTUZUMAB 4MG/KG IV WITH FIRST DOSE OF PACLITAXEL. ; (FIRST DOSE - ONLY TO BE APPROVED WITH PACLITAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY)	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
173	CMU0106 -L-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 2MG/KG IV WEEKLY ; (TO BE APPROVED WITH PACLITAXEL CYCLES 2 - 12. MAY BE APPROVED AS STANDALONE FOR THE UPTO 1 YEAR EVERY WEEK OR TRASTUZUMAB 6MG PACKAGE MAY BE USED ONCE EVERY 21 DAYS UPTO 1 YEAR)	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
174	CMU0106 -N : BREAST CANCER - TAMOXIFEN	MEDICAL ONCOLOGY	100	100	100	100	100	100	100	100
175	CMU0106 -O : BREAST CANCER - AROMATASE INHIBITORS	MEDICAL ONCOLOGY	1100	1100	1100	1100	1100	1100	1100	1100
176	CMU0106 -P : BREAST CANCER - ZOLEDRONIC ACID FOR SKELETAL METASTASIS	MEDICAL ONCOLOGY	2900	2900	2900	2900	2900	2900	2900	2900
177	CMU0107 : BLADDER CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
178	CMU0107 -a-I : BLADDER CANCER - DDMVAC ; DAY 1 - METHOTREXATE 30MG/M2 IV; DAY 2 - VINBLASTINE 3MG/M2 IV, DOXORUBICIN 30MG/M2 IV, CISPLATIN 70MG/M2 IV; ; REPEAT EVERY 2 WEEKS FOR 3-4 CYCLES	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
179	CMU0107 -a-II : BLADDER CANCER - GEMCITABINE + CISPLATIN ; DAYS 1, 8, AND 15 - GEMCITABINE 1, 000MG/M2 IV; DAY 2 - CISPLATIN 70MG/M2. ; REPEAT EVERY 4 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	6700	6700	6700	6700	6700	6700	6700	6700
180	CMU0107 -a-III : BLADDER CANCER - CISPLATIN + METHOTREXATE + VINBLASTINE (CMV) ; DAY 1 - METHOTREXATE 30MG/M2 IV, VINBLASTINE 4MG/M2 IV; DAY 2 - CISPLATIN 100MG/M2 IV, LEUCOVORIN 15MG ORAL OR IV EVERY 6 HOURS FOR 4 DOSES; DAY 8 - METHOTREXATE 30MG/M2 IV, VINBLASTINE 4MG/M2 IV DAY 9 - LEUCOVORIN 15MG ORAL EVERY 6 HOURS FOR 4 DOSES ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	5100	5100	5100	5100	5100	5100	5100	5100
181	CMU0107 -a-IV : BLADDER CANCER - RADIOSENSITIZING - CISPLATINC + 5-FU ; DAYS 1, 2, 3, 15, 16, AND 17 - IV HYDRATION AT A RATE OF 500ML/HOUR; FOLLOWED BY 5-FU 400MG/M2 IV PUSH; FOLLOWED BY CISPLATIN 15MG/M2 IV OVER 1 HOUR AS INDUCTION AND CONSOLIDATION THERAPY	MEDICAL ONCOLOGY	10300	10300	10300	10300	10300	10300	10300	10300
182	CMU0107 -a-V : BLADDER CANCER -RADIOSENSITIZING - CISPLATIN + PACLITAXEL ; DAYS 1, 8, AND 15 - PACLITAXEL 50MG/M2 ; DAY 1-3, 8-10, 15-17 - CISPLATIN 15MG/M2; FOLLOWED BY TWICE-DAILY RADIOTHERAPY FOR 8 DAYS	MEDICAL ONCOLOGY	19300	19300	19300	19300	19300	19300	19300	19300
183	CMU0107 -a-VI : BLADDER CANCER -RADIOSENSITIZING - 5-FU + MITOMYCIN32 ; DAY 1 OF RADIOTHERAPY - MITOMYCIN 12MG/M2 IV BOLUS, PLUS ; WEEK 1 (FRACTIONS 1-5) AND WEEK 4 (FRACTIONS 16-20) OF RADIOTHERAPY - 5-FU 500MG/M2 CONTINUOUS IV INFUSION (10 DAYS TOTAL)	MEDICAL ONCOLOGY	15900	15900	15900	15900	15900	15900	15900	15900
184	CMU0107 -c : BLADDER CANCER - CONCURRENT CISPLATIN; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 5 CYCLES	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
185	CMU0108 : LUNG CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
186	CMU0108 -i : LUNG CANCER - MESOTHELIOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
187	CMU0108 -i-a : LUNG CANCER - MESOTHELIOMA - PEMETREXED + CISPLATIN ; DAY 1 - PEMETREXED 500MG/M2 IV, CISPLATIN 75MG/M2 ; REPEAT EVERY 21 DAYS UP TO 12 CYCLES.	MEDICAL ONCOLOGY	15200	15200	15200	15200	15200	15200	15200	15200
188	CMU0108 -i-b : LUNG CANCER - MESOTHELIOMA - PEMETREXED + CARBOPLATIN ; DAY 1 - PEMETREXED 500MG/M2 IV, CARBOPLATIN AUC 5MG/MIN/ML IV. ; REPEAT EVERY 21 DAYS FOR A MAX OF 9 CYCLES.	MEDICAL ONCOLOGY	17300	17300	17300	17300	17300	17300	17300	17300
189	CMU0108 -i-c : LUNG CANCER - MESOTHELIOMA - CISPLATIN & GEMCITABINE ; DAY 1 - CISPLATIN 80-100MG/M2 IV ; DAYS 1, 8, AND 15 - GEMCITABINE 1000-1250MG/M2 IV ; REPEAT EVERY 21 - 28 DAYS FOR 6 CYCLES.	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
190	CMU0108 -i-d : LUNG CANCER - MESOTHELIOMA - VINORELBINE ; VINORELBINE 25-30MG/M2 (MAX 60MG) IV ; REPEAT EVERY WEEK FOR 12 WEEKS.	MEDICAL ONCOLOGY	9500	9500	9500	9500	9500	9500	9500	9500
191	CMU0108 -i-e : LUNG CANCER - MESOTHELIOMA - PEMETREXED ; DAY 1 - PEMETREXED 500MG/M2 IV. ; REPEAT EVERY 21 DAYS FOR 4 CYCLES (IF FIRST LINE) OR REPEAT EVERY 21 DAYS FOR 8 CYCLES (IF SECOND LINE)	MEDICAL ONCOLOGY	15200	15200	15200	15200	15200	15200	15200	15200
192	CMU0108 -i-f : LUNG CANCER - MESOTHELIOMA - GEMCITABINE ; DAYS 1, 8, AND 15 - GEMCITABINE 1250MG/M2 IV. ; REPEAT EVERY 28 DAYS FOR A MAX OF 10 CYCLES.	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
193	CMU0108 -ii : LUNG CANCER - NSCLC	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
194	CMU0108 -ii-a : LUNG CANCER - NSCLC - CISPLATIN & VINORELBINE - (I) ; DAYS 1 AND 8 - CISPLATIN 50MG/M2 IV AND DAYS 1, 8, 15 AND 22 - VINORELBINE 25MG/M2 IV ; (OR) ; DAY 1 - CISPLATIN 100MG/M2 IV AND DAYS 1, 8, 15 AND 22 - VINORELBINE 30MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	35300	35300	35300	35300	35300	35300	35300	35300
195	CMU0108 -ii-b : LUNG CANCER - NSCLC - CISPLATIN & VINORELBINE - (II) ; DAY 1 - CISPLATIN 75-80MG/M2 ; DAYS 1 AND 8 - VINORELBINE 25-30MG/M2. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	18800	18800	18800	18800	18800	18800	18800	18800
196	CMU0108 -ii-c : LUNG CANCER - NSCLC - CISPLATIN & ETOPOSIDE ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	5200	5200	5200	5200	5200	5200	5200	5200
197	CMU0108 -ii-d : LUNG CANCER - NSCLC - CISPLATIN & DOCETAXEL ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	6600	6600	6600	6600	6600	6600	6600	6600
198	CMU0108 -ii-e : LUNG CANCER - NSCLC - CISPLATIN & GEMCITABINE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 1 AND 8 - GEMCITABINE 1, 250MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	6400	6400	6400	6400	6400	6400	6400	6400
199	CMU0108 -ii-f : LUNG CANCER - NSCLC - PEMETREXED + CISPLATIN (FOR NON SQUAMOUS CELL CA) ; DAY 1 - CISPLATIN 75MG/M2 IV, PEMETREXED 500MG/M2 IV. ; REPEAT EVERY - 21 DAYS FOR 4 CYCLES.	MEDICAL ONCOLOGY	15200	15200	15200	15200	15200	15200	15200	15200
200	CMU0108 -ii-g : LUNG CANCER - NSCLC - PACLITAXEL/CARBOPLATIN ; DAY 1 - PACLITAXEL 200MG/M2 IV, CARBOPLATIN AUC 6MG PER MIN/ML IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	8500	8500	8500	8500	8500	8500	8500	8500
201	CMU0108 -ii-h : LUNG CANCER - NSCLC - CISPLATIN & ETOPOSIDE ; DAYS 1, 8, 29 AND 36 - CISPLATIN 50MG/M2 IV ; DAYS 1-5 AND 29-33 - ETOPOSIDE 50MG/M2 IV ; CONCURRENT THORACIC RADIOTHERAPY 1.8GY/DAY FOR 5 DAYS/WEEK (TOTAL DOSE, 61GY).	MEDICAL ONCOLOGY	8900	8900	8900	8900	8900	8900	8900	8900
202	CMU0108 -ii-i : LUNG CANCER - NSCLC - CISPLATIN & VINBLASTINE ; DAYS 1 AND 29 - CISPLATIN 100MG/M2 IV ; DAYS 1, 8, 15, 22 AND 29 - VINBLASTINE 5MG/M2 IV ; CONCURRENT THORACIC RADIOTHERAPY (TOTAL DOSE, 60GY).	MEDICAL ONCOLOGY	8600	8600	8600	8600	8600	8600	8600	8600
203	CMU0108 -iii : LUNG CANCER - SCLC	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
204	CMU0108 -iii-a : LUNG CANCER - SCLC - CISPLATIN & ETOPOSIDE ; DAY 1 - CISPLATIN 60MG/M2 IV, DAYS 1-3 - ETOPOSIDE 120MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR AT LEAST 4 CYCLES. ;(OR) ; DAY 1 - CISPLATIN 80MG/M2 IV, DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4-6 CYCLES.	MEDICAL ONCOLOGY	5200	5200	5200	5200	5200	5200	5200	5200
205	CMU0108 -iii-b : LUNG CANCER - SCLC - CARBOPLATIN & ETOPOSIDE ; DAY 1 - CARBOPLATIN AUC 5-6MG PER MIN/ML IV ; DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS OR 28 DAYS FOR 4 - 6 CYCLES	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
206	CMU0108 -iii-c : LUNG CANCER - SCLC - CISPLATIN + IRINOTECAN ; DAY 1 - CISPLATIN 60MG/M2 IV. ; DAYS 1, 8, AND 15 - IRINOTECAN 60MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
207	CMU0108 -iii-d : LUNG CANCER - SCLC - CISPLATIN + IRINOTECAN ; DAY 1 AND 8 - CISPLATIN 30MG/M2 IV, IRINOTECAN 65MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4-6 CYCLES.	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
208	CMU0108 -iii-e : LUNG CANCER - SCLC - CARBOPLATIN & IRINOTECAN ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAYS 1, 8, AND 15 - IRINOTECAN 50MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	8100	8100	8100	8100	8100	8100	8100	8100
209	CMU0108 -ii-j : LUNG CANCER - NSCLC - CARBOPLATIN + PEMETREXED ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAY 1 - PEMETREXED 500 MG/M2 IV ; WITH CONCURRENT THORACIC RADIOTHERAPY. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	17300	17300	17300	17300	17300	17300	17300	17300
210	CMU0108 -ii-k : LUNG CANCER - NSCLC - CISPLATIN + PEMETREXED ; DAY 1 - CISPLATIN 75 MG/M2 IV. ; DAY 1 - PEMETREXED 500 MG/M2 IV ; WITH CONCURRENT THORACIC RADIOTHERAPY. ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	15700	15700	15700	15700	15700	15700	15700	15700
211	CMU0108 -ii-l : LUNG CANCER - NSCLC - PACLITAXEL + CARBOPLATIN ; PACLITAXEL 45MG/M2 IV + CARBOPLATIN AUC 2MG PER MIN/ML IV ; WITH CONCURRENT THORACIC RADIOTHERAPY (TOTAL DOSE, 60GY) ; REPEAT WEEKLY FOR 6 WEEKS	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
212	CMU0109 : OESOPHAGEAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
213	CMU0109 -i : ESOPHAGEAL CANCER - NEO ADJUVANT	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
214	CMU0109 -i-a : ESOPHAGEAL CANCER - NEO ADJUVANT - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV + CARBOPLATIN AUC 2MG/MIN/ML IV. ; REPEAT WEEKLY FOR 5 WEEKS	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
215	CMU0109 -i-b : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & CISPLATIN ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV.	MEDICAL ONCOLOGY	12600	12600	12600	12600	12600	12600	12600	12600
216	CMU0109 -i-c : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & CISPLATIN ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 AND DAYS 22-26 - 5-FU 800 MG/M2 IV ; REPEAT EVERY 21 DAYS FOR 2 CYCLES	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
217	CMU0109 -i-d : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL + OXALIPLATIN + LEUCOVORIN ; DAY 1 - OXALIPLATIN 85MG/M2, LEUCOVORIN 200MG/M2 AND 5-FU 400MG/M2 BOLUS, WITH 1, 600MG/M2 INFUSION; ; REPEAT EVERY 14 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
218	CMU0109 -i-e : ESOPHAGEAL CANCER - NEO ADJUVANT - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE WEEKLY FOR 5 WEEKS	MEDICAL ONCOLOGY	2600	2600	2600	2600	2600	2600	2600	2600
219	CMU0109 -i-f : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & OXALIPLATIN ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY IV	MEDICAL ONCOLOGY	27100	27100	27100	27100	27100	27100	27100	27100
220	CMU0109 -i-g : ESOPHAGEAL CANCER - NEO ADJUVANT - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS.	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
221	CMU0109 -i-h : ESOPHAGEAL CANCER - NEO ADJUVANT - IRINOTECAN & CISPLATIN ; DAYS 1, 8, 22, AND 29 - IRINOTECAN 65MG/M2 IV, CISPLATIN 30MG/M2 IV.	MEDICAL ONCOLOGY	10200	10200	10200	10200	10200	10200	10200	10200
222	CMU0109 -i-i : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45MG/M2 IV ; DAYS 1-5 - 5-FU 300MG/M2/DAY IV INFUSION. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
223	CMU0109 -ii : ESOPHAGEAL CANCER - PERI-OPERATIVE	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
224	CMU0109 -ii-a : ESOPHAGEAL CANCER - PERI-OPERATIVE - ECF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; CISPLATIN 60MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV CONTINUOUS INFUSION ONCE DAILY; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY	MEDICAL ONCOLOGY	17600	17600	17600	17600	17600	17600	17600	17600
225	CMU0109 -ii-b : ESOPHAGEAL CANCER - PERI-OPERATIVE - EOF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY.	MEDICAL ONCOLOGY	19700	19700	19700	19700	19700	19700	19700	19700
226	CMU0109 -ii-c : ESOPHAGEAL CANCER - PERI-OPERATIVE - EOC (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY.	MEDICAL ONCOLOGY	8200	8200	8200	8200	8200	8200	8200	8200
227	CMU0109 -ii-d : ESOPHAGEAL CANCER - PERI-OPERATIVE - FLUOROURACIL & CISPLATIN ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV ; REPEAT CYCLE EVERY 28 DAYS FOR 2-4 CYCLES	MEDICAL ONCOLOGY	12600	12600	12600	12600	12600	12600	12600	12600
228	CMU0109 -ii-e : ESOPHAGEAL CANCER - PERI-OPERATIVE - FLUOROURACIL & CISPLATIN ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 - 5-FU 800 MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS. ; CYCLED EVERY 21 DAYS FOR 2 CYCLESCYCLED EVERY 21 DAYS FOR 2 CYCLES	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
229	CMU0109 -iii : ESOPHAGEAL CANCER - POST-OPERATIVE	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
230	CMU0109 -iii-a : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACIL + LEUCOVORIN (I) ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV, FOLLOWED BY 4 WEEKS BREAK AND CCRT ; RT DAYS 1-4 AND 23-25 - 5-FU 400MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV FOLLOWED BY ONE MONTH BREAK AND ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV FOLLOWED BY ONE MONTH BREAK AND ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV.	MEDICAL ONCOLOGY	26700	26700	26700	26700	26700	26700	26700	26700
231	CMU0109 -iii-b : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACIL + LEUCOVORIN (II) ; DAYS 1, 2, 15, AND 16 - LEUCOVORIN 200MG/M2 IV, 5-FU 400MG/M2 IV PUSH AND 5-FU 600MG/M2 INFUSION	MEDICAL ONCOLOGY	9500	9500	9500	9500	9500	9500	9500	9500
232	CMU0109 -iii-c : ESOPHAGEAL CANCER - POST-OPERATIVE - CAPECITABINE (I) ; DAYS 1-14 - CAPECITABINE 750-1000MG/M2 ORALLY TWICE DAILY; ; REPEAT EVERY 28 DAYS; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION	MEDICAL ONCOLOGY	3300	3300	3300	3300	3300	3300	3300	3300
233	CMU0109 -iii-d : ESOPHAGEAL CANCER - POST-OPERATIVE - CAPECITABINE (II) ; DAYS 1-5 OR DAYS 1-7 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY, ; ONCE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	1700	1700	1700	1700	1700	1700	1700	1700
234	CMU0109 -iii-e : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACILDAYS 1-5 OR DAYS 1-7 - 5-FU 200-250MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS DAILY, ; ONCE WEEKLY FOR 5 WEEKS.ONCE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
235	CMU0109 -i-j : ESOPHAGEAL CANCER - NEO ADJUVANT - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
236	CMU0109 -iv : ESOPHAGEAL CANCER - DEFINITIVE	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
237	CMU0109 -iv-a : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & CISPLATIN (I) ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV	MEDICAL ONCOLOGY	12600	12600	12600	12600	12600	12600	12600	12600
238	CMU0109 -iv-b : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & CISPLATIN (II) ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 - 5-FU 800 MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS. ; CYCLED EVERY 21 DAYS FOR 2 CYCLES	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
239	CMU0109 -iv-c : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & OXALIPLATIN ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY CONTINUOUS IV INFUSION.	MEDICAL ONCOLOGY	27100	27100	27100	27100	27100	27100	27100	27100
240	CMU0109 -iv-d : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE WEEKLY FOR 5 WEEKS	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
241	CMU0109 -iv-e : ESOPHAGEAL CANCER - DEFINITIVE - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
242	CMU0109 -iv-f : ESOPHAGEAL CANCER - DEFINITIVE - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV AND CARBOPLATIN 2MG/MIN/ML IV ; REPEAT WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
243	CMU0109 -iv-g : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH DOCETAXEL (I) ; DAYS 1 AND 22 - DOCETAXEL 60MG/M2 IV ; DAYS 1 AND 22 - CISPLATIN 60-80MG/M2 IV GIVEN FOR 1 CYCLE	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
244	CMU0109 -iv-h : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH DOCETAXEL (II) ; DAY 1 - DOCETAXEL 20-30MG/M2 IV ; DAY 1 - CISPLATIN 20-30MG/M2 IV ; REPEAT WEEKLY FOR 5 WEEKS	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
245	CMU0109 -iv-i : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH PACLITAXEL ; DAYS 1, 8, 15, AND 22 - PACLITAXEL 60MG/M2 IV ; DAY 1 - CISPLATIN 75MG/M2 IV GIVEN FOR 1 CYCLE.	MEDICAL ONCOLOGY	13800	13800	13800	13800	13800	13800	13800	13800
246	CMU0109 -iv-j : ESOPHAGEAL CANCER - DEFINITIVE - IRINOTECAN & CISPLATIN ; DAYS 1, 8, 22, AND 29 - IRINOTECAN 65MG/M2 IV ; DAYS 1, 8, 22, AND 29 - CISPLATIN 30MG/M2 IV.	MEDICAL ONCOLOGY	10200	10200	10200	10200	10200	10200	10200	10200
247	CMU0109 -iv-k : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45MG/M2 IV ; DAYS 1-5 - 5-FU 300MG/M2/DAY IV ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
248	CMU0109 -iv-l : ESOPHAGEAL CANCER - DEFINITIVE - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 PO TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
249	CMU0109 -v : ESOPHAGEAL CANCER - CONCURRENT CISPLATIN; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 5 CYCLES	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
250	CMU0110 : GASTRIC CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
251	CMU0110 -i : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
252	CMU0110 -i-a : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV, CARBOPLATIN AUC 2MG/MIN/ML IV. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
253	CMU0110 -i-b : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & CISPLATIN (I) ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1000MG/M2/DAY IV	MEDICAL ONCOLOGY	12600	12600	12600	12600	12600	12600	12600	12600
254	CMU0110 -i-c : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & CISPLATIN (II) ; DAYS 1-5 - CISPLATIN 15MG/M2 IV ONCE DAILY, 5-FU 800MG/M2/DAY IV ; REPEAT CYCLE EVERY 21 DAYS FOR 2 CYCLES.	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
255	CMU0110 -i-d : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & OXALIPLATIN (I)DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY IV.	MEDICAL ONCOLOGY	27100	27100	27100	27100	27100	27100	27100	27100
256	CMU0110 -i-e : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & OXALIPLATIN (II)DAY 1 - OXALIPLATIN 85MG/M2 AND LEUCOVORIN 400MG/M2 FOLLOWED BY 5-FU 400MG/M2 BOLUS, THEN 800MG/M2 24-HOUR CONTINUOUS INFUSION OVER DAYS 1 AND 2; THE FIRST 3 CYCLES WERE DELIVERED DURING RADIOTHERAPY (RT), THE OTHER 3 AFTER RT; 6 BIMONTHLY (14 DAYS) CYCLES.	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
257	CMU0110 -i-f : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
258	CMU0110 -i-g : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
259	CMU0110 -i-h : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45-50MG/M2 IV WEEKLY ; DAYS 1-5 - 5-FU 300MG/M2 IV ; REPEAT CYCLE WEEKLY FOR 5 WEEKS	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
260	CMU0110 -ii : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
261	CMU0110 -i-i : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	3300	3300	3300	3300	3300	3300	3300	3300
262	CMU0110 -ii-a : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - ECF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV, CISPLATIN 60MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2/DAY IV ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY	MEDICAL ONCOLOGY	17600	17600	17600	17600	17600	17600	17600	17600
263	CMU0110 -ii-b : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - EOF (EPIRUBICIN/ OXALIPLATIN /FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY.	MEDICAL ONCOLOGY	19300	19300	19300	19300	19300	19300	19300	19300
264	CMU0110 -ii-c : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - EPIRUBICIN + CISPLATIN + CAPECITABINE ; DAY 1 - EPIRUBICIN 50MG/M2 IV + CISPLATIN 60MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY.	MEDICAL ONCOLOGY	6200	6200	6200	6200	6200	6200	6200	6200
265	CMU0110 -ii-d : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - ECF MODIFICATION (EPIRUBICIN + OXALIPLATIN + CAPECITABINE) ; DAY 1 - EPIRUBICIN 50MG/M2 IV + OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELYREPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY	MEDICAL ONCOLOGY	8200	8200	8200	8200	8200	8200	8200	8200
266	CMU0110 -ii-e : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL & CISPLATIN ; DAY 1 - CISPLATIN 75-80MG/M2 IV ; DAYS 1-5 - 5-FU 800MG/M2 IV ; REPEAT CYCLE EVERY 28 DAYS FOR 2-3 CYCLES PREOPERATIVELY AND 3-4 CYCLES POSTOPERATIVELY FOR A TOTAL OF 6 CYCLES.	MEDICAL ONCOLOGY	7300	7300	7300	7300	7300	7300	7300	7300
267	CMU0110 -iii : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
268	CMU0110 -iii-a : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL + LEUCOVORIN (I) ; CYCLES 1, 3, AND 4 (BEFORE AND AFTER RADIATION) DAYS 1-5 - LEUCOVORIN 20MG/M2 IV, 5-FU 425MG/M2/DAY IV ; REPEAT CYCLE EVERY 28 DAYS. ; CYCLE 2 (WITH RADIATION) DAYS 1-4 AND 31-33 - LEUCOVORIN 20MG/M2 IVP ; DAYS 1-4 - 5-FU 400MG/M2/DAY IVP. ; REPEAT CYCLE EVERY 35 DAYS	MEDICAL ONCOLOGY	26700	26700	26700	26700	26700	26700	26700	26700
269	CMU0110 -iii-b : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL + LEUCOVORIN (II) ; DAYS 1, 2, 15, AND 16 - LEUCOVORIN 400MG/M2 IV, 5-FU 400MG/M2 IV AND 5-FU 1200MG/M2 INFUSION; ; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION. ; REPEAT CYCLE EVERY 28 DAYSREPEAT CYCLE EVERY 28 DAYS	MEDICAL ONCOLOGY	15700	15700	15700	15700	15700	15700	15700	15700
270	CMU0110 -iii-c : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CAPECITABINE (I) ; DAYS 1-14 - CAPECITABINE 750-1000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 28 DAYS; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION.	MEDICAL ONCOLOGY	3300	3300	3300	3300	3300	3300	3300	3300
271	CMU0110 -iii-d : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CAPECITABINE (II) ; DAYS 1-5 OR DAYS 1-7 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY; WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	1700	1700	1700	1700	1700	1700	1700	1700
272	CMU0110 -iii-e : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL ; DAYS 1-5 OR DAYS 1-7 - 5-FU 200-250MG/M2 IV; ; WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
273	CMU0110 -iii-f : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 60MG/M2 IV. ; DAYS 1-14 - CAPECITABINE 1000MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE EVERY 21 DAYS FOR 6 CYCLES.	MEDICAL ONCOLOGY	4200	4200	4200	4200	4200	4200	4200	4200
274	CMU0110 -iii-h : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - OXALIPLATIN + CAPECITABINE ; DAY 1 - OXALIPLATIN 130MG/M2 IV. ; DAYS 1-14 - CAPECITABINE 1000MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE EVERY 21 DAYS FOR 8 CYCLES.REPEAT CYCLE EVERY 21 DAYS FOR 8 CYCLES.	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
275	CMU0111 : COLORECTAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
276	CMU0111 -i : COLORECTAL CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
277	CMU0111 -i-a : COLORECTAL CARCINOMA - FOLFOX (STAGE - III) - (OXALIPLATIN, LEUCOVORIN, 5-FU) ; DAY 1 - OXALIPLATIN 85MG/M2 IV, LEUCOVORIN 400MG/M2 IV, 5-FU 400MG/M2 IV, FOLLOWED BY 5-FU 1, 200MG/M2/DAY IV X 2 DAYS (TOTAL 2, 400MG/M2) OVER 46-48-HOUR CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS- UPTO 12 CYCLES	MEDICAL ONCOLOGY	8400	8400	8400	8400	8400	8400	8400	8400
278	CMU0111 -i-b : COLORECTAL CARCINOMA - CAPEOX (STAGE - III) (OXALIPLATIN, CAPECITABINE) ; DAY 1 - OXALIPLATIN 130MG/M2 IV OVER 2 HOURS ; DAYS 1-14 - CAPECITABINE 1, 000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 MONTHS	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
279	CMU0111 -i-c : COLORECTAL CARCINOMA - FLOX (STAGE - III) (5-FU, LEUCOVORIN, OXALIPLATIN) ; 5-FU 500MG/M2 IV BOLUS WEEKLY X 6, LEUCOVORIN 500MG/M2 IV WEEKLY X 6, EACH ; OXALIPLATIN 85MG/M2 IV ON WEEKS 1, 3, AND 5 ; 8-WEEK CYCLE X 3 CYCLES ;	MEDICAL ONCOLOGY	31500	31500	31500	31500	31500	31500	31500	31500
280	CMU0111 -i-d : COLORECTAL CARCINOMA - CAPECITABINE ; CAPECITABINE 1, 250MG/M2 - BD / TDS D 1-14 ; EVERY 3 WEEKS * 24 WEEKSL CARCINOMA - CAPECITABINE ; CAPECITABINE 1, 250MG/M2 - BD / TDS D 1-14 ; EVERY 3 WEEKS * 24 WEEKS	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
281	CMU0111 -i-e : COLORECTAL CARCINOMA - FLUOROURACIL + LEUCOVORIN (I) ; LEUCOVORIN 500MG/M2 WEEKLY X 6 WEEKS, ; 5-FU 500MG/M2 WEEKLY X 6 WEEKS. ; REPEAT CYCLE EVERY 8 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	24900	24900	24900	24900	24900	24900	24900	24900
282	CMU0111 -i-f : COLORECTAL CARCINOMA - FLUOROURACIL + LEUCOVORIN (II)SIMPLIFIED BIWEEKLY INFUSION. ; LEUCOVORIN 400MG/M2 IV, 5-FU BOLUS 400MG/M2 AND THEN 1, 200MG/M2/DAY X 2 DAYS (TOTAL 2, 400MG/M2 OVER 46-48 HOURS) ; REPEAT CYCLE EVERY 2 WEEKS FOR 6 CYCLES.	MEDICAL ONCOLOGY	5500	5500	5500	5500	5500	5500	5500	5500
283	CMU0111 -ii : COLORECTAL CARCINOMA - CONCURRENT	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
284	CMU0111 -ii-a : COLORECTAL CARCINOMA - CONCURRENT - 5FU - WITH XRT ; DAYS 1-5 OR 1-7 - 5-FU 225MG/M2 IV ; WITH EXTERNAL BEAM RADIOTHERAPY	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
285	CMU0111 -ii-b : COLORECTAL CARCINOMA - CONCURRENT - FLUOROURACIL + LEUCOVORIN - WITH XRT ; DAYS 1-4 - 5-FU 400MG/M2 IV + LEUCOVORIN 20MG/M2 IV. ; REPEAT CYCLE DURING WEEKS 1 AND 5 OF XRT.	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
286	CMU0111 -ii-c : COLORECTAL CARCINOMA - CONCURRENT - CAPECITABINE - WITH XRT ; CAPECITABINE TABLET 825MG / M2 TWICE DAILY ON DAYS 1-5 ; REPEAT CYCLE WEEKLY FOR 5 WEEKS.	MEDICAL ONCOLOGY	1400	1400	1400	1400	1400	1400	1400	1400
287	CMU0112 : OSTEOSARCOMA/ BONE TUMORS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
288	CMU0112 -i-a : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - CISPLATIN + DOXORUBICIN ; DAYS 1-3 - DOXORUBICIN 25MG/M2/DAY IV, ; DAY 1 - CISPLATIN 100MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES	MEDICAL ONCOLOGY	5900	5900	5900	5900	5900	5900	5900	5900
289	CMU0112 -i-b-1 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - PRE OPERATIVE ; DAYS 1 AND 28 - METHOTREXATE 8G/M2 IV ; DAYS 7-9 AND 34-36 - CISPLATIN 120MG/M2 BY INFUSION FOR 72 HOURS. ; DAYS 9 AND 36 - DOXORUBICIN 60MG/M2 IV	MEDICAL ONCOLOGY	25500	25500	25500	25500	25500	25500	25500	25500
290	CMU0112 -i-b-2 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - POST OPERATIVE NECROSIS < 90% ; DAYS 1, 48, 96, AND 144 - DOXORUBICIN 45MG/M2/DAY FOR 2 CONSECUTIVE DAYS ; DAYS 21, 69, AND 117 - METHOTREXATE 8G/M2 IV ; DAYS 27, 75, AND 123 - CISPLATIN 120MG/M2 BY INFUSION FOR 72 HOURS.	MEDICAL ONCOLOGY	42000	42000	42000	42000	42000	42000	42000	42000
291	CMU0112 -i-b-3 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - POST OPERATIVE NECROSIS > 90%POSTOPERATIVE CHEMOTHERAPY (NECROSIS	MEDICAL ONCOLOGY	62000	62000	62000	62000	62000	62000	62000	62000
292	CMU0112 -i-c : DOXORUBICIN + CISPLATIN + IFOSFAMIDE + HIGH-DOSE METHOTREXATE (INCLUDING SURGERY COST)	MEDICAL ONCOLOGY	117100	117100	117100	117100	117100	117100	117100	117100
293	CMU0112 -i-d : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - IFOSFAMIDE + CISPLATIN + EPIRUBICIN ; DAY 1 - EPIRUBICIN 90MG/M2 IV, CISPLATIN 100MG/M2 IV ; DAYS 2-4 - IFOSFAMIDE 2.0G/M2 WITH MESNA ; REPEAT CYCLE EVERY 21 DAYS. (3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY).	MEDICAL ONCOLOGY	8700	8700	8700	8700	8700	8700	8700	8700
294	CMU0112 -ii : OTHER BONE TUMORS - CHORDROMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
295	CMU0112 -ii-a : OTHER BONE TUMORS - CHORDROMA - IMATINIB ; IMATINIB 800 MG ONCE DAILY	MEDICAL ONCOLOGY	4700	4700	4700	4700	4700	4700	4700	4700
296	CMU0112 -ii-b : OTHER BONE TUMORS - CHORDROMA - IMATINIB + CISPLATIN ; IMATINIB 400MG OD + CISPLATIN 25MG/M2 WEEKLY.	MEDICAL ONCOLOGY	4700	4700	4700	4700	4700	4700	4700	4700
297	CMU0112 -ii-c : OTHER BONE TUMORS - CHORDROMA - IMATINIB + SIROLIMUS ; IMATINIB 400MG OD + SIROLIMUS 2MG OD	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
298	CMU0112 -ii-d : OTHER BONE TUMORS - CHORDROMA - ERLOTINIB ; ERLOTINIB 150MG OD	MEDICAL ONCOLOGY	2300	2300	2300	2300	2300	2300	2300	2300
299	CMU0112 -ii-e : OTHER BONE TUMORS - CHORDROMA - SUNITINIB ; SUNITINIB 37.5MG OD	MEDICAL ONCOLOGY	29900	29900	29900	29900	29900	29900	29900	29900
300	CMU0112 -iii : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
301	CMU0112 -iii-a : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - DENOSUMAB ; DENOSUMAB 120MG SUBCUTANEOUS ON WEEK 1, 2 AND 3 OF A 4 WEEK CYCLE	MEDICAL ONCOLOGY	58800	58800	58800	58800	58800	58800	58800	58800
302	CMU0112 -iii-b : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - INTERFERON ALFA ; INTERFERON ALFA- 2A THRICE WEEKLY	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
303	CMU0112 -iii-c : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - PEGINTERFERON ; PEGINTERFERON ALFA-2A 1.0MCG/KG SQ INJECTION WEEKLY.	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
304	CMU0112 -iv : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
305	CMU0112 -iv-a : VAC AND IE CYCLES	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
306	CMU0112 -iv-b : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA VAIA ; DAY 1 - VINCRISTINE 1.5MG/M2 IV ; DAYS 1-3 - IFOSFAMIDE 2, 000MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS.	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
307	CMU0112 -vi : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA VIDE (VINCRISTINE + IFOSFAMIDE + DOXORUBICIN + ETOPOSIDE) ; DAY 1 - VINCRISTINE 1.4MG/M2 (MAX 2MG), ; DAYS 1-3 - DOXORUBICIN 20MG/M2 IV + IFOSFAMIDE 3MG/M2 IV + MESNA 3G/M2 + ETOPOSIDE 150MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES.	MEDICAL ONCOLOGY	9700	9700	9700	9700	9700	9700	9700	9700
308	CMU0113 : WILMS TUMOR	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
309	CMU0113 -a : WILMS TUMOR - VINCRISTINE & ACTINOMYCIN D ; DACTINOMYCIN 45MCG/KG - WEEK - 0, 3, 6, 9, 12, 15, 18 ; VINCRISTINE 1.5 MG/M2 - WEEK - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18	MEDICAL ONCOLOGY	20400	20400	20400	20400	20400	20400	20400	20400
310	CMU0113 -b : WILMS TUMOR - DACTINOMYCIN, VINCRISTINE & ADRIAMYCIN ; DACTINOMYCIN 1.35 MG /M2 - WEEK - 0, 6, 12, 18, 24 ; ADRIYAMYCIN 30-45 MG /M2- WEEK - 3, 9, 15, 21 ; VINCRISTINE 2MG MAX- WEEK - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 21, 24	MEDICAL ONCOLOGY	24400	24400	24400	24400	24400	24400	24400	24400
311	CMU0113 -c : WILMS TUMOR - ADRIAMYCIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, VINCRISTINE ; CYCLOPHOSPHAMIDE 440MG/M2/DAY - WEEK 3, 9, 15, 21 FOR 5 DAYS, WEEK - 6, 12, 18, 24 FOR 3 DAYS ; ADRIYAMYCIN 30-45MG /M2- WEEK -0, 6, 12, 18, 24 ; VINCRISTINE 2MG (MAX)- WEEK - 1, 2, 4, 5, 6, 7, 8, 10, 11, 12, 13, 18, 24 ; ETOPOSIDE 100MG /M2- WEEK - 3, 9, 15, 21	MEDICAL ONCOLOGY	56400	56400	56400	56400	56400	56400	56400	56400
312	CMU0113 -d : WILMS TUMOR - CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN ; CYCLOPHOSPHAMIDE 440MG/M2/DAY - WEEK 6, 15, 24 *5 DAYS / WEEK ; CARBOPLATIN 500MG/M2 - WEEK - 0, 3, 9, 12, 18, 21 *2 DAYS / WEEK ; ETOPOSIDE 100MG/M2 - WEEK - 0, 3, 9, 12, 18, 21 *5 DAYS / WEEK	MEDICAL ONCOLOGY	88700	88700	88700	88700	88700	88700	88700	88700
313	CMU0114 : HEPATOBLASTOMA- OPERABLEHEPATOBLASTOMA- OPERABLE	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
314	CMU0114 -a : HEPATOBLASTOMA- OPERABLE - PLADO - CISPLATIN + DOXORUBICIN ; CISPLATIN (PLA) (80MG/M2 / IV), DOXORUBICIN (DO) (30 MG/M2 IV ; EVERY 21 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
315	CMU0114 -b : HEPATOBLASTOMA- OPERABLE - CISPLATIN + VINCRISTINE +5FU ; CISPLATIN (90 MG/M2), VINCRISTINE (1.5MG/M2), 5-FU(5-FLUROURACIL- 600 MG/M2) ; EVERY 21 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	2600	2600	2600	2600	2600	2600	2600	2600
316	CMU0115 : HEPATOCELLULAR CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
317	CMU0115 -a : HEPATOCELLULAR CARCINOMA - SORAFENIB ; SORAFENIB 400 MG PO BID	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
318	CMU0116 : NEUROBLASTOMA ALL STAGES	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
319	CMU0116 A : NEUROBLASTOMA ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN	MEDICAL ONCOLOGY	8400	8400	8400	8400	8400	8400	8400	8400
320	CMU0116 B : NEUROBLASTOMA ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300MG/M2 ; ADRIAMYCIN 60MG/M2 ; VINCRISTINE 1.5MG/M2	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
321	CMU0116 C : NEUROBLASTOMA ALL STAGES - CISPLATIN & ETOPOSIDE ; DAYS 1-5 - CISPLATIN - 20MG/M2 ; DAYS 1-5 - ETOPOSIDE - 70 MG/M2	MEDICAL ONCOLOGY	5200	5200	5200	5200	5200	5200	5200	5200
322	CMU0116 D : NEUROBLASTOMA ALL STAGES - CARBOPLATIN & ETOPOSIDE ; DAYS 1-2 - CARBOPLATIN - 500MG/M2 ; DAYS 1-5 - ETOPOSIDE 100MG/M2	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
323	CMU0116 E : NEUROBLASTOMA ALL STAGES - FOR STAGE IV PALLIATIVE CHEMOTHERAPY ONLY	MEDICAL ONCOLOGY	10500	10500	10500	10500	10500	10500	10500	10500
324	CMU0117 : RETINOBLASTOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
325	CMU0117 -a : RETINOBLASTOMA - MELPHALAN - INTRA-ARTERIAL ; MELPHALAN - 3-7.5MG - INTRA-ARTERIAL	MEDICAL ONCOLOGY	10200	10200	10200	10200	10200	10200	10200	10200
326	CMU0117 -b : RETINOBLASTOMA - CARBOPLATIN - INTRA-ARTERIAL ; CARBOPLATIN 15-30 MG - INTRA-ARTERIAL	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
327	CMU0117 -c : RETINOBLASTOMA - TOPOTECAN - INTRA-ARTERIAL ; TOPOTECAN 0.15-1.5 MG - INTRA-ARTERIAL	MEDICAL ONCOLOGY	10400	10400	10400	10400	10400	10400	10400	10400
328	CMU0117 -d : RETINOBLASTOMA - METHOTREXATE - INTRA-ARTERIAL ; METHOTREXATE 6-12 MG - INTRA-ARTERIAL	MEDICAL ONCOLOGY	9100	9100	9100	9100	9100	9100	9100	9100
329	CMU0117 -e : RETINOBLASTOMA - CARBOPLATIN - PERI OCULAR ; CARBOPLATIN 20MG/M2 - PERI OCULAR	MEDICAL ONCOLOGY	2000	2000	2000	2000	2000	2000	2000	2000
330	CMU0117 -f : RETINOBLASTOMA - TOPOTECAN - PERI OCULAR ; TOPOTECAN 0.09 - 0.27 - PERI OCULAR	MEDICAL ONCOLOGY	4500	4500	4500	4500	4500	4500	4500	4500
331	CMU0117 -g : RETINOBLASTOMA - MELPHALAN - INTRA-VITREAL ; MELPHALAN 20-30 MCG / 0.1CC - INTRA-VITREAL	MEDICAL ONCOLOGY	300	300	300	300	300	300	300	300
332	CMU0117 -h : RETINOBLASTOMA - CARBOPLATIN - INTRA-VITREAL ; CARBOPLATIN 3-6MCG / 0.05CC - INTRA-VITREAL	MEDICAL ONCOLOGY	2000	2000	2000	2000	2000	2000	2000	2000
333	CMU0117 -i : RETINOBLASTOMA - METHOTREXATE - INTRA-VITREAL ; METHOTREXATE 400MCG/0.1CC - INTRA-VITREAL	MEDICAL ONCOLOGY	1700	1700	1700	1700	1700	1700	1700	1700
334	CMU0117 -j : RETINOBLASTOMA - CARBOPLATIN + ETOPOSIDE + VINCRISTINE ; CARBOPLATIN 560MG/M2 ; ETOPOSIDE 150MG/M2 ; VINCRISTINE 1.5MG/M2	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
335	CMU0118 : HISTIOCYTOSIS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
336	CMU0118 -a : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - 1; PREDNISOLONE AND VINBLASTINE - 1 ; PREDNISOLONE - 6 WEEKS ORAL ; VINBLASTINE 1, 2, 3, 4, 5, 6	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
337	CMU0118 -b : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - 2; PREDNISOLONE AND VINBLASTINE - 1 ; PREDNISOLONE - 6 WEEKS ORAL ; VINBLASTINE 1, 2, 3, 4, 5, 6	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
338	CMU0118 -c : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - CONTINUATION; PREDNISOLONE AND VINBLASTINE - CONTINUATION AFTER EITHER COURSE 1 OR BOTH 1 & 2 ; PREDNISOLONE - 5 DAYS A WEEK ORAL ; VINBLASTINE -IV ; REPEAT EVERY 3 WEEKS TILL 1 YEAR	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
339	CMU0119 : RHABDOMYOSARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
340	CMU0119 -a : RHABDOMYOSARCOMA - VAC (VINCRISTINE + DACTINOMYCIN + CYCLOPHOSPHAMIDE + MESNA ) ; DAY -1 - VINCRISTINE 1.5 MG /M2 IV (2 MG MAX), DOXORUBICIN 75 MG /M2 IV, CYCLOPHOSPHAMIDE 1200 MG /M2 IV + MESNA ; REPEAT AT 21 DAY INTERVALS FOR 4-6 CYCLES	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
341	CMU0119 -b : RHABDOMYOSARCOMA - IVA (VINCRISTINE + DACTINOMYCIN + IFOSFAMIDE + MESNA ) ; DAY 1, 2 - IFOSFAMIDE IV 3 G/M2 + MESNA ; DAY 1 - VINCRISTINE IV 1.5 MG/M2 (MAX 2 MG), ACTINOMYCIN-D IV 1.5 MG/M2 (MAX 2 MG) ; REPEAT AT 21 DAY INTERVALS FOR 6 CYCLES	MEDICAL ONCOLOGY	5900	5900	5900	5900	5900	5900	5900	5900
342	CMU0119 -c : RHABDOMYOSARCOMA - IVAD (VINCRISTINE + DOXORUBICIN + IFOSFAMIDE + MESNA ) ; DAYS 1 AND 2 - IFOSFAMIDE 3 G/M2 + MESNA, DOXORUBICIN 30MG/M2 ; DAY 1 - VINCRISTINE 1.5 MG/M2, ACTINOMYCIN-D 1.5 MG/M2 ; REPEAT AT 21 DAY INTERVALS FOR 6 CYCLES	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
343	CMU0120 : EWINGS SARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
344	CMU0120 -i : EWINGS SARCOMA - INDUCTION TREATMENT I	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
345	CMU0120 -i-a : EWINGS SARCOMA - INDUCTION TREATMENT - VIDE ; DAY 1 - VINCRISTINE 1.5MG/M2(MAX 2MG) IV ; DAYS 1-3 - DOXORUBICIN 20MG/M2 IV, IFOSFAMIDE 3G/M2IV, MESNA CONTINUOUS IV, ETOPOSIDE 150MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES	MEDICAL ONCOLOGY	8800	8800	8800	8800	8800	8800	8800	8800
346	CMU0120 -i-b : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
347	CMU0120 -i-b-1 : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE - VAC ; DAY 1 - VINCRISTINE 2MG/M2 (MAX 2MG) IV, DOXORUBICIN 75MG/M2 IV BOLUS, CYCLOPHOSPHAMIDE 1, 200MG/M2 IV, MESNA. ; DACTINOMYCIN 1.25MG/M2 IV CAN BE SUBSTITUTED FOR DOXORUBICIN WHEN A TOTAL DOXORUBICIN DOSE OF 375MG/M2 IS REACHED.	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
348	CMU0120 -i-b-2 : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE - IE ; IE CYCLES ; DAYS 1-5 - IFOSFAMIDE 1, 800MG/M2 IV + MESNA + ETOPOSIDE 100MG/M2 IV. ; REPEAT EACH CYCLE EVERY 3 WEEKS FOR 17 CYCLES.	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
349	CMU0120 -i-c : EWINGS SARCOMA - INDUCTION TREATMENT - VAIA - 4 DAY REGIMEN ; DAY 1 - VINCRISTINE 1.5MG/M2IV ; DAYS 1-3 - IFOSFAMIDE 2, 000MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, THEN LOCAL THERAPY, FOLLOWED BY 10 ADDITIONAL CYCLES OF VAIA FOR HIGH RISK AND ; 10 ADDITIONAL CYCLES OF VAIA OR 10 CYCLES OF VACA FOR STANDARD-RISK PATIENTS	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
350	CMU0120 -i-d : EWINGS SARCOMA - INDUCTION TREATMENT - VAIA - 24 DAY REGIMEN ; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.5MG/M2 IV ; DAYS 1, 2, 22, 23, 43, AND 44 - IFOSFAMIDE 3, 000MG/M2 IV + MESNA ; DAYS 1, 2, 43, AND 44 - DOXORUBICIN 30MG/M2 IV ; DAYS 22, 23, AND 24 - DACTINOMYCIN 0.5MG/M2 IV ; AFTER COMPLETION OF ONE 9-WEEK CYCLE, LOCAL THERAPY FOLLOWED BY 3 ADDITIONAL CYCLES.	MEDICAL ONCOLOGY	18600	18600	18600	18600	18600	18600	18600	18600
351	CMU0120 -i-e : EWINGS SARCOMA - INDUCTION TREATMENT - VACA ; DAY 1 - VINCRISTINE 1.5MG/M2 IV + CYCLOPHOSPHAMIDE 1, 200MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 10 CYCLES.	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
352	CMU0120 -ii : EWINGS SARCOMA - MAINTENANCE TREATMENT	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
353	CMU0120 -ii-a : EWINGS SARCOMA - MAINTENANCE TREATMENT - ETOPOSIDE/IFOSFAMIDE ; DAYS 1-5 - IFOSFAMIDE 1, 800MG/M2/DAY IV + MESNA ; DAYS 1-5 - ETOPOSIDE 100MG/M2/DAY IV.	MEDICAL ONCOLOGY	8700	8700	8700	8700	8700	8700	8700	8700
354	CMU0121 : PALLIATIVE CHEMOTHERAPY (ANY REGIMEN)- MAXIMUM PAYABLE	MEDICAL ONCOLOGY	10500	10500	10500	10500	10500	10500	10500	10500
355	CMU0122 : CERVICAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
356	CMU0122 -a : CERVICAL CANCER - CISPLATIN ; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 6 CYCLES	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
357	CMU0122 -b : CERVICAL CANCER - CISPLATIN & 5FU WITH RT ; DAYS 1-5 OF RADIOTHERAPY - CISPLATIN 75MG/M2 IV, 5-FU 4, 000MG/M2 IV OVER 96 HOURS ; REPEAT CYCLE EVERY 3 WEEKS FOR 3	MEDICAL ONCOLOGY	9700	9700	9700	9700	9700	9700	9700	9700
358	CMU0122 -c : CERVICAL CANCER - CISPLATIN & 5FU ; DAYS 1 AND 29 - CISPLATIN 50MG/M2 IV ; DAYS 2-5, AND 30-33 - 5-FU 1, 000MG/M2 IV	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
359	CMU0123 : VULVAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
360	CMU0123 -a : VULVAL CANCER - CISPLATIN ; DAY 1 - 40 MG/M 2 IV	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
361	CMU0123 -b : VULVAL CANCER - CISPLATIN + 5FU ; DAYS 1-5 OF RADIOTHERAPY - CISPLATIN 75MG/M2 IV, 5-FU 4, 000MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS - TOTAL 3 CYCLES	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
362	CMU0123 -c : VULVAL CANCER - 5-FU + MITOMYCIN ; 5-FU + MITOMYCIN ; DAYS 1-4 AND 29-32 - 5-FU 1, 000MG/M2/DAY CONTINUOUS IV INFUSION ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS (MAXIMUM 20MG PER COURSE),	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
363	CMU0123 -e : VULVAL CANCER - CISPLATIN + 5FU ; DAYS 1 AND 29 - CISPLATIN 50MG/M2 IV ; DAYS 2-5, AND 30-33 - 5-FU 1, 000MG/M2 IV	MEDICAL ONCOLOGY	11700	11700	11700	11700	11700	11700	11700	11700
364	CMU0124 : VAGINAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
365	CMU0124 -a : VAGINAL CANCER - CISPLATIN ; CISPLATIN 75MG/M2 ; ONCE WEEKLY FOR UP TO 6 DOSES	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
366	CMU0125 : OVARIAN CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
367	CMU0125 -a : OVARIAN CANCER - PACLITAXEL + CISPLATIN ; DAY 1 - PACLITAXEL 135MG/M2 CONTINUOUS IV ; DAY 2 - CISPLATIN 75-100MG/M2 ; DAY 8 - PACLITAXEL 60MG/M2 ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES.	MEDICAL ONCOLOGY	9300	9300	9300	9300	9300	9300	9300	9300
368	CMU0125 -b : OVARIAN CANCER - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 175MG/M2 IV, CARBOPLATIN AUC 5-6 MG/MIN/ML IV ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
369	CMU0125 -c : OVARIAN CANCER - DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 60-75MG/M2 IV, CARBOPLATIN AUC 5-6 MG/MIN/ML ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES	MEDICAL ONCOLOGY	9200	9200	9200	9200	9200	9200	9200	9200
370	CMU0126 : ENDOMETRIAL CANCER (PALLIATIVE CHEMOTHERAPY ONLY)	MEDICAL ONCOLOGY	10500	10500	10500	10500	10500	10500	10500	10500
371	CMU0127 : OVARY- GERM CELL TUMOR	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
372	CMU0127 -a : OVARY- GERM CELL TUMOR - BEP (BLEOMYCIN + ETOPOSIDE + CISPLATIN) ; DAYS 1, 8, 15 - BLEOMYCIN 30 UNITS/WK IV, ETOPOSIDE 100 MG/M 2/DAY IV ; DAYS 1-5 - CISPLATIN 20 MG/M 2/DAY IV ; REPEAT EVERY 21 DAYS 3-4 CYCLES	MEDICAL ONCOLOGY	11400	11400	11400	11400	11400	11400	11400	11400
373	CMU0127 -b : OVARY- GERM CELL TUMOR - EP ( ETOPOSIDE + CARBOPLATIN) ; DAY 1 - CARBOPLATIN 400 MG/M 2 IV ON DAYS 1-3 ; REPEAT EVERY 28 DAYS FOR THREE CYCLES	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
374	CMU0128 : GESTATIONAL TROPHOBLAST DISEASES	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
375	CMU0128 -a : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE (5 DAYS REGIMEN) ; DAYS 1-5 - MTX 0.4 MG/KG/DAY IV OR IM FOR 5 DAYS, NOT TO EXCEED 25 MG/DAY ; REPEAT CYCLE EVERY 14 DAYS	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
376	CMU0128 -b : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE (8-DAY ALTERNATING REGIMEN) ; DAYS 1, 3, 5, AND 7 - MTX 1 MG/KG IM, ; DAYS 2, 4, 6, AND 8 - FOLINIC ACID 15 MG ; REPEAT CYCLE EVERY 14 DAYS	MEDICAL ONCOLOGY	3100	3100	3100	3100	3100	3100	3100	3100
377	CMU0128 -c : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE + FOLINIC ACID ; DAY 1 - MTX 100 MG/M 2 IVP, THEN 200 MG/M 2 INFUSION ; DAY 2 - FOLINIC ACID 15 MG IM/PO Q12H FOR 4 DOSES ; REPEAT CYCLE EVERY 18 DAYS	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
378	CMU0128 -d : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE - WEEKLY ; MTX 30-50 MG/M 2 IM WEEKLY	MEDICAL ONCOLOGY	1400	1400	1400	1400	1400	1400	1400	1400
379	CMU0128 -e : GESTATIONAL TROPHOBLAST DISEASES - ACT-D ; ACT-D 10-13 MCG/KG OR 0.5-MG FLAT DOSE IV QD FOR 5D ; REPEAT CYCLE EVERY 14 DAYS	MEDICAL ONCOLOGY	8200	8200	8200	8200	8200	8200	8200	8200
380	CMU0128 -f : GESTATIONAL TROPHOBLAST DISEASES - ACTINOMYCIN ; ACTINOMYCIN 1.25 MG/M 2 IV ; REPEAT EVERY 2 WEEKS	MEDICAL ONCOLOGY	2300	2300	2300	2300	2300	2300	2300	2300
381	CMU0128 -g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (COMPLETE) ; DAY 1 - ACT-D - 0.5 MG IV, ETOPOSIDE - 100 MG/M2 IV, MTX - 300 MG/M2 IV ; DAY 2 - ACT-D - 0.5 MG IV, ETOPOSIDE - 100 MG/M2 IV, LEUCOVORIN - 15 MG PO/IM Q12H 4 DOSES ; DAY 8 - VINCRISTINE - 0.8 MG/M2 IV, CYCLOPHOSPHAMIDE - 600 MG/M2 IV ; REPEAT CYCLE EVERY 14 DAYS	MEDICAL ONCOLOGY	6700	6700	6700	6700	6700	6700	6700	6700
382	CMU0129 : TESTICULAR CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
383	CMU0129 -a : TESTICULAR CANCER - EP ; DAYS 1-5 - ETOPOSIDE 100MG/M2, CISPLATIN 20MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	5700	5700	5700	5700	5700	5700	5700	5700
384	CMU0129 -b : TESTICULAR CANCER - BEP ; DAYS 1-5 - CISPLATIN 20MG/M2, ETOPOSIDE 100MG/M2 ; DAYS 1, 8, AND 15 OR DAYS 2, 9, OR 16 - BLEOMYCIN 30 UNITS IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	10500	10500	10500	10500	10500	10500	10500	10500
385	CMU0129 -c : TESTICULAR CANCER - VIP ; DAY 1 (BEFORE IFOSFAMIDE) - MESNA 120MG/M2 IV ; DAYS 1-5 - ETOPOSIDE 75MG/M2 IV, MESNA 1, 200MG/M2 IV, IFOSFAMIDE 1, 200MG/M2 IV + CISPLATIN 20MG/M2. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	6600	6600	6600	6600	6600	6600	6600	6600
386	CMU0130 : PROSTATE CANCERPROSTATE CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
387	CMU0130 -a : PROSTATE CANCER - DOCETAXEL + PREDNISONE ; DAY 1 - DOCETAXEL 75MG/M2 IV, PREDNISONE 5MG ORALLY TWICE DAILY. ; ONCE EVERY 3 WEEKS, REPEAT FOR UP TO 10 CYCLES IF TOLERATED	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
388	CMU0130 -c : PROSTATE CANCER - ZOLEDRONIC ACID FOR SKELETAL METASTASIS	MEDICAL ONCOLOGY	2900	2900	2900	2900	2900	2900	2900	2900
389	CMU0131 : FEBRILE NEUTROPENIA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
390	CMU0131 -a : FEBRILE NEUTROPENIA - FIRST-LINE MONOTHERAPY ; PIPERACILLIN-TAZOBACTAM 4.5 G ; CEFEPIME 2 G ; MEROPENEM 1 G ; IMIPENEM-CILASTATIN 500 MG	MEDICAL ONCOLOGY	14200	14200	14200	14200	14200	14200	14200	14200
391	CMU0131 -b : FEBRILE NEUTROPENIA - SECOND-LINE DUAL THERAPY ; PIPERACILLIN-TAZOBACTAM 4.5 G IV PLUS AN AMINOGLYCOSIDE ; MEROPENEM 1 G IV PLUS AN AMINOGLYCOSIDE ; IMIPENEM-CILASTATIN 500 MG IV PLUS AN AMINOGLYCOSIDE	MEDICAL ONCOLOGY	20500	20500	20500	20500	20500	20500	20500	20500
392	CMU0132 : THYROID CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
393	CMU0132 -a : THYROID CANCER - SORAFENIB ; SORAFENIB 400 MG PO BID	MEDICAL ONCOLOGY	3100	3100	3100	3100	3100	3100	3100	3100
394	CMU0132 -b : THYROID CANCER - SUNITINIB ; SUNITINIB 50 MG	MEDICAL ONCOLOGY	29900	29900	29900	29900	29900	29900	29900	29900
395	CMU0132 -c : THYROID CANCER - PAZOPANIB	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
396	CMU0132 -d : THYROID CANCER - DOXORUBICIN ; DOXORUBICIN 60 MG/M2 AS MONOTHERAPY OR IN COMBINATION WITH CISPLATIN 40 MG/M2	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
397	CMU0133 : THYMOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
398	CMU0133 -a : THYMOMA - CAP ; DAY 1 - CISPLATIN 50MG/M2 IV, DOXORUBICIN 50MG/M2 IV, CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT EVERY 21 DAYS FOR A MAX OF 8 CYCLES.	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
399	CMU0133 -b : THYMOMA - CAPP ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV ; DAYS 1-3 - CISPLATIN 30MG/M2 IV ; DAYS 1-3 - DOXORUBICIN 20MG/M2 ; DAYS 1-5 - PREDNISONE 100MG. ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
400	CMU0133 -c : THYMOMA - ADOC ; DAY 1 - CISPLATIN 50MG/M2 IV, DOXORUBICIN 40MG/M2 IV ; DAY 3 - VINCRISTINE 0.6MG/M2 IV ; DAY 4 - CYCLOPHOSPHAMIDE 700MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 5 CYCLES.	MEDICAL ONCOLOGY	6200	6200	6200	6200	6200	6200	6200	6200
401	CMU0133 -d : THYMOMA - PE ; DAY 1 - CISPLATIN 60MG/M2 IV ; DAYS 1-3 - ETOPOSIDE 120MG/M2 IV ; REPEAT EVERY 3 WEEKS FOR A MAX OF 8 CYCLES.	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
402	CMU0133 -e : THYMOMA - VIP ; DAYS 1-4 - ETOPOSIDE 75MG/M2 IV, IFOSFAMIDE 1.2G/M2 IV, CISPLATIN 20MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
403	CMU0133 -f : THYMOMA - CARBOPLATIN+PACLITAXEL ; DAY 1 - PACLITAXEL 225MG/M2 IV, CARBOPLATIN AUC = 6 IV ; REPEAT EVERY 3 WEEKS FOR A MAX OF 6 CYCLES.	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
404	CMU0134 : BRAIN CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
405	CMU0134 -i : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
406	CMU0134 -i-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - COMBINATION PCV (LOMUSTINE + PROCARBAZINE + VINCRISTINE) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY. ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY. ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS.	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
407	CMU0134 -i-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE (7 WEEKS) ; DAYS 1-49 - TEMOZOLOMIDE 75MG/M2 ORALLY. ; REPEAT CYCLE EVERY 11 WEEKS (7 WEEKS ON/4 WEEKS OFF) FOR 6 CYCLES.	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
408	CMU0134 -i-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE MONTHLY 5-DAY COURSE ; TEMOZOLOMIDE MONTHLY 5-DAY COURSES AT DOSES OF 180 - 200MG/M2/DAY	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
409	CMU0134 -i-d : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE (3 WEEKS) ; DAYS 1-21 - TEMOZOLOMIDE 75MG/M2/DAY ORALLY. ; REPEAT CYCLE EVERY 28 DAYS.	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
410	CMU0134 -ii : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMASSYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
411	CMU0134 -ii-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - TEMOZOLOMIDE MONTHLY 5-DAY COURSE ; DAYS 1-5 - TEMOZOLOMIDE 200MG/M2/DAY ORALLY. ; REPEAT CYCLE EVERY 4 WEEKS UNTIL DISEASE PROGRESSION OR FOR UP TO 24 CYCLES.	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
412	CMU0134 -ii-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - PCV WITH DEFERRED RT (LOMUSTINE + PROCARBAZINE + VINCRISTINE) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
413	CMU0134 -ii-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
414	CMU0134 -ii-c-1 : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; DAILY ORAL TEMOZOLOMIDE (75MG/M2/DAY, 7 DAYS PER WEEK FROM THE FIRST TO THE LAST DAY OF RADIOTHERAPY)	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
415	CMU0134 -ii-c-2 : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - ADJUVANT TEMOZOLOMIDE - PRECEEDED BY CONCURRENT TEMOZOLOMIDE (WITH RT) ; TEMOZOLOMIDE 150-200MG/M2/DAY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
416	CMU0134 -ii-d : ADJUVANT TEMOZOLOMIDE	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
417	CMU0134 -ii-e : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - PCV FOR 1P19Q CO-DELETED (WITH RADIOTHERAPY) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS. FOR 6 CYCLES	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
418	CMU0134 -iii : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
419	CMU0134 -iii-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; DAILY ORAL TEMOZOLOMIDE (75MG/M2/DAY, 7 DAYS PER WEEK FROM THE FIRST TO THE LAST DAY OF RADIOTHERAPY)	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
420	CMU0134 -iii-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - ADJUVANT TEMOZOLOMIDE (PRECEEDED BY CONCURRENT TEMOZOLZMIDE) ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2/DAY ORALLY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES.	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
421	CMU0134 -iii-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - TEMOZOLOMIDE (POST RT) ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2/DAY ORALLY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
422	CMU0134 -iii-d : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - TEMOZOLOMIDE (200MG) WITH STANDARD RT ; DAYS 1-5 - TEMOZOLOMIDE 200MG/M2, ORALLY	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
423	CMU0134 -iv : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
424	CMU0134 -iv-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) - VINCRISTINE + CISPLATIN + LOMUSTINE ; DAY 1 - LOMUSTINE 75MG/M2 ORALLY ; DAY 2 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS; ; DURING CRANIO-SPINAL RT	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
425	CMU0134 -iv-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) - VINCRISTINE + CISPLATIN + CYCLOPHOSPHAMIDE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS ; DAYS 22, 23 - CYCLOPHOSPHAMIDE 1, 000MG/M2 IV.	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
426	CMU0134 -v : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMAPRIMARY CNS LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
427	CMU0134 -v-a : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPYHIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
428	CMU0134 -v-a-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE + CYTARABINE ; DAY 1 - MTX 3.5G/M2 ; DAYS 2-3 - CYTARABINE 2G/M2 IV TWICE A DAY.	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
429	CMU0134 -v-a-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE + LEUCOVORIN + IFOSFAMIDE + MESNA ; DAY 1 - MTX 4GM/M2 IV, ; DAYS 2-5 - LEUCOVORIN 20-25MG IV (UPTO 40MG) ; DAYS 3-5 - IFOSFAMIDE 1.5GM/M2 IV + MESNA 400MG IV	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
430	CMU0134 -v-b : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPY HIGH DOSE METHOTREXATE (MTX 2.5-4.0MG/M2) + CHEMOTHERAPY MONOCLONAL ANTIBODY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
431	CMU0134 -v-b-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + MTX + VINCRISTINE +PROCARBAZINE ; DAY 1 - RITUXIMAB 500MG/M2 IV ; DAY 2 - MTX 3.5MG/M2 IV PLUS VINCRISTINE 1.4MG/M2 ; PROCARBAZINE 100MG/M2/DAY ADMINISTERED FOR 7 DAYS WITH ODD-NUMBERED CYCLES	MEDICAL ONCOLOGY	44000	44000	44000	44000	44000	44000	44000	44000
432	CMU0134 -v-c : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE (MTX 8.0MG/M2) + CHEMOTHERAPY +/- MONOCLONAL ANTIBODY HIGH DOSE METHOTREXATE (MTX 8.0MG/M2) + CHEMOTHERAPY MONOCLONAL ANTIBODY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
433	CMU0134 -v-c-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE INDUCTION ; MTX 8G/M2 IV ; REPEAT EVERY 2 WEEKS UNTIL COMPLETE RESPONSE ACHIEVED OR MAX OF 8 CYCLES REACHED. ;	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
434	CMU0134 -v-c-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE CONSOLIDATION ; MTX 8G/M2 IV ADMINISTERED ; REPEAT EVERY 2 WEEKS FOR 2 CYCLES.	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
435	CMU0134 -v-c-3-i : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE MAINTANANCE (CYCLES 1-4) ; DAY 1 - MTX 8G/M2 IV, RITUXIMAB 375MG/M2 IV. ; REPEAT EVERY 4 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	27600	27600	27600	27600	27600	27600	27600	27600
436	CMU0134 -v-c-3-ii : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE MAINTANANCE (CYCLES 5-11) ; MTX 8G/M2 IV ADMINISTERED EVERY 4 WEEKS FOR 11 CYCLES. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
437	CMU0134 -v-d : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
438	CMU0134 -v-d-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN - INDUCTION ; DAY 1 - RITUXIMAB 375MG/M2 IV, FOLLOWED BY ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2 ORALLY DAILY, AFTER RITUXIMAB INFUSION. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	22700	22700	22700	22700	22700	22700	22700	22700
439	CMU0134 -v-d-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN - MAINTANANCEDAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2 ORALLY DAILY. ; REPEAT CYCLE EVERY 4 WEEKS FOR 8 CYCLES.	MEDICAL ONCOLOGY	1700	1700	1700	1700	1700	1700	1700	1700
440	CMU0134 -v-e : BRAIN CARCINOMA - MENINGIOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
441	CMU0134 -v-e-1 : BRAIN CARCINOMA - MENINGIOMA - INTERFERON-ALFAINTERFERON-ALFA ; ALPHA-IFN 106 UNITS/M2 SC EVERY OTHER DAY FOR 4 WEEKS. ; REPEAT CYCLE EVERY 4 WEEKS. ;	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
442	CMU0134 -v-e-2 : BRAIN CARCINOMA - MENINGIOMA -SOMATOSTATIN ANALOG ; SANDOSTATIN LAR DEPOT 10-30MG IM ; REPEAT EVERY 4 WEEKS. ;	MEDICAL ONCOLOGY	5700	5700	5700	5700	5700	5700	5700	5700
443	CMU0134 -v-e-3 : BRAIN CARCINOMA - MENINGIOMA - SUNITINIB ; DAYS 1-28 - SUNITINIB 50MG ORALLY DAILY. ; REPEAT CYCLE EVERY 42 DAYS.	MEDICAL ONCOLOGY	3100	3100	3100	3100	3100	3100	3100	3100
444	CMU0135 : HEAD AND NECK CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
445	CMU0135 -i : HEAD AND NECK CANCER - SQUAMOUS CELL CANCERS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
446	CMU0135 -i-a : HEAD AND NECK CANCER - HIGH DOSE CISPLATIN ; CISPLATIN 100MG/M2 IV + CONCURRENT RADIOTHERAPY; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
447	CMU0135 -i-b : HEAD AND NECK CANCER - CARBOPLATIN + INFUSIONAL 5-FU ; DAYS 1-4 - 5-FU 600MG/M2/DAY AS CONTINUOUS IV I, CARBOPLATIN 70MG/M2/DAY IV ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES (GIVEN CONCURRENTLY WITH RADIOTHERAPY).	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
448	CMU0135 -i-c : HEAD AND NECK CANCER - 5-FU + HYDROXYUREA ; DAY 1 - HYDROXYUREA 1, 000MG ORALLY EVERY 12 HOURS (11 DOSES/CYCLE), 5-FU 800MG/M2/DAY ; REPEAT EVERY OTHER WEEK FOR 7 CYCLES. WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	2400	2400	2400	2400	2400	2400	2400	2400
449	CMU0135 -i-d : HEAD AND NECK CANCER - CISPLATIN + PACLITAXEL ; DAY 1 - PACLITAXEL 30MG/M2 IV (EVERY MONDAY), ; DAY 2 - CISPLATIN 20MG/M2 IV (EVERY TUESDAY). ; REPEAT CYCLE EVERY WEEK FOR 7 CYCLES, WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
450	CMU0135 -i-e : HEAD AND NECK CANCER - CISPLATIN + INFUSIONAL 5-FU ; DAY 1 - CISPLATIN 60MG/M2 OVER ; DAYS 1-5 - 5-FU 800MG/M2/DAY ; REPEAT EVERY OTHER WEEK FOR 7 CYCLES. WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
451	CMU0135 -i-f : HEAD AND NECK CANCER - CARBOPLATIN + PACLITAXEL ; DAY 1 - PACLITAXEL 40-45MG/M2, CARBOPLATIN 100MG/M2 ; REPEAT CYCLE EVERY WEEK FOR 8 CYCLES, WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
452	CMU0135 -i-g : HEAD AND NECK CANCER - WEEKLY CISPLATIN ; CISPLATIN 40MG/M2 IV PER WEEK	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
453	CMU0135 -i-h : HEAD AND NECK CANCER - CISPLATIN (FOR HIGH RISK OROPHARYNGEAL CARCINOMA) ; DAYS 1, 22, AND 43 - CISPLATIN 100MG/M2 IV + RADIOTHERAPY.	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
454	CMU0135 -i-i : HEAD AND NECK CANCER - DOCETAXEL + CISPLATIN + 5-FU ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV, ; DAYS 1-5 - 5-FU 750MG/M2/DAY IV. ; REPEAT EVERY 3 WEEKS FOR UP TO 4 CYCLES.	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
455	CMU0135 -ii : HEAD AND NECK CANCER - NASOPHARYNX CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
456	CMU0135 -ii-a : NASOPHARYNX CANCER - CONCURRENT CISPLATIN FOLLOWED BY CONCURRENT CISPLATIN +5FUC ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
457	CMU0135 -ii-a-1 : NASOPHARYNX CANCER - CONCURRENT CISPLATIN (FOLLOWED BY CONCURRENT CISPLATIN +5FU) ; DAY 1 - CISPLATIN 100MG/M2 IV; PLUS RADIOTHERAPY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES; FOLLOWED BY CONCURRENT CISPLATIN +5FU	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
458	CMU0135 -ii-a-2 : NASOPHARYNX CANCER - CONCURRENT CISPLATIN +5FU - PRECEEDED BY (CONCURRENT CISPLATIN 3 CYCLES) ; DAYS 1-4 - CISPLATIN 80MG/M2/DAY, 5-FU 1, 000MG/M2/DAY IV ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 CYCLES	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
459	CMU0135 -ii-b : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN FOLLOWED BY CONCURRENT CARBOPLATIN +5FU	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
460	CMU0135 -ii-b-1 : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN - (FOLLOWED BY CONCURRENT CARBOPLATIN +5FU) ; DAY 1 - CARBOPLATIN AUC 6MG/MIN/ML IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES;	MEDICAL ONCOLOGY	4500	4500	4500	4500	4500	4500	4500	4500
461	CMU0135 -ii-b-2 : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN +5FU - PRECEEDED BY (CONCURRENT CARBOPLATIN ) ; DAY 1 - CARBOPLATIN AUC 5MG/MIN/ML IV ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	14200	14200	14200	14200	14200	14200	14200	14200
462	CMU0135 -ii-c : NASOPHARYNX CANCER - CONCURRENT CISPLATIN ; CISPLATIN 40MG/M2 ; REPEAT WEEKLY FOR 7 CYCLES	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
463	CMU0135 -ii-d : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN + 5-FU FOLLOWED BY CISPLATIN ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
464	CMU0135 -ii-d-1 : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN + 5-FU - FOLLOWED BY CISPLATIN AFTER 3 CYCLES ; DAY 1 - DOCETAXEL 70MG/M2 IV, CISPLATIN 75MG/M2 IV ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY IV ; REPEAT EVERY WEEK FOR 3 CYCLES	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
465	CMU0135 -ii-d-2 : NASOPHARYNX CANCER - CISPLATIN - WEEKLY - PRECEDED BY 3 CYCLES OF DOCETAXEL + 5-FU ; DAY 1 - CISPLATIN 100MG/M2; ; REPEAT EVERY 3 WEEKS, TILL RADIATION	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
466	CMU0135 -ii-e : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
467	CMU0135 -ii-e-1 : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN - FOLLOWED BY CISPLATIN AFTER 2 CYCLES ; DAY 1 - DOCETAXEL 75MG/M2 IV + CISPLATIN 75MG/M2 IV ; REPEAT EVERY 3 WEEKS FOR TWO CYCLES	MEDICAL ONCOLOGY	4100	4100	4100	4100	4100	4100	4100	4100
468	CMU0135 -ii-e-2 : NASOPHARYNX CANCER - CISPLATIN - WEEKLY - PRECEDED BY 2 CYCLES OF DOCETAXEL + CISPLATIN ; CISPLATIN 40MG/M2 IV ; WEEKLY CONCURRENT WITH RADIOTHERAPY.	MEDICAL ONCOLOGY	2400	2400	2400	2400	2400	2400	2400	2400
469	CMU0135 -ii-f : NASOPHARYNX CANCER - CISPLATIN + 5-FU ; DAY 1 - CISPLATIN 100MG/M2/DAY IV. ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY CONTINUOUS IV INFUSION FOR 4 DAYS. ; REPEAT CYCLE EVERY 3 WEEKS FOR A MINIMUM OF 6 CYCLES	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
470	CMU0135 -i-j : HEAD AND NECK CANCER - PACLITAXEL + CISPLATIN+ INFUSIONAL 5-FU ; DAY 1 - PACLITAXEL 175MG/M2 ; DAY 2 - CISPLATIN 100MG/M2 ; DAY 2-6 - 5-FU 500MG/M2/DAY IV ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
471	CMU0136 : RENAL CELL CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
472	CMU0136 -a : RENAL CELL CARCINOMA - PAZOPANIB	MEDICAL ONCOLOGY	20000	20000	20000	20000	20000	20000	20000	20000
473	CMU0136 -b : RENAL CELL CARCINOMA - SUNITINIB	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
474	CMU0136 -c : RENAL CELL CARCINOMA - SORAFENIB	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
475	CMU0136 Ia : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	20200	20200	20200	20200	20200	20200	20200	20200
476	CMU0136 Ib : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF.	MEDICAL ONCOLOGY	30700	30700	30700	30700	30700	30700	30700	30700
477	CMU0136 Ic : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - BEVACIZUMAB + IFN-ALPHA ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS + IFN-ALPHA.	MEDICAL ONCOLOGY	70100	70100	70100	70100	70100	70100	70100	70100
478	CMU0136 Id : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
479	CMU0136 IIa : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - EVEROLIMUS ; EVEROLIMUS 10MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	39100	39100	39100	39100	39100	39100	39100	39100
480	CMU0136 IIb : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	20200	20200	20200	20200	20200	20200	20200	20200
481	CMU0136 IIc : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
482	CMU0136 IId : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF.	MEDICAL ONCOLOGY	30700	30700	30700	30700	30700	30700	30700	30700
483	CMU0136 IIe : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - BEVACIZUMAB ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS.	MEDICAL ONCOLOGY	69600	69600	69600	69600	69600	69600	69600	69600
484	CMU0136 IIIa : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF.	MEDICAL ONCOLOGY	30700	30700	30700	30700	30700	30700	30700	30700
485	CMU0136 IIIb : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - BEVACIZUMAB ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS.	MEDICAL ONCOLOGY	69600	69600	69600	69600	69600	69600	69600	69600
486	CMU0136 IIIc : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - EVEROLIMUS ; EVEROLIMUS 10MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	39100	39100	39100	39100	39100	39100	39100	39100
487	CMU0136 IIId : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - ERLOTINIB ; ERLOTINIB 150MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
488	CMU0136 IIIe : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY	MEDICAL ONCOLOGY	20200	20200	20200	20200	20200	20200	20200	20200
489	CMU0136 IIIf : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
490	CMU0137 : UNKNOWN PRIMARY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
491	CMU0137 -i : UNKNOWN PRIMARY - ADENOCARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
492	CMU0137 -i-a : UNKNOWN PRIMARY - ADENOCARCINOMA - PACLITAXEL + CARBOPLATIN + ETOPOSIDE ; DAY 1 - PACLITAXEL 200 MG/M 2 IV, CARBOPLATIN AUC 6 ; DAYS 1-10 - ETOPOSIDE 50 MG PO ALTERNATING WITH 100 MG DAILY ; REPEAT EVERY 21DAYS FOR 2-3 CYCLES; RESTAGE, CAN BE TREATED UPTO 8 CYCLES	MEDICAL ONCOLOGY	8400	8400	8400	8400	8400	8400	8400	8400
493	CMU0137 -i-b : UNKNOWN PRIMARY - ADENOCARCINOMA - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 200 MG/M 2, CARBOPLATIN AUC 6 ; REPEAT CYCLE EVERY 3 WEEKS, MAXIMUM 8 CYCLES	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
494	CMU0137 -i-c : UNKNOWN PRIMARY - ADENOCARCINOMA - DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 65MG/M2 IV, CARBOPLATIN AUC 6 ; REPEAT CYCLE EVERY 3 WEEKS, MAXIMUM 8 CYCLES.	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
495	CMU0137 -i-d : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + CISPLATIN ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAY 1 AND 8 - GEMCITABINE 1250MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
496	CMU0137 -i-e : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + DOCETAXEL ; DAY 1 AND 8 - GEMCITABINE 1000MG/M2 IV OVER 30 MINUTES ; DAY 8 - DOCETAXEL 75MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR A MAXIMUM OF 6 CYCLES	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
497	CMU0137 -i-f : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + IRINOTECAN ; DAYS 1 AND 8 - IRINOTECAN 100MG/M2 IV, GEMCITABINE 1000MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES.RESTAGE EVERY 2-3 CYCLES	MEDICAL ONCOLOGY	5900	5900	5900	5900	5900	5900	5900	5900
498	CMU0137 -i-g : UNKNOWN PRIMARY - ADENOCARCINOMA - MFOLFOX ; DAY 1 - OXALIPLATIN 85MG/M2 IV OVER 2 HOURS + LEUCOVORIN 400MG/M2 IV OVER 2 HOURS + 5-FU 400MG/M2 IV BOLUS THEN ; DAYS 1 AND 2 - 5-FU 1200MG/M2 (TOTAL 2400MG/M2 OVER 46-48 HOURS) IV CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS FOR 24 CYCLES	MEDICAL ONCOLOGY	8400	8400	8400	8400	8400	8400	8400	8400
499	CMU0137 -i-h : UNKNOWN PRIMARY - ADENOCARCINOMA - CAPEOX ; DAY 1 - OXALIPLATIN 130MG/M2 IV OVER 2 HOURS ; DAY 1-14 - CAPECITABINE 850-1000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 16 CYCLES.	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
500	CMU0137 -i-i : UNKNOWN PRIMARY - ADENOCARCINOMA - IRINOTECAN + CARBOPLATIN ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAYS 1, 8, AND 15 - IRINOTECAN 60MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR UP TO 6 CYCLES	MEDICAL ONCOLOGY	8100	8100	8100	8100	8100	8100	8100	8100
501	CMU0137 -ii : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
502	CMU0137 -ii-a : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA - PACLITAXEL + CISPLATIN + 5-FU ; PACLITAXEL 175 MG/M 2 IV, ; DAY 2 - CISPLATIN 100 MG/M 2 IV, ; DAY 5-FU (5-FLUOROURACIL) 500 MG/M 2/DAY IV ; REPEAT EVERY 21D	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
503	CMU0137 -ii-b : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA - DOCETAXEL + CISPLATIN + 5-FU ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV. ; DAYS 1-5 - 5-FU 750MG/M2/DAY IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
504	CMU0137 -ii-c : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -PACLITAXEL + CARBOPLATIN ; DAY 1 - CARBOPLATIN AUC 6MG PER MIN/ML IV OVER 30 MINUTES + PACLITAXEL 200MG/M2 IV OVER 3 HOURS. ; REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES IN RESPONDING PATIENTS AND FOR 6 CYCLES MAXIMUM IN PATIENTS WITH STABLE DISEASE	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
505	CMU0137 -ii-d : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -CISPLATIN + GEMCITABINE ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAY 1 AND 8 - GEMCITABINE 1250MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	5500	5500	5500	5500	5500	5500	5500	5500
506	CMU0137 -ii-e : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -MFOLFOX ; DAY 1 - OXALIPLATIN 85MG/M2 IV OVER 2 HOURS + LEUCOVORIN 400MG/M2 IV OVER 2 HOURS + 5-FU 400MG/M2 IV BOLUS THEN ; DAYS 1 AND 2 - 5-FU 1200MG/M2 (TOTAL 2400MG/M2 OVER 46-48 HOURS) IV CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS FOR 24 CYCLES.	MEDICAL ONCOLOGY	8400	8400	8400	8400	8400	8400	8400	8400
507	CMU0137 -ii-f : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -PACLITAXEL + CISPLATIN ; DAY 1 - PACLITAXEL 175MG/M2 IV + CISPLATIN 60MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS.	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
508	CMU0137 -ii-g : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 75MG/M2 IV OVER 30 MINUTES + CARBOPLATIN AUC 5MG PER MIN/ML IV OVER 30 MINUTES. ; REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES	MEDICAL ONCOLOGY	9200	9200	9200	9200	9200	9200	9200	9200
509	CMU0137 -ii-h : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CISPLATIN ; DAY 1 - DOCETAXEL 60MG/M2 IV + CISPLATIN 80MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 2 CYCLES AND AN ADDITIONAL 4 CYCLES UNTIL DISEASE PROGRESSION IS DEMONSTRATED	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
510	CMU0137 -iii : UNKNOWN PRIMARY - NEUROENDOCRINE TUMORS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
511	CMU0137 -ii-i : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CISPLATIN ; DAY 1 - DOCETAXEL 75MG/M2 IV + CISPLATIN 75MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES.	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
512	CMU0137 -iii-b : UNKNOWN PRIMARY - NEUROENDOCRINE TUMORS - ETOPOSIDE + CISPLATIN ; DAYS 1-3 - ETOPOSIDE 100 MG/M 2 ; DAYS 2-3 - CISPLATIN 45 MG/M 2 IV ; REPEAT EVERY 28 DAYS	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
513	CMU0137 -ii-j : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -CISPLATIN + FLUOROURACIL ; DAYS 1-5 - CISPLATIN 20MG/M2 IV ; DAYS 1-5 - FLUOROURACIL 700MG/M2/DAY IV VIA CONTINUOUS INFUSION OVER 24 HOURS. ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 CYCLES.	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
514	CMU0138 : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMACA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
515	CMU0138 -a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - GEMCITABINE + CISPLATIN ; DAYS 1 AND 8 - CISPLATIN 25MG/M2 IV, GEMCITABINE 1, 000MG/M2 IV ; REPEAT EVERY 21 DAYS FOR 4 CYCLES, RE-EVALUATE AND CONTINUE AN ADDITIONAL 4 CYCLES IF WARRANTED	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
516	CMU0138 -b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV	MEDICAL ONCOLOGY	4300	4300	4300	4300	4300	4300	4300	4300
517	CMU0138 -c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - CAPECITABINE ; CAPECITABINE ORAL ; REPEAT EVERY 21 DAYS	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
518	CMU0139 : PANCREAS CARCINOMAPANCREAS CARCINOMA -	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
519	CMU0139 -i : PANCREAS CARCINOMA - PATIENTS WITH RESECTABLE PANCREATIC CANCER - LOCALLY ADVANCED ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
520	CMU0139 -i-a : PANCREAS CARCINOMA - PATIENTS WITH RESECTABLE PANCREATIC CANCER - LOCALLY ADVANCED GEMCITABINE ; DAYS 1, 8, AND 15 - GEMCITABINE 1, 000MG/M2 IV ; REPEAT EVERY 4 WEEKS FOR SIX CYCLES	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
521	CMU0139 -ii : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
522	CMU0139 -ii-a : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - 5-FU + LEUCOVORIN ; DAYS 1-5 - LEUCOVORIN 20MG/M2 IV, 5-FU 425MG/M2 IV ; REPEAT CYCLE EVERY 4 WEEKS	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
523	CMU0139 -ii-b : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - GEMCITABINE & 5FU ; PRIOR TO CHEMORADIATION - ; DAYS 1, 8 AND 15 - GEMCITABINE 1, 000MG/M2 IV; INITIATE 1-2 WEEKS PRIOR TO CHEMORADIATION (50.4GY + 5-FU 250MG/M2/DAY). ; AFTER CHEMORADIATION - ; DAYS 1, 8 AND 15 - GEMCITABINE 1, 000MG/M2 IV; INITIATE 3-5 WEEKS FOLLOWING CHEMORADIATION. ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 MONTHS.	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
524	CMU0139 -ii-c : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - CONTINUOUS INFUSION 5-FU (WITH RADIATION) ; PRIOR TO CHEMORADIATION - ; DAYS 1-21 - 5-FU 250MG/M2/DAY CONTINUOUS IV INFUSION; INITIATE 1-2 WEEKS PRIOR TO CHEMORADIATION (50.4GY + 5-FU 250MG/M2/DAY). ; AFTER CHEMORADIATION - ; DAYS 1-28 - 5-FU 250MG/M2/DAY CONTINUOUS IV INFUSION; INITIATE 3-5 WEEKS FOLLOWING CHEMORADIATION. ; REPEAT CYCLE EVERY 6 WEEKS FOR 3 MONTHS.	MEDICAL ONCOLOGY	21800	21800	21800	21800	21800	21800	21800	21800
525	CMU0139 -iii : PANCREAS CARCINOMA - NEOADJUVANT THERAPY - NEOADJUVANT THERAPY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
526	CMU0139 -iii-a : PANCREAS CARCINOMA - NEOADJUVANT THERAPY - CAPECITABINECAPECITABINE ; CAPECITABINE ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 52 WEEKS.	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
527	CMU0140 : PERI AMPULLARY CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
528	CMU0140 -a : PERI AMPULLARY CARCINOMA - 5-FU ; FLUOROURACIL 425 MG/M2 ADMINISTERED ON DAYS 1 TO 5 AND 29-33	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
529	CMU0141 : NEURO ENDOCRINE CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
530	CMU0141 -a : NEURO ENDOCRINE CARCINOMA - ALL NECS ARE COVERED UNDER ORGAN CANCERS. IF UNCOVERED - UNLISTED ONLY.	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
531	CMU0142 : SARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
532	CMU0142 -i : SARCOMA - GASTROINTESTINAL STROMAL TUMOR - GIST	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
533	CMU0142 -i-a : SARCOMA - GASTROINTESTINAL STROMAL TUMOR - GIST - IMATINIB ; IMATINIB 400MG ORALLY ONCE DAILY TO TWICE DAILY	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
534	CMU0142 -ii : SARCOMA - SOFT TISSUE SARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
535	CMU0142 -ii-a : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN + DACARBAZINE (AD) ; DAYS 1-4 - DOXORUBICIN 60MG/M2 + DACARBAZINE 750MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS	MEDICAL ONCOLOGY	12100	12100	12100	12100	12100	12100	12100	12100
536	CMU0142 -ii-b : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN + IFOSFAMIDE + MESNA ; DAYS 1 AND 2 - DOXORUBICIN 30MG/M2/DAY IV, IFOSFAMIDE 3, 750MG/M2/DAY IV, MESNA 750MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS	MEDICAL ONCOLOGY	9700	9700	9700	9700	9700	9700	9700	9700
537	CMU0142 -ii-c : SARCOMA - SOFT TISSUE SARCOMA - MESNA + DOXORUBICIN + IFOSFAMIDE + DACARBAZINE (MAID) ; DAYS 1-3 - DOXORUBICIN 20MG/M2/DAY, IFOSFAMIDE 2, 500MG/M2/DAY, DACARBAZINE 300MG/M2/DAY IV ; DAYS 1-4 - MESNA 2, 500MG/M2/DAY IV FOR 84 TO 96 HOURS. ; REPEAT CYCLE EVERY 3 WEEKS.	MEDICAL ONCOLOGY	11300	11300	11300	11300	11300	11300	11300	11300
538	CMU0142 -ii-d : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE + EPIRUBICIN + MESNA ; DAYS 1 AND 2 - EPIRUBICIN 60MG/M2/DAY IV ; DAYS 1-5 - IFOSFAMIDE 1.8G/M2/DAY IV + MESNA. ; REPEAT CYCLE EVERY 3 WEEKS FOR 5 CYCLES.	MEDICAL ONCOLOGY	13500	13500	13500	13500	13500	13500	13500	13500
539	CMU0142 -ii-e : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + DOCETAXEL ; DAYS 1 AND 8 - GEMCITABINE 900MG/M2 IV ; DAY 8 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
540	CMU0142 -ii-f : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + VINORELBINE ; DAYS 1 AND 8 - VINORELBINE 25MG/M2 IV, GEMCITABINE 800MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS	MEDICAL ONCOLOGY	15500	15500	15500	15500	15500	15500	15500	15500
541	CMU0142 -ii-g : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + DACARBAZINE ; DAY 1 - GEMCITABINE 1, 800MG/M2 IV + DACARBAZINE 500MG/M2 IV. ; REPEAT CYCLE EVER 2 WEEKS FOR A TOTAL OF 12 CYCLES;	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
542	CMU0142 -ii-h : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN ; DOXORUBICIN 60-75MG/M2 IV ; ONCE EVERY 3 WEEKS	MEDICAL ONCOLOGY	3100	3100	3100	3100	3100	3100	3100	3100
543	CMU0142 -ii-i : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE ; DAYS 1-3 - IFOSFAMIDE 2, 000-3, 000MG/M2/DAY IV FOR 3 TO 4 DAYS + MESNA ; REPEAT EVERY 3 WEEKS.	MEDICAL ONCOLOGY	10500	10500	10500	10500	10500	10500	10500	10500
544	CMU0142 -ii-j : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE ; DAY 1 - IFOSFAMIDE 5, 000MG/M2 + MESNA 5, 000MG/M2 IV ; DAY 2 - MESNA 400-600MG/M2 IV ; IFOSFAMIDE, MESNA ; REPEAT EVERY 3 WEEKS	MEDICAL ONCOLOGY	2000	2000	2000	2000	2000	2000	2000	2000
545	CMU0142 -ii-k : SARCOMA - SOFT TISSUE SARCOMA - EPIRUBICIN ; EPIRUBICIN 160MG/M2 IV ; REPEAT EVERY 3 WEEKS	MEDICAL ONCOLOGY	6200	6200	6200	6200	6200	6200	6200	6200
546	CMU0142 -ii-l : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE ; DAYS 1 AND 8 - GEMCITABINE 1, 200MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS.	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
547	CMU0142 -ii-m : SARCOMA - SOFT TISSUE SARCOMA - DACARBAZINE (I) ; DACARBAZINE 250MG/M2/DAY IV FOR 5 DAYS ; REPEAT EVERY 3 WEEKS.	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
548	CMU0142 -ii-n : SARCOMA - SOFT TISSUE SARCOMA - DACARBAZINE (II) ; DACARBAZINE 800-1, 000MG/M2 IV ; REPEAT EVERY 3 WEEKS.	MEDICAL ONCOLOGY	2500	2500	2500	2500	2500	2500	2500	2500
549	CMU0142 -ii-o : SARCOMA - SOFT TISSUE SARCOMA - LIPOSOMAL DOXORUBICIN ; LIPOSOMAL DOXORUBICIN 30-50MG/M2 IV ; REPEAT EVERY 4 WEEKS.	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
550	CMU0142 -ii-p : SARCOMA - SOFT TISSUE SARCOMA - TEMOZOLOMIDE ; TEMOZOLOMIDE 200MG/M2 ORALLY TWICE DAILY FOR 5 DAYS, FOLLOWED BY 9 DOSES OF 90MG/M2 ORALLY ; REPEAT EVERY 4 WEEKS	MEDICAL ONCOLOGY	4400	4400	4400	4400	4400	4400	4400	4400
551	CMU0143 : PRIMITIVE NEURO ECTODERMAL TUMOR	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
552	CMU0143 -a : PRIMITIVE NEURO ECTODERMAL TUMOR - WEEKLY VINCRISTINE ; VINCRISTINE 1.5MG/M2 IV, MAX 2MG ; FOR 5 TO 6 WEEKS	MEDICAL ONCOLOGY	1800	1800	1800	1800	1800	1800	1800	1800
553	CMU0143 -b : PRIMITIVE NEURO ECTODERMAL TUMOR - VINCRISTINE + CISPLATIN + LOMUSTINE ; DURING CRANIOSPINAL RADIOTHERAPY (RT) ; DAY 1 - LOMUSTINE 75MG/M2 ORALLY ; DAY 2 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS; UP TO MAX 8 DOSES	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
554	CMU0143 -c : PRIMITIVE NEURO ECTODERMAL TUMOR - VINCRISTINE + CISPLATIN + CYCLOPHOSPHAMIDE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV, MAX 2MG ; DAYS 22, 23 - CYCLOPHOSPHAMIDE 1, 000MG/M2 IV	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
555	CMU0144 : ANAL CANAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
556	CMU0144 -a : ANAL CANAL CANCER - 5-FU + MITOMYCIN ; DAYS 1-4 AND 29-32 - 5-FU 1, 000MG/M2/DAY IV ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS (MAXIMUM 20MG PER COURSE), WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
557	CMU0144 -b : ANAL CANAL CANCER - CAPECITABINE + MITOMYCIN (I) ; DAYS 1-5 - CAPECITABINE 825MG/M2 ORALLY TWICE DAILY WEEKLY FOR 6 WEEKS, ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS, WITH CONCURRENT RADIOTHERAPY.	MEDICAL ONCOLOGY	8500	8500	8500	8500	8500	8500	8500	8500
558	CMU0144 -c : ANAL CANAL CANCER - CAPECITABINE + MITOMYCIN (II) ; DAYS 1-5 - CAPECITABINE 825MG/M2 ORALLY TWICE DAILY WEEKLY FOR 6 WEEKS, ; DAY 1 - MITOMYCIN 12MG/M2 IV BOLUS, WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
559	CMU0144 -d : ANAL CANAL CANCER - CISPLATIN + 5-FU ; DAYS 1-5 - 5-FU 1, 000MG/M2/DAY IV ; DAY 2 - CISPLATIN 100MG/M2 IV ; REPEAT CYCLE EVERY 4 WEEKS, WITH CONCURRENT RADIOTHERAPY	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
560	CMU0145 : CA-PENIS	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
561	CMU0145-a : CA-PENIS - CISPLATIN + 5-FU ; DAY 1 - 5 FU 1000mg/m2 D1-D4 and Day 1 - Cisplatin 75mg/m2 Every 4 weeks	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
562	CMU0145-b : CA-PENIS -Paclitaxel; Paclitaxel 80 mg/m2 D1 every week	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
563	CMU0145-c : CA-PENIS - Paclitaxel; Paclitaxel 175 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
2665	CMU0975 : SURGERY/CHEMOTHERAPY/RADIOTHERAPY FOR ALL LEUKEMIAS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2666	CMU0975 A : ALL LEUKEMIA( CHEMOTHERAPHY)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2667	CMU0975 A-I : CHRONIC MYELOID LEUKEMIA (CML) - CHRONIC MYELOID LEUKEMIA (CML)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2668	CMU0975 A-II : ACUTE MYELOID LEUKEMIA (AML) - ACUTE MYELOID LEUKEMIA (AML)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2669	CMU0975 A-II-a : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE 1 - AGE	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
2670	CMU0975 A-I-i-a : CHRONIC MYELOID LEUKEMIA (CML) - IMATINIB - LOW TO INTERMEDIATE RISK - IMATINIB 400MG ORALLY DAILY	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
2671	CMU0975 A-II-b : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE - AGE	MEDICAL ONCOLOGY	24400	24400	24400	24400	24400	24400	24400	24400
2672	CMU0975 A-I-i-b : CHRONIC MYELOID LEUKEMIA (CML) - NILOTINIB - LOW TO INTERMEDIATE RISK - NILOTINIB 300MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
2673	CMU0975 A-II-c : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE 2 - AGE	MEDICAL ONCOLOGY	10900	10900	10900	10900	10900	10900	10900	10900
2674	CMU0975 A-II-d : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE (HIGH DOSE) - AGE	MEDICAL ONCOLOGY	17600	17600	17600	17600	17600	17600	17600	17600
2675	CMU0975 A-II-e : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE (HIGH DOSE) - AGE	MEDICAL ONCOLOGY	31100	31100	31100	31100	31100	31100	31100	31100
2676	CMU0975 A-II-f : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN (90MG) + CYTARABINE - AGE 60 YEARS, DAYS 1-3; DAUNORUBICIN 45-90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
2677	CMU0975 A-II-g : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE - AGE 60 YEARS, DAYS 1-3; IDARUBICIN 12MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	24400	24400	24400	24400	24400	24400	24400	24400
2678	CMU0975 A-II-h : ACUTE MYELOID LEUKEMIA (AML) - MITOXANTRONE + CYTARABINE - AGE 60 YEARS, DAYS 1-3; MITOXANTRONE 12MG/M2 IV), DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	10800	10800	10800	10800	10800	10800	10800	10800
2679	CMU0975 A-II-i : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE - AGE 60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-10; CYTARABINE 20MG SC TWICE DAILY	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
2680	CMU0975 A-III : CHRONICLYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2681	CMU0975 A-I-ii : CHRONICMYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2682	CMU0975 A-I-ii-a : CML - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - INDUCTION - 4 WEEKS OF STANDARD INDUCTION CHEMOTHERAPY - CYCLOPHOSPHAMIDE 1200 MG/M 2 (800 MG/M2 - OLDER THAN 60 Y) IV ON DAY 1 +DAUNORUBICIN 45 MG/M 2/DAY (30 MG/M 2/DAY - OLDER THAN 60 Y) IV ON DAYS 1-3 +VINCRISTINE 2 MG IV ON DAYS 1, 8, 15, AND 22 +PREDNISONE 60 MG/M 2/DAY PO ON DAYS 1-21 (DAYS 1-7- OLDER THAN 60 Y) + L-ASPARAGINASE 6000 U/M 2 SC ON DAYS 5, 8, 11, 15, 18, AND 22	MEDICAL ONCOLOGY	13500	13500	13500	13500	13500	13500	13500	13500
2683	CMU0975 A-III-a-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 1 - DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY	MEDICAL ONCOLOGY	1200	1200	1200	1200	1200	1200	1200	1200
2684	CMU0975 A-III-a-ii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 3 - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY	MEDICAL ONCOLOGY	21800	21800	21800	21800	21800	21800	21800	21800
2685	CMU0975 A-III-a-iii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 4-8 - DAY 1; RITUXIMAB 500MG/M2 IV, DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY.	MEDICAL ONCOLOGY	28100	28100	28100	28100	28100	28100	28100	28100
2686	CMU0975 A-III-a-iv : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - MAINTANANCE - RITUXIMAB - RITUXIMAB AT DOSE OF 375MG/M2 IV EVERY 2 MONTHS FOR 2 YEARS	MEDICAL ONCOLOGY	21700	21700	21700	21700	21700	21700	21700	21700
2687	CMU0975 A-III-b : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB DAY 1, 8, 15, AND 22 - DAY 1, 8, 15, AND 22; RITUXIMAB 375MG/M2/DAY IV.	MEDICAL ONCOLOGY	85500	85500	85500	85500	85500	85500	85500	85500
2688	CMU0975 A-I-ii-b : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - IMATINIB - IMATINIB 400MG ORALLY DAILY	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
2689	CMU0975 A-III-c : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - CHLORAMBUCIL - DAYS 1-28; CHLORAMBUCIL 0.4MG/KG/DAY WITH AN INCREASE TO 0.8MG/KG ORALLY DAILY. REPEAT CYCLE EVERY 28 DAYS FOR 12 CYCLES	MEDICAL ONCOLOGY	2500	2500	2500	2500	2500	2500	2500	2500
2690	CMU0975 A-I-ii-c : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
2691	CMU0975 A-III-d-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE + RITUXIMAB (CYCLE -1) - DAY 0; RITUXIMAB 375MG/M2 IV, DAYS 1 AND 2; BENDAMUSTINE 70MG/M2 IV. REPEAT NEXT CYCLE AFTER 28 DAYS	MEDICAL ONCOLOGY	31100	31100	31100	31100	31100	31100	31100	31100
2692	CMU0975 A-III-d-ii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE + RITUXIMAB (CYCLES 2-6) - RITUXIMAB 500MG/M2 ON DAY 1 AND BENDAMUSTINE - 90MG/M2. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE	MEDICAL ONCOLOGY	32300	32300	32300	32300	32300	32300	32300	32300
2693	CMU0975 A-III-d-iii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE (70MG) (CYCLE -1) - DAYS 1 AND 2; BENDAMUSTINE 70MG/M2 IV. REPEAT NEXT CYCLE AFTER 28 DAYS	MEDICAL ONCOLOGY	13100	13100	13100	13100	13100	13100	13100	13100
2694	CMU0975 A-III-d-iv : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE (90 MG) (CYCLES 2-6) - DAY 1 - BENDAMUSTINE 90MG/M2. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
2695	CMU0975 A-III-e : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - FLUDARABINE + CYCLOPHOSPHAMIDE + RITUXIMAB (FCR) - DAY 1; RITUXIMAB 375MG OR 500/M2 IV, DAYS 1-3; FLUDARABINE 25MG/M2/DAY IV PLUS CYCLOPHOSPHAMIDE 250MG/M2/DAY IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE	MEDICAL ONCOLOGY	27200	27200	27200	27200	27200	27200	27200	27200
2696	CMU0975 A-III-f : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - FLUDARABINE + RITUXIMAB (FR) - DAYS 1-5; FLUDARABINE 25MG/M2 IV, DAY 1; RITUXIMAB 50MG/M2 IV, DAY 3; RITUXIMAB 325MG/M2 IV, DAY 5; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES WITH RITUXIMAB GIVEN AT A DOSE OF 375MG/M2 ON DAY 1 OF SUBSEQUENT CYCLES.	MEDICAL ONCOLOGY	57800	57800	57800	57800	57800	57800	57800	57800
2697	CMU0975 A-III-g : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - ALEMTUZUMAB + RITUXIMAB - DAY 1; ALEMTUZUMAB 3MG IV, DAY 2; ALEMTUZUMAB 10MG IV, DAY 3, 10, 12, 17, 19, 24, AND 26; ALEMTUZUMAB 30MG IV	MEDICAL ONCOLOGY	92700	92700	92700	92700	92700	92700	92700	92700
2698	CMU0975 A-III-h : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - ALEMTUZUMAB WITHOUT RITUXIMAB - DAY 1; ALEMTUZUMAB 3MG IV, DAY 2; ALEMTUZUMAB 10MG IV, DAY 3, 10, 12, 17, 19, 24, AND 26; ALEMTUZUMAB 30MG IV	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
2699	CMU0975 A-III-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - HIGH-DOSE METHYLPREDNISOLONE + RITUXIMAB - DAYS 1-3; METHYLPREDNISOLONE 1G/M2 IV, DAYS 1, 8, 15, AND 22; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 3 CYCLES	MEDICAL ONCOLOGY	88400	88400	88400	88400	88400	88400	88400	88400
2700	CMU0975 A-I-iii : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2701	CMU0975 A-I-iii-a : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN (90MG/M2)+ CYTARABINE - < 60 YEARS, DAYS 1-3; DAUNORUBICIN 90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
2702	CMU0975 A-I-iii-b : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN + CYTARABINE + CLADRIBINE - AGE	MEDICAL ONCOLOGY	10900	10900	10900	10900	10900	10900	10900	10900
2703	CMU0975 A-I-iii-c : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN + CYTARABINE (HIGH DOSE) - AGE	MEDICAL ONCOLOGY	17600	17600	17600	17600	17600	17600	17600	17600
2704	CMU0975 A-I-iii-d : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN (90MG) + CYTARABINE - AGE >60 YEARS - DAYS 1-3; DAUNORUBICIN 45-90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	12900	12900	12900	12900	12900	12900	12900	12900
2705	CMU0975 A-I-iii-e : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IDARUBICIN + CYTARABINE (HIGH DOSE) - DAYS 1-3; IDARUBICIN 12MG/M2, DAYS 1-6; HIGH-DOSE CYTARABINE 2G/M2 IV EVERY 12 HOURS, OR DAYS 1-4; HIGH-DOSE CYTARABINE 3G/M2 IV EVERY 12 HOURS	MEDICAL ONCOLOGY	31100	31100	31100	31100	31100	31100	31100	31100
2706	CMU0975 A-I-iii-f : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IDARUBICIN + CYTARABINE - AGE 60 YEARS, DAYS 1-3; IDARUBICIN 12MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	24400	24400	24400	24400	24400	24400	24400	24400
2707	CMU0975 A-I-iii-g : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - MITOXANTRONE + CYTARABINE - AGE 60 YEARS, DAYS 1-3; MITOXANTRONE 12MG/M2 IV), DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV.	MEDICAL ONCOLOGY	11400	11400	11400	11400	11400	11400	11400	11400
2708	CMU0975 A-I-iii-h : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IMATINIB - IMATINIB 400MG ORALLY DAILY	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
2709	CMU0975 A-I-iii-i : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
2710	CMU0975 A-III-j : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - HIGH-DOSE METHYLPREDNISOLONE - DAYS 1-3; METHYLPREDNISOLONE 1G/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 3 CYCLES	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
2711	CMU0975 A-II-j : ACUTE MYELOID LEUKEMIA (AML) - DECITABINE - AGE 60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-5; DECITABINE 20MG/M2 IV FOR A 4-WEEK CYCLE.	MEDICAL ONCOLOGY	26300	26300	26300	26300	26300	26300	26300	26300
2712	CMU0975 A-II-k : ACUTE MYELOID LEUKEMIA (AML) - AZACYTIDINE - AGE 60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-7; 5-AZACYTIDINE 75MG/M2 IV EVERY 28 DAYS	MEDICAL ONCOLOGY	81400	81400	81400	81400	81400	81400	81400	81400
2713	CMU0975 A-II-l : ACUTE MYELOID LEUKEMIA (AML) - HYDROXYUREA - AGE 60 YEARS, HYDROXYUREA 10-70MG/KG/DAY ORALLY IN DIVIDED DOSES.	MEDICAL ONCOLOGY	1700	1700	1700	1700	1700	1700	1700	1700
2714	CMU0975 A-II-m : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE - HIGH DOSE - AGE	MEDICAL ONCOLOGY	10200	10200	10200	10200	10200	10200	10200	10200
2715	CMU0975 A-II-n : ACUTE MYELOID LEUKEMIA (AML) - CLADRIBINE + CYTARABINE + IDARUBICIN + GCSF - DAYS 1-5; CLADRIBINE 5MG/M2 IV, DAYS 1-5; CYTARABINE 2G/M2 IV, DAYS 0-5; GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) 300MCG SC, DAYS 1-3; IDARUBICIN 10MG/M2 IV.	MEDICAL ONCOLOGY	89400	89400	89400	89400	89400	89400	89400	89400
2716	CMU0975 A-II-o : ACUTE MYELOID LEUKEMIA (AML) - CLADRIBINE + CYTARABINE + MITOXANTRONE + GCSF - DAYS 1-5; CLADRIBINE 5MG/M2 IV, DAYS 1-5; CYTARABINE 2G/M2 IV, DAYS 0-5; GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) 300MCG SC, DAYS 1-3; MITOXANTRONE 10MG/M2 IV.	MEDICAL ONCOLOGY	42700	42700	42700	42700	42700	42700	42700	42700
2717	CMU0975 A-II-p : ACUTE MYELOID LEUKEMIA (AML) - FLUDARABINE + CYTARABINE + IDARUBICIN + GCSF -DAYS 1-5; FLUDARABINE 30MG/M2 IV OVER 0.5 HOURS, DAYS 1-5; CYTARABINE 2G/M2 IV OVER 4 HOURS, DAYS 0 TO POLYMORPHONUCLEAR RECOVERY (>0.5 X 109/L); G-CSF 5MCG/KG OR 300MCG/M2. (G-CSF MAY ALSO START ON DAY +6 UNTIL ENGRAFTMENT.) + DAYS 1-3; IDARUBICIN 10MG/M2 IV.	MEDICAL ONCOLOGY	70100	70100	70100	70100	70100	70100	70100	70100
2718	CMU0975 A-II-q : ACUTE MYELOID LEUKEMIA (AML) - ETOPOSIDE +CYTARABINE+MITOXANTRONE - ETOPOSIDE +CYTARABINE+MITOXANTRONE, DAYS 1-6; ETOPOSIDE 80MG/M2 IV OVER 1 HOUR, DAYS 1-6; CYTARABINE 1G/M2 IV OVER 6 HOURS + DAYS 1-6; MITOXANTRONE 6MG/M2 IV BOLUS	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
2719	CMU0975 A-II-r : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE SC - DAYS 1-10; CYTARABINE 20MG SC TWICE DAILY	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
2720	CMU0975 A-II-s : ACUTE MYELOID LEUKEMIA (AML) - AZACYTIDINE - DAYS 1-7; 5-AZACYTIDINE 75MG/M2 IV EVERY 28 DAYS	MEDICAL ONCOLOGY	81400	81400	81400	81400	81400	81400	81400	81400
2721	CMU0975 A-II-t : ACUTE MYELOID LEUKEMIA (AML) - DECITABINE - DAYS 1-5; DECITABINE 20MG/M2 IV EVERY 28 DAYS.	MEDICAL ONCOLOGY	26800	26800	26800	26800	26800	26800	26800	26800
2722	CMU0975 A-IV : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2723	CMU0975 A-IV-i : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2724	CMU0975 A-IV-i-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 INDUCTION PHASE; INDUCTION; 4 WEEKS OF STANDARD INDUCTION CHEMOTHERAPY; CYCLOPHOSPHAMIDE 1200 MG/M 2 (800 MG/M 2 IF PATIENTS OLDER THAN 60 Y) IV ON DAY 1 +DAUNORUBICIN 45 MG/M 2/DAY (30 MG/M 2/DAY IF PATIENTS OLDER THAN 60 Y) IV ON DAYS 1 - 3 +VINCRISTINE 2 MG IV ON DAYS 1, 8, 15, AND 22 +PREDNISONE 60 MG/M 2/DAY PO ON DAYS 1 - 21 (DAYS 1 - 7 IF PATIENTS OLDER THAN 60 Y);	MEDICAL ONCOLOGY	14000	14000	14000	14000	14000	14000	14000	14000
2725	CMU0975 A-IV-i-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 - (3 WEEKS); DAY 1 - METHOTREXATE (MTX) INTRATHECALLY (IT), ETOPOSIDE 100MG/M2/DAY INTRAVENOUSLY (IV), IFOSFAMIDE 3.4G/M2/DAY IV; DAYS 1 - 21 - IMATINIB 340MG/M2/DAY ORALLY; DAYS 6 - 15 - FILGRASTIM 5G/KG/DAY SUBCUTANEOUSLY (SC) +/- IMATINIB; DAYS 8 AND 15 - CNS LEUKEMIA ONLY - MTX IT, HYDROCORTISONE IT, CYTARABINE IT;	MEDICAL ONCOLOGY	18000	18000	18000	18000	18000	18000	18000	18000
2726	CMU0975 A-IV-i-a-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 (3 WEEKS); DAY 1 - AGE ADJUSTED - MTX IT, HYDROCORTISONE IT, CYTARABINE IT + MTX 5G/M2 IV OVER 24 HOURS; DAYS 1 - 21 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF PATIENT DOES NOT ACHIEVE COUNT RECOVERY WITHIN 2 WEEKS OF LAST DOSE OF PREVIOUS COURSE); DAYS 2 - 3 - LEUCOVORIN 75MG/M2 36 HOURS AFTER MTX, FOLLOWED BY 15MG/M2 IV OR ORALLY EVERY 6 HOURS FOR 6 DOSES + CYTARABINE 3G/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES; DAYS 4 - 13 - FILGRASTIM 5G/KG/DAY SC	MEDICAL ONCOLOGY	20200	20200	20200	20200	20200	20200	20200	20200
2727	CMU0975 A-IV-i-a-4 : ALL - PH(+) AYA - COG AALL-0031 REINDUCTION ; DAY 1 - VINCRISTINE 1.5MG/M2 IV + AGE ADJUSTED - MTX IT, HYDROCORTISONE IT, CYTARABINE IT; DAYS 1 - 2 - DAUNORUBICIN 45MG/M2/DAY IV BOLUS; DAYS 1 - 21 - DEXAMETHASONE 6MG/M2/DAY ORALLY +/- IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAYS 3 - 4 - CYCLOPHOSPHAMIDE 250MG/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES + MESNA 125MG/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES; DAYS 4, 6, 8, 10, 12, 15, 17, 19, AND 21 - L - ASPARAGINASE 6, 000 IU/M2 INTRAMUSCULARLY (IM); DAYS 5 - 14 - FILGRASTIM 5G/KG/DAY SC; DAYS 8 AND 15 - VINCRISTINE 1.5MG/M2 IV; DAY 15 - MTX IT, HYDROCORTISONE IT, CYTARABINE IT.	MEDICAL ONCOLOGY	26600	26600	26600	26600	26600	26600	26600	26600
2728	CMU0975 A-IV-i-a-5 : ALL - PH(+) AYA - COG AALL-0031 INTENSIFICATION; DAY 1 - MTX, HYDROCORTISONE, CYTARABINE - IT + MTX IV; DAYS 1-63 - IMATINIB ORAL; DAYS 2-3 - LEUCOVORIN ; DAY 8 - MTX IV; DAYS 9-10 - LEUCOVORIN; DAY 15 - MTX , HYDROCORTISONE , CYTARABINE - IT; DAYS 15-19 - ETOPOSIDE + CYCLOPHOSPHAMIDE + MESNA - IV; DAYS 20-29 - FILGRASTIM SC; DAYS 36-37 - CYTARABINE; DAY 37 - L - ASPARAGINASE IM +/- IMATINIB; DAYS 43-44 - CYTARABINE IV; DAY 44 - L - ASPARAGINASE IM +/- IMATINIB;	MEDICAL ONCOLOGY	43500	43500	43500	43500	43500	43500	43500	43500
2729	CMU0975 A-IV-i-a-6 : ALL - PH(+) AYA - COG AALL-0031 MAINTENANCE CYCLES 1-4 (8 WEEKS); DAY 1 - MTX, HYDROCORTISONE, CYTARABINE - IT + VINCRISTINE + MTX IV; DAYS 1 - 5 - DEXA; DAYS 1 - 56 - IMATINIB; DAY 2 - LEUCOVORIN 36 HOURS AFTER MTX; DAYS 8, 15, AND 22 - MTX ORAL; DAYS 8 - 28 - 6-MP; DAY 29 - MTX, HYDROCORTISONE, CYTARABINE - IT + VINCRISTINE IV; DAYS 29 - 33 - DEXA; DAYS 29 - 40 - IMATINIB; DAYS 36 - 40 - ETOPOSIDE + CYCLOPHOSPHAMIDE IV; DAYS 41 - 50 - FILGRASTIM SC;	MEDICAL ONCOLOGY	37400	37400	37400	37400	37400	37400	37400	37400
2730	CMU0975 A-IV-i-a-7 : ALL - PH(+) AYA -COG AALL-0031 MAINTENANCE CYCLES 5-12 (8 WEEKS); CYCLE 5 ONLY - CRANIAL IRRADIATION 12 GY; DAY 1 - VINCRISTINE 1.5MG/M2 IV; DAYS 1 - 5 - DEXAMETHASONE 6MG/M2/DAY ORALLY; DAYS 1 - 14 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAYS 8, 15, AND 22 - MTX 20MG/M2/WEEK ORALLY; DAYS 8 - 28 - 6 - MP 75MG/M2/DAY; DAY 29 - VINCRISTINE 1.5MG/M2 IV; DAYS 29 - 33 - DEXAMETHASONE 6MG/M2/DAY ORALLY; DAYS 29 - 42 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAY 36 - MTX 20MG/M2/WEEK ORALLY; DAYS 36 - 56 - 6 - MP 75MG/M2/DAY; DAYS 43 AND 50 - MTX 20MG/M2/WEEK ORALLY;	MEDICAL ONCOLOGY	13500	13500	13500	13500	13500	13500	13500	13500
2731	CMU0975 A-IV-i-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 (CYCLES 1 AND 3 ONLY) - RITUXIMAB 375MG/M2 IV.	MEDICAL ONCOLOGY	62400	62400	62400	62400	62400	62400	62400	62400
2732	CMU0975 A-IV-i-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4); HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	65500	65500	65500	65500	65500	65500	65500	65500
2733	CMU0975 A-IV-i-b-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
2734	CMU0975 A-IV-i-b-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8	MEDICAL ONCOLOGY	14100	14100	14100	14100	14100	14100	14100	14100
2735	CMU0975 A-IV-i-b-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION II - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 8 - 63 - IMATINIB 600MG ORALLY; DAY 29 - MTX 15MG IT, CYTARABINE 40MG IT, DEXAMETHASONE 4MG IT	MEDICAL ONCOLOGY	15900	15900	15900	15900	15900	15900	15900	15900
2736	CMU0975 A-IV-i-b-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION III - PRETREATMENT FOR 7 DAYS - PREDNISONE AT INCREASING DOSES FROM 10 - 40MG/M2/DAY; DAYS 1 - 45 - IMATINIB 800MG ORALLY DAILY + PREDNISONE 40MG/M2 DAILY	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
2737	CMU0975 A-IV-i-b-7 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) MAINTENANCE - MTX WEEKLY + 6 - MP DAILY + VINCRISTINE PULSE MONTHLY + PREDNISONE PULSE MONTHLY FOR 2 TO 3 YEARS.	MEDICAL ONCOLOGY	10400	10400	10400	10400	10400	10400	10400	10400
2738	CMU0975 A-IV-i-c-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS INDUCTION PHASE - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAYS 8 - 63 - IMATINIB 600MG ORALLY DAILY; DAY 29 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT.	MEDICAL ONCOLOGY	15900	15900	15900	15900	15900	15900	15900	15900
2739	CMU0975 A-IV-i-c-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION I - DAY 1 - MTX 1G/M2 IV OVER 24 HOURS + MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; DAYS 1 - 3 - METHYLPREDNISOLONE 50MG IV OVER 1 HOUR × 2 DOSES; DAYS 2 AND 3 - CYTARABINE 2G/M2 IV OVER 3 HOURS; REPEAT FOR 4 CYCLES.	MEDICAL ONCOLOGY	8900	8900	8900	8900	8900	8900	8900	8900
2740	CMU0975 A-IV-i-c-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION II - DAY 1 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; REPEAT FOR 4 CYCLES; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY.	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
2741	CMU0975 A-IV-i-c-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS MAINTENANCE - DAY 1 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 5 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY; REPEAT EVERY 4 WEEKS UP TO 2 YEARS FROM THE DATE OF COMPLETE REMISSION.	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
2742	CMU0975 A-IV-i-c-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - IMATINIB - IMATINIB 400MG ORALLY DAILY	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
2743	CMU0975 A-IV-i-c-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
2744	CMU0975 A-IV-ii : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2745	CMU0975 A-IV-ii-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	62400	62400	62400	62400	62400	62400	62400	62400
2746	CMU0975 A-IV-ii-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	65500	65500	65500	65500	65500	65500	65500	65500
2747	CMU0975 A-IV-ii-a-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
2748	CMU0975 A-IV-ii-a-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES	MEDICAL ONCOLOGY	14100	14100	14100	14100	14100	14100	14100	14100
2749	CMU0975 A-IV-ii-a-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION II - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 8 - 63 - IMATINIB 600MG ORALLY; DAY 29 - MTX 15MG IT, CYTARABINE 40MG IT, DEXAMETHASONE 4MG IT.	MEDICAL ONCOLOGY	15900	15900	15900	15900	15900	15900	15900	15900
2750	CMU0975 A-IV-ii-a-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION III - PRETREATMENT FOR 7 DAYS - PREDNISONE AT INCREASING DOSES FROM 10 - 40MG/M2/DAY; DAYS 1 - 45 - IMATINIB 800MG ORALLY DAILY + PREDNISONE 40MG/M2 DAILY	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
2751	CMU0975 A-IV-ii-a-7 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) MAINTENANCE - MTX WEEKLY + 6 - MP DAILY + VINCRISTINE PULSE MONTHLY + PREDNISONE PULSE MONTHLY FOR 2 TO 3 YEARS.	MEDICAL ONCOLOGY	10400	10400	10400	10400	10400	10400	10400	10400
2752	CMU0975 A-IV-ii-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS INDUCTION PHASE - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAYS 8 - 63 - IMATINIB 600MG ORALLY DAILY; DAY 29 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT.	MEDICAL ONCOLOGY	16400	16400	16400	16400	16400	16400	16400	16400
2753	CMU0975 A-IV-ii-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION I - DAY 1 - MTX 1G/M2 IV OVER 24 HOURS + MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; DAYS 1 - 3 - METHYLPREDNISOLONE 50MG IV OVER 1 HOUR × 2 DOSES; DAYS 2 AND 3 - CYTARABINE 2G/M2 IV OVER 3 HOURS; REPEAT FOR 4 CYCLES.	MEDICAL ONCOLOGY	12700	12700	12700	12700	12700	12700	12700	12700
2754	CMU0975 A-IV-ii-b-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION II - DAY 1 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; REPEAT FOR 4 CYCLES; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY.	MEDICAL ONCOLOGY	3400	3400	3400	3400	3400	3400	3400	3400
2755	CMU0975 A-IV-ii-b-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS MAINTENANCE - DAY 1 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 5 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY; REPEAT EVERY 4 WEEKS UP TO 2 YEARS FROM THE DATE OF COMPLETE REMISSION.	MEDICAL ONCOLOGY	6700	6700	6700	6700	6700	6700	6700	6700
2756	CMU0975 A-IV-ii-b-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - IMATINIB - IMATINIB 400MG ORALLY DAILY	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
2757	CMU0975 A-IV-ii-b-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
2758	CMU0975 A-IV-ii-c : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CORTICOSTEROIDS + TKIS - PRETREATMENT	MEDICAL ONCOLOGY	9500	9500	9500	9500	9500	9500	9500	9500
2759	CMU0975 A-IV-iii : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2760	CMU0975 A-IV-iii-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 INDUCTION - CORTICOSTEROID PRE-PHASE - 1-7 DAYS BEFORE INDUCTION THERAPY; PREDNISONE 60MG/M2/DAY, 4-7 DAYS BEFORE INDUCTION THERAPY; MTX 15MG IT. INDUCTION I - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2/DAY + VINCRISTINE 2MG IV, DAYS 1-3; DAUNORUBICIN 50MG/M2/DAY, DAYS 1-14; PREDNISONE 60MG/M2/DAY, DAY 8; VINCRISTINE 2MG IV + L-ASPARAGINASE 6, 000IU/M2/DAY, DAYS 10 AND 12; L-ASPARAGINASE 6, 000IU/M2/DAY, DAY 15; VINCRISTINE 2MG IV, DAY 15; FOR GOOD EARLY RESPONDERS; CYCLOPHOSPHAMIDE 750MG/M2/DAY.	MEDICAL ONCOLOGY	16500	16500	16500	16500	16500	16500	16500	16500
2761	CMU0975 A-IV-iii-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 SALVAGE - DAYS 1-3; IDARUBICIN 12MG/M2/DAY, DAYS 1-4; CYTARABINE 2G/M2/12 HOURS, DAY 9; FILGRASTIM TO MYELOID RECOVERY.	MEDICAL ONCOLOGY	30200	30200	30200	30200	30200	30200	30200	30200
2762	CMU0975 A-IV-iii-a-3 : ALL - PH(-) AYA - GRAALL-2003 CONSOLIDATION - BLOCKS 1, 4, AND 7; - DAYS 1 AND 2; CYTARABINE 2G/M2/12 HOURS + DEXAMETHASONE 10MG/12 HOURS, DAY 3; L-ASPARAGINASE 10, 000IU/M2/DAY, DAYS 7-13; FILGRASTIM TO MYELOID RECOVERY. BLOCKS 2, 5, AND 8 - DAY 15; MTX 3G/M2 CONTINUOUS INFUSION + VINCRISTINE 2MG IV + 6-MP 60MG/M2/DAY, DAY 16; L-ASPARAGINASE 10, 000IU/M2/DAY, DAYS 16-21; 6-MP 60MG/M2/DAY, DAYS 22-27; FILGRASTIM TO MYELOID RECOVERY. BLOCKS 3, 6, AND 9 - DAY 29; MTX 25MG/M2/DAY, DAYS 29 AND 30; CYCLOPHOSPHAMIDE 500MG/M2/DAY + ETOPOSIDE 75MG/M2/DAY, DAY 31; FILGRASTIM TO MYELOID RECOVERY. TO BE APPROVED 3 TIMES (BLOCKS - 1, 2, 3; BLOCKS - 4, 5, 6; BLOCKS - 7, 8, 9	MEDICAL ONCOLOGY	32300	32300	32300	32300	32300	32300	32300	32300
2763	CMU0975 A-IV-iii-a-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 LATE INTENSIFICATION BETWEEN CONSOLIDATION BLOCKS 6 AND 7 (FOR PATIENTS IN COMPLETE REMISSION [CR] AFTER THE FIRST INDUCTION COURSE) - DAY 1; VINCRISTINE 2MG IV, DAYS 1-3; DAUNORUBICIN 30MG/M2/DAY, DAYS 1-14; PREDNISONE 60MG/M2/DAY	MEDICAL ONCOLOGY	16300	16300	16300	16300	16300	16300	16300	16300
2764	CMU0975 A-IV-iii-a-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 LATE INTENSIFICATION BETWEEN CONSOLIDATION BLOCKS 6 AND 7 (FOR PATIENTS IN CR AFTER SALVAGE COURSE) - DAYS 1-3; IDARUBICIN 9MG/M2/DAY, DAYS 1-4; CYTARABINE 2G/M2/12 HOURS, DAY 9; FILGRASTIM TO MYELOID RECOVERY.	MEDICAL ONCOLOGY	28600	28600	28600	28600	28600	28600	28600	28600
2765	CMU0975 A-IV-iii-a-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 MAINTENANCE	MEDICAL ONCOLOGY	59800	59800	59800	59800	59800	59800	59800	59800
2766	CMU0975 A-IV-iii-b : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CNS THERAPY-TREATMENT OF PATIENTS WITH INITIAL CNS INVOLVEMENT	MEDICAL ONCOLOGY	22200	22200	22200	22200	22200	22200	22200	22200
2767	CMU0975 A-IV-iii-v : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CCG-1961	MEDICAL ONCOLOGY	19200	19200	19200	19200	19200	19200	19200	19200
2768	CMU0975 A-IV-iv : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2769	CMU0975 A-IV-iv-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CALGB 8811 (LARSON REGIMEN) INDUCTION	MEDICAL ONCOLOGY	19000	19000	19000	19000	19000	19000	19000	19000
2770	CMU0975 A-IV-iv-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CALGB 8811 (LARSON REGIMEN) CONSOLIDATION	MEDICAL ONCOLOGY	17500	17500	17500	17500	17500	17500	17500	17500
2771	CMU0975 A-IV-iv-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - HYPER-CVAD WITH OR WITHOUT RITUXIMAB CYCLE 1, 3, 5, 7 - DAYS 1 - 3 - CYCLOPHOSPHAMIDE IV EVERY 12 HOURS + MESNA CONTINUOUS IV INFUSION STARTING 1 HOUR BEFORE CYCLOPHOSPHAMIDE UNTIL 12 HOURS AFTER COMPLETION OF CYCLOPHOSPHAMIDE; DAYS 1 - 4 AND 11 - 14 - DEXAMETHASONE ORALLY DAILY, +/-; DAYS 1 AND 8 - RITUXIMABIV; DAY 4 - DOXORUBICIN IV OVER 24 HOURS; DAYS 4 AND 11 - VINCRISTINE IV	MEDICAL ONCOLOGY	64000	64000	64000	64000	64000	64000	64000	64000
2772	CMU0975 A-IV-iv-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - HYPER-CVAD WITH OR WITHOUT RITUXIMAB CYCLE 2, 4, 6, 8 - DAY 1 - METHOTREXATE IV OVER 2 HOURS FOLLOWED BY CONTINUOUS IV INFUSION OVER 22 HOURS FOLLOWED BY LEUCOVORIN IV EVERY 6 HOURS STARTING 12 HOURS AFTER COMPLETION OF MTX; DAYS 2 - 3 - CYTARABINE (IV OVER 2 HOURS EVERY 12 HOURS, +/-; DAYS 1 AND 8 - RITUXIMAB 375MG/M2 IV; CNS PROPHYLAXIS; DAY 2 - METHOTREXATE 12MG IT; DAY 8 - CYTARABINE 100MG IT.	MEDICAL ONCOLOGY	59700	59700	59700	59700	59700	59700	59700	59700
2773	CMU0976 A : ALL LYMPHOMACHEMOTHERAPHY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2774	CMU0976 A-I : HODGKINS LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2775	CMU0976 A-I-a : HODGKINSLYMPHOMA - ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES. REPEAT CYCLE EVERY 4 WEEKS FOR 2-4 CYCLES OR UPTO 6 CYCLES - MAY BE FOLLOWED BY ESCALATED BEACOPP	MEDICAL ONCOLOGY	4700	4700	4700	4700	4700	4700	4700	4700
2776	CMU0976 A-I-b : HODGKINSLYMPHOMA - ESCALATED BEACOPP - DAY 1; CYCLOPHOSPHAMIDE 1, 250MG/M2 IV OVER 60 MINUTES + DOXORUBICIN 35MG/M2 IV PUSH, DAYS 1-3; ETOPOSIDE 200MG/M2 IV OVER 2 HOURS	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
2777	CMU0976 A-I-c : HODGKINSLYMPHOMA - ABVD + RITUXIMAB (CYLED EVERY 4 WEEKS) -	MEDICAL ONCOLOGY	24300	24300	24300	24300	24300	24300	24300	24300
2778	CMU0976 A-I-d-i : HODGKINS LYMPHOMA - ABVD + RITUXIMAB (1 CYCLE - WEEKLY RITUXIMAB 4 DOSES) FOLLOWED BY ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES, DAYS 1, 8, 15, AND 22; RITUXIMAB 375MG/M2 IV FOR CYCLE 1 ONLY. REPEAT ABVD CYCLE EVERY 4 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION (OR ) 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION	MEDICAL ONCOLOGY	87200	87200	87200	87200	87200	87200	87200	87200
2779	CMU0976 A-I-d-ii : HODGKINS LYMPHOMA - ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES. REPEAT CYCLE EVERY 4 WEEKS FOR 2-4 CYCLES OR UPTO 6 CYCLES - MAY BE FOLLOWED BY ESCALATED BEACOPP	MEDICAL ONCOLOGY	4700	4700	4700	4700	4700	4700	4700	4700
2780	CMU0976 A-I-e-i : HODGKINS LYMPHOMA - CHOP + RITUXIMAB - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, DAY 1; RITUXIMAB 375MG/M2 IV, REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	22800	22800	22800	22800	22800	22800	22800	22800
2781	CMU0976 A-I-e-ii : HODGKINS LYMPHOMA - CHOP - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
2782	CMU0976 A-I-f-i : HODGKINS LYMPHOMA - CVP +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	22000	22000	22000	22000	22000	22000	22000	22000
2783	CMU0976 A-I-f-ii : HODGKINS LYMPHOMA - CVP - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
2784	CMU0976 A-I-g : HODGKINSLYMPHOMA - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 7 DAYS FOR 4 WEEKS WITH OR WITHOUT MAINTENANCE RITUXIMAB (375MG/M2 IV ONCE WEEKLY FOR 4 WEEKS EVERY 6 MONTHS FOR UP TO 2 YEARS)	MEDICAL ONCOLOGY	21700	21700	21700	21700	21700	21700	21700	21700
2785	CMU0976 A-II : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2786	CMU0976 A-II-a : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BORTEZOMIB + DEXAMETHASONE - DAYS 1, 4, 8, AND 11; BORTEZOMIB 1.3MG/M2 IV, DAYS 1, 4, 8, AND 11; DEXAMETHASONE 40MG IV. REPEAT FOR 4 CONSECUTIVE CYCLES AS INDUCTION THERAPY AND FOLLOW WITH 4 MAINTENANCE CYCLES, EACH GIVEN 3 MONTHS APART.	MEDICAL ONCOLOGY	57900	57900	57900	57900	57900	57900	57900	57900
2787	CMU0976 A-II-b : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE + RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 IV + DOXORUBICIN 50MG/M2 IV + VINCRISTINE 1.4MG/M2 (MAX 2MG) IV + RITUXIMAB 375MG/M2 IV, DAYS 1-5; PREDNISONE 100MG ORALLY. REPEAT EVERY 3 WEEKS FOR 6 CYCLES	MEDICAL ONCOLOGY	22800	22800	22800	22800	22800	22800	22800	22800
2788	CMU0976 A-II-c : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 7 DAYS FOR 4 WEEKS	MEDICAL ONCOLOGY	21700	21700	21700	21700	21700	21700	21700	21700
2789	CMU0976 A-II-d : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - RITUXIMAB + CYCLOPHOSPHAMIDE + PREDNISONE - DAY 1; RITUXIMAB 375MG/M2 IV + CYCLOPHOSPHAMIDE 1, 000MG/M2 IV, DAYS 1-5; PREDNISONE 100MG ORALLY. REPEAT EVERY 21 DAYS FOR 6 CYCLES	MEDICAL ONCOLOGY	21900	21900	21900	21900	21900	21900	21900	21900
2790	CMU0976 A-II-e : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - RITUXIMAB + CYCLOPHOSPHAMIDE + DEXAMETHASONE - DAY 1; DEXAMETHASONE 20MG IV FOLLOWED BY RITUXIMAB 375MG/M2 IV, DAYS 1-5; CYCLOPHOSPHAMIDE 100MG/M2 ORALLY TWICE DAILY. REPEAT EVERY 21 DAYS FOR 6 MONTHS	MEDICAL ONCOLOGY	21700	21700	21700	21700	21700	21700	21700	21700
2791	CMU0976 A-II-f-i : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB (WEEKS 1 AND 2) - THALIDOMIDE 200MG ORALLY DAILY	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
2792	CMU0976 A-II-f-ii : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB (WEEKS 3-50) - THALIDOMIDE 400MG ORALLY DAILY	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
2793	CMU0976 A-II-f-iii : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB (WEEKS 50-52) - THALIDOMIDE 400MG ORALLY DAILY	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
2794	CMU0976 A-II-f-iv : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB WEEKS 2-5 AND 13-16 - RITUXIMAB 375MG/M2 IV ONCE WEEKLY FOR A TOTAL OF 8 INFUSIONS AS ADD-ON	MEDICAL ONCOLOGY	20400	20400	20400	20400	20400	20400	20400	20400
2795	CMU0976 A-II-g-i : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BENDAMUSTINE WITH OR WITHOUT RITUXIMAB DAYS 1-2; BENDAMUSTINE 90MG/M2 IV, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 4 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	31100	31100	31100	31100	31100	31100	31100	31100
2796	CMU0976 A-II-g-ii : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BENDAMUSTINE - RITUXIMAB - DAYS 1-2; BENDAMUSTINE 90MG/M2 IV, REPEAT EVERY 4 WEEKS FOR 4 CYCLES.	MEDICAL ONCOLOGY	13100	13100	13100	13100	13100	13100	13100	13100
2797	CMU0976 A-II-h-i : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CLADRIBINE WITH OR WITHOUT RITUXIMAB - DAYS 1-5; CLADRIBINE 0.1MG/KG SUBCUTANEOUS INJECTION, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 4 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	27500	27500	27500	27500	27500	27500	27500	27500
2798	CMU0976 A-II-h-ii : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CLADRIBINE - RITUXIMAB - DAYS 1-5; CLADRIBINE 0.1MG/KG SUBCUTANEOUS INJECTION. REPEAT EVERY 4 WEEKS FOR 4 CYCLES	MEDICAL ONCOLOGY	8700	8700	8700	8700	8700	8700	8700	8700
2799	CMU0976 A-III : NON HODGKINS LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2800	CMU0976 A-II-i : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BENDAMUSTINE - DAYS 1-2; BENDAMUSTINE 90MG/M2 IV	MEDICAL ONCOLOGY	13100	13100	13100	13100	13100	13100	13100	13100
2801	CMU0976 A-III-i : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2802	CMU0976 A-III-i-a-1 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLE 1 - DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS, DAYS 1-5; CYCLOPHOSPHAMIDE 200MG/M2 IV, DAYS 1-7; PREDNISONE 60MG/M2 ORALLY.	MEDICAL ONCOLOGY	9400	9400	9400	9400	9400	9400	9400	9400
2803	CMU0976 A-III-i-a-2 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLES 2 (BEGINNING DAY 8) - DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS PROPHYLAXIS - DAYS 1-5; IFOSFAMIDE 800MG/M2 IV + DEXAMETHASONE 10MG/M2 IV	MEDICAL ONCOLOGY	69400	69400	69400	69400	69400	69400	69400	69400
2804	CMU0976 A-III-i-a-3 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLES 3, 5, AND 7 - DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS PROPHYLAXIS, DAYS 1-5; CYCLOPHOSPHAMIDE 200MG/M2 IV + DEXAMETHASONE 10MG/M2 IV	MEDICAL ONCOLOGY	34800	34800	34800	34800	34800	34800	34800	34800
2805	CMU0976 A-III-i-a-4 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLES 4, AND 6. DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS PROPHYLAXIS, DAYS 1-5; IFOSFAMIDE 800MG/M2 IV + DEXAMETHASONE 10MG/M2 IV, DAY 1; METHOTREXATE 1.5G/M2 IV (WITH LEUCOVORIN RESCUE) + VINCRISTINE 2MG IV, DAYS 4 AND 5; CYTARABINE 1G/M2 IV + ETOPOSIDE 80MG/M2 IV, DAY 8; 375MG/M2 IV. DELIVER CYCLES EVERY 21 DAYS.	MEDICAL ONCOLOGY	38200	38200	38200	38200	38200	38200	38200	38200
2806	CMU0976 A-III-i-b : NHL - BURKITT LYMPHOMA - CODOX-M (ORIGINAL OR MODIFIED) (CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE WITH INTRATHECAL MTX + CYTARABINE, FOLLOWED BY SYSTEMIC MTX AND CYTARABINE) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE + DOXORUBICIN, DAYS 2-5; CYCLOPHOSPHAMIDE IV, DAYS 1, 3; CYTARABINE INTRATHECAL, DAYS 1, 8; VINCRISTINE IV, DAY 10; MTX IV 1 HOUR, THEN INFUSION OVER 23 HOURS, DAY 11; LEUCOVORIN IV, EVERY 6 HOURS, DAY 13; G-CSF SC DAILY, DAY 15; MTX INTRATHECAL	MEDICAL ONCOLOGY	39800	39800	39800	39800	39800	39800	39800	39800
2807	CMU0976 A-III-i-c-1 : NHL - BURKITT LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 1 & 2) - DAY 1; RITUXIMAB 375MG/M2 IV DAYS 1-4; ETOPOSIDE 50MG/M2 IV INFUSION + DOXORUBICIN 10MG/M2 IV INFUSION + VINCRISTINE 0.4MG/M2 IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORAL BD, DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL	MEDICAL ONCOLOGY	28100	28100	28100	28100	28100	28100	28100	28100
2808	CMU0976 A-III-i-c-2 : NHL - BURKITT LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + MTX - IT+ RITUXIMAB (CYCLES 3-6) - DAY 1; RITUXIMAB 375MG/M2 IV DAYS 1-4; ETOPOSIDE 50MG/M2 IV INFUSION + DOXORUBICIN 10MG/M2 IV INFUSION + VINCRISTINE 0.4MG/M2 IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORAL BD. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG UNTIL ANC >5, 000/uL, DAYS 1 AND 5 ; MTX 12MG - IT REPEAT EVERY 3 WEEKS FOR 6 CYCLES	MEDICAL ONCOLOGY	27700	27700	27700	27700	27700	27700	27700	27700
2809	CMU0976 A-III-i-d-1 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	62400	62400	62400	62400	62400	62400	62400	62400
2810	CMU0976 A-III-i-d-2 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	65000	65000	65000	65000	65000	65000	65000	65000
2811	CMU0976 A-III-i-d-3 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY	MEDICAL ONCOLOGY	11500	11500	11500	11500	11500	11500	11500	11500
2812	CMU0976 A-III-i-d-4 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES	MEDICAL ONCOLOGY	13600	13600	13600	13600	13600	13600	13600	13600
2813	CMU0976 A-III-i-e-1 : NHL - BURKITT LYMPHOMA - CODOX-M ALTERNATED WITH IVAC- CODOX-M (ORIGINAL OR MODIFIED) - DAY 1- CYCLOPHOSPHAMIDE + DOXORUBICIN - IV, DAYS 2-5- CYCLOPHOSPHAMIDE IV, DAYS 1, 3- CYTARABINE IT, DAYS 1, 8; VINCRISTINE IV, DAY 10; MTX IV 1 HOUR, THEN INFUSION FOR 23 HOURS, DAY 11; LEUCOVORIN IV - 6TH HOURLY; DAY 13- G-CSF SC DAILY, DAY 15; MTX - IT DAY 16- LEUCOVORIN ORAL G, +/- DAY 1; RITUXIMAB IV. REPEAT FOR 4 CYCLES ALTERNATE BETWEEN CODOX-M AND IVAC	MEDICAL ONCOLOGY	39800	39800	39800	39800	39800	39800	39800	39800
2814	CMU0976 A-III-i-e-2 : NHL - BURKITT LYMPHOMA - CODOX-M ALTERNATED WITH IVAC - IVAC (IFOSFAMIDE + CYTARABINE + ETOPOSIDE) AND IT MTX +/- RITUXIMAB - DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES. DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, + MESNA 360MG/M2, DAY 5; MTX 12MG IT DAY 6; LEUCOVORIN 15MG ORAL - MTX, DAY 7; G-CSF 5uG/KG SC DAILY UNTIL GRANULOCYTE COUNT >/=1 X 109/L, +/- DAY 1; RITUXIMAB 375 MG/M2 IV. REPEAT FOR 4 CYCLES ALTERNATE BETWEEN CODOX-M AND IVAC.	MEDICAL ONCOLOGY	36500	36500	36500	36500	36500	36500	36500	36500
2815	CMU0976 A-III-i-f : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - RICE (RITUXIMAB + IFOSFAMIDE + CARBOPLATIN + ETOPOSIDE) - DAY 1; RITUXIMAB 375MG/M2 IV, DAY 2; IFOSFAMIDE 5, 000MG/M2 AND MESNA 5, 000MG/M2 IV + CARBOPLATIN AUC 5 MG / MIN/ML (MAXIMUM 800MG) IV, DAY 1-3; ETOPOSIDE 100MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS.	MEDICAL ONCOLOGY	28100	28100	28100	28100	28100	28100	28100	28100
2816	CMU0976 A-III-i-g : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - RIVAC (RITUXIMAB + IFOSFAMIDE + CYTARABINE + ETOPOSIDE) - DAY 1; RITUXIMAB 375MG/M2 IV, DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES, DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, +MESNA 360MG/M2, DAY 5; METHOTREXATE 12MG INTRATHECALLY	MEDICAL ONCOLOGY	37400	37400	37400	37400	37400	37400	37400	37400
2817	CMU0976 A-III-i-h : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - RGDP (RITUXIMAB + GEMCITABINE + DEXAMETHASONE + CISPLATIN) - DAY 1; RITUXIMAB 375MG/M2 IV, DAY 1 AND 8; GEMCITABINE 1, 000MG/M2 IV, DAY 1-3; CISPLATIN 25MG/M2 IV, DAY 1-4; DEXAMETHASONE 40MG IV. REPEAT CYCLE EVERY 3 WEEKS.	MEDICAL ONCOLOGY	27500	27500	27500	27500	27500	27500	27500	27500
2818	CMU0976 A-III-ii : NON HODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - NON HODGKIN LYMPHOMA -- ADULT T-CELL LEUKEMIA / LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2819	CMU0976 A-III-i-i : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - HDAC + RITUXIMAB - DAYS 1, 3, AND 5; HIGH-DOSE CYTARABINE 3G/M2 IV EVERY 12 HOURS, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT FOR 4 CYCLES	MEDICAL ONCOLOGY	23700	23700	23700	23700	23700	23700	23700	23700
2820	CMU0976 A-III-ii-a-1 : NON HODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - ZIDOVUDINE + ALPHA-INTERFERON (INDUCTION) - ZIDOVUDINE 1G ORALLY DAILY + ALPHA-INTERFERON 9 MILLION UNITS SC DAILY FOR 2 MONTHS, FOLLOWED BY MAINTENANCE THERAPY	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
2821	CMU0976 A-III-ii-a-2 : NON HODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - ZIDOVUDINE + ALPHA-INTERFERON (MAINTENANCE THERAPY) - ZIDOVUDINE 600MG ORALLY DAILY + ALPHA-INTERFERON 4.5 MILLION UNITS SC DAILY FOR 1 MONTH, REPEAT 12 MONTHS	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
2822	CMU0976 A-III-ii-b : NONHODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
2823	CMU0976 A-III-ii-c : NONHODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - CHOEP - DAYS 1-4; ETOPOSIDE 50MG/M2/DAY CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2/DAY CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2/DAY CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY DAILY, DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV OVER 15 MINUTES. REPEAT CYCLE EVERY 3 WEEKS FOR 6-8 CYCLES.	MEDICAL ONCOLOGY	9100	9100	9100	9100	9100	9100	9100	9100
2824	CMU0976 A-III-ii-d : NONHODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) - DAYS 1-4 - ETOPOSIDE 50MG/M2/DAY CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2/DAY CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2/DAY CONTINUOUS IV INFUSION, DAYS 1-5- PREDNISONE 60MG/M2 ORAL DAILY, DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV OVER 15 MINUTES. REPEAT CYCLE EVERY 3 WEEKS FOR 6-8 CYCLES. ADJUST DOSES BASED ON ANC.	MEDICAL ONCOLOGY	7300	7300	7300	7300	7300	7300	7300	7300
2825	CMU0976 A-III-iii : NONHODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2826	CMU0976 A-III-iii-a : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CDE (CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE) + RITUXIMAB - DAYS 1-4; CYCLOPHOSPHAMIDE 187.5-200MG/M2 IV + DOXORUBICIN 12.5MG/M2 IV + ETOPOSIDE 60MG/M2 IV, DAY 1; RITUXIMAB 375MG/M2 IV JUST BEFORE CDE REGIMEN. REPEAT CYCLE EVERY 4 WEEKS FOR A MAXIMUM OF 6 CYCLES.	MEDICAL ONCOLOGY	2600	2600	2600	2600	2600	2600	2600	2600
2827	CMU0976 A-III-iii-b-1 : NHL - DIFFUSE LARGE B CELL LYMPHOMA - CODOX-M ALTERNATED WITH IVAC (CODOX-M) CODOX-M (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE MTX ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYCLOPHOSPHAMIDE + DOXORUBICIN IV, DAYS 2-5; CYCLOPHOSPHAMIDE IV, DAYS 1, 3; CYTARABINE -IT, DAYS 1, 8-VINCRISTINE IV, DAY 10; MTX IV, DAY 11; LEUCOVORIN, DAY 13; G-CSF SC DAILY, DAY 15; MTX -IT, DAY 16; LEUCOVORIN ORAL, +/- DAY 1; RITUXIMAB IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS.	MEDICAL ONCOLOGY	49100	49100	49100	49100	49100	49100	49100	49100
2828	CMU0976 A-III-iii-b-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CODOX-M ALTERNATED WITH IVAC (IVAC) CODOX-M/IVAC (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE METHOTREXATE ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES. DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, +MESNA 360MG/M2, DAY 5; METHOTREXATE 12MG INTRATHECALLY, DAY 6; LEUCOVORIN 15MG ORALLY 24 HOURS AFTER INTRATHECAL MTX, DAY 7; G-CSF 5uG/KG SC DAILY UNTIL ABSOLUTE GRANULOCYTE COUNT >/=1 X 109/L, +/- DAY 1; RITUXIMAB 375 MG/M2 IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS.	MEDICAL ONCOLOGY	45000	45000	45000	45000	45000	45000	45000	45000
2829	CMU0976 A-III-iii-c-1 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 1&2) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL	MEDICAL ONCOLOGY	28100	28100	28100	28100	28100	28100	28100	28100
2830	CMU0976 A-III-iii-c-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 3-6) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL, DAYS 1 AND 5; METHOTREXATE 12MG INTRATHECALLY. REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES	MEDICAL ONCOLOGY	27700	27700	27700	27700	27700	27700	27700	27700
2831	CMU0976 A-III-iii-d-1 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	62400	62400	62400	62400	62400	62400	62400	62400
2832	CMU0976 A-III-iii-d-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	65000	65000	65000	65000	65000	65000	65000	65000
2833	CMU0976 A-III-iii-d-3 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY	MEDICAL ONCOLOGY	11500	11500	11500	11500	11500	11500	11500	11500
2834	CMU0976 A-III-iii-d-4 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES	MEDICAL ONCOLOGY	13600	13600	13600	13600	13600	13600	13600	13600
2835	CMU0976 A-III-iii-e-1 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (R-CHOP) RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, +/- DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	22800	22800	22800	22800	22800	22800	22800	22800
2836	CMU0976 A-III-iii-e-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
2837	CMU0976 A-III-iv : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2838	CMU0976 A-III-iv-a : NONHODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CDE (CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE) + RITUXIMAB - CDE (CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE) + RITUXIMAB - DAYS 1-4; CYCLOPHOSPHAMIDE 187.5-200MG/M2 IV + DOXORUBICIN 12.5MG/M2 IV + ETOPOSIDE 60MG/M2 IV, DAY 1; RITUXIMAB 375MG/M2 IV JUST BEFORE CDE REGIMEN. REPEAT CYCLE EVERY 4 WEEKS FOR A MAXIMUM OF 6 CYCLES.	MEDICAL ONCOLOGY	2600	2600	2600	2600	2600	2600	2600	2600
2839	CMU0976 A-III-iv-b-1 : NHL - AIDS-RELATED B-CELL LYMPHOMAS - CODOX-M ALTERNATED WITH IVAC (CODOX-M) (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE MTX ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYCLOPHOSPHAMIDE IV + DOXORUBICIN IV, DAYS 2-5; CYCLOPHOSPHAMIDE IV, DAYS 1 AND 3; CYTARABINE IT, DAYS 1 AND 8; VINCRISTINE IV, DAY 10; MTX IV OVER 1 HOUR, THEN IV INFUSION FOR 23 HOURS, DAY 11; LEUCOVORIN IV, FOLLOWED BY EVERY 6 HOURS, DAY 13; G-CSF SC DAILY UNTIL ABSOLUTE GRANULOCYTE COUNT >/=1 X 109/L, DAY 15; MTX IT, DAY 16; LEUCOVORIN 15MG ORAL, +/- DAY 1; RITUXIMAB IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS.	MEDICAL ONCOLOGY	49100	49100	49100	49100	49100	49100	49100	49100
2840	CMU0976 A-III-iv-b-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CODOX-M ALTERNATED WITH IVAC (IVAC) CODOX-M/IVAC (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE METHOTREXATE ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES. DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, +MESNA 360MG/M2, DAY 5; METHOTREXATE 12MG INTRATHECALLY, DAY 6; LEUCOVORIN 15MG ORALLY 24 HOURS AFTER INTRATHECAL MTX, DAY 7; G-CSF 5uG/KG SC DAILY UNTIL ABSOLUTE GRANULOCYTE COUNT >/=1 X 109/L, +/- DAY 1; RITUXIMAB 375 MG/M2 IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS.	MEDICAL ONCOLOGY	45000	45000	45000	45000	45000	45000	45000	45000
2841	CMU0976 A-III-iv-c-1 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 1&2) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL	MEDICAL ONCOLOGY	28100	28100	28100	28100	28100	28100	28100	28100
2842	CMU0976 A-III-iv-c-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 3-6) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL DAYS 1 AND 5; METHOTREXATE 12MG INTRATHECALLY. REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES	MEDICAL ONCOLOGY	27700	27700	27700	27700	27700	27700	27700	27700
2843	CMU0976 A-III-iv-d-1 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	62400	62400	62400	62400	62400	62400	62400	62400
2844	CMU0976 A-III-iv-d-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV	MEDICAL ONCOLOGY	65000	65000	65000	65000	65000	65000	65000	65000
2845	CMU0976 A-III-iv-d-3 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY	MEDICAL ONCOLOGY	11500	11500	11500	11500	11500	11500	11500	11500
2846	CMU0976 A-III-iv-d-4 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES	MEDICAL ONCOLOGY	13600	13600	13600	13600	13600	13600	13600	13600
2847	CMU0976 A-III-iv-e-1 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, +/- DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	22800	22800	22800	22800	22800	22800	22800	22800
2848	CMU0976 A-III-iv-e-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
2849	CMU0976 A-III-v : NON HODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2850	CMU0976 A-III-v-a-1 : NON HODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	22800	22800	22800	22800	22800	22800	22800	22800
2851	CMU0976 A-III-v-a-2 : NON HODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
2852	CMU0976 A-III-v-b : NONHODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 7 DAYS FOR 4 WEEKS	MEDICAL ONCOLOGY	21700	21700	21700	21700	21700	21700	21700	21700
2853	CMU0976 A-III-vi : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2854	CMU0976 A-III-vi-a-1 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - BENDAMUSTINE WITH OR WITHOUT RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1 AND 2; BENDAMUSTINE 90MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 TO 8 CYCLES	MEDICAL ONCOLOGY	31100	31100	31100	31100	31100	31100	31100	31100
2855	CMU0976 A-III-vi-a-2 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - BENDAMUSTINE (-) RITUXIMAB DAYS 1 AND 2; BENDAMUSTINE 90MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 TO 8 CYCLES	MEDICAL ONCOLOGY	13100	13100	13100	13100	13100	13100	13100	13100
2856	CMU0976 A-III-vi-b-1 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	22800	22800	22800	22800	22800	22800	22800	22800
2857	CMU0976 A-III-vi-b-2 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION.	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
2858	CMU0976 A-III-vi-c : NONHODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - CYCLOPHOSPHAMIDE + VINCRISTINE + PREDNISONE + RITUXIMAB (RCVP) - DAY 1;RITUXIMAB 375MG/M2 IV, CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 40MG/M2 ORALLY DAILY, REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES	MEDICAL ONCOLOGY	22000	22000	22000	22000	22000	22000	22000	22000
2859	CMU0976 A-III-vi-d : NONHODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 7 DAYS FOR 4 WEEKS	MEDICAL ONCOLOGY	21700	21700	21700	21700	21700	21700	21700	21700
2860	CMU0976 A-III-vi-e : NONHODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - LENALIDOMIDE + RITUXIMAB - DAYS 1-21; LENALIDOMIDE 25MG ORALLY DAILY, RITUXIMAB -APPLIED SEPARATELY ON DAYS 1, 8, 15, AND 22 AS AN ADDON	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
2861	CMU0976 A-III-vi-e1 : NONHODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - LENALIDOMIDE + RITUXIMAB - DAYS 1-21; LENALIDOMIDE 25MG ORALLY DAILY, RITUXIMAB -APPLIED SEPARATELY ON DAYS 1, 8, 15, AND 22 AS AN ADDON	MEDICAL ONCOLOGY	21700	21700	21700	21700	21700	21700	21700	21700
2862	CMU0976 A-III-vii : NONHODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2863	CMU0976 A-III-vii-a : NON HODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA - SMILE - DAY 1; METHOTREXATE 2G/M2 IV, DAYS 2-4; DEXAMETHASONE 40MG IV OR ORALLY + LEUCOVORIN 15MG × 4 DOSES/DAY IV OR ORALLY + IFOSFAMIDE 1500MG/M2 IV + ETOPOSIDE 100MG/M2 IV, DAYS 8, 10, 12, 14, 16, 18, AND 20; L-ASPARAGINASE 6000U/M2 IV. REPEAT EVERY 21 DAYS FOR 3 CYCLES.	MEDICAL ONCOLOGY	28900	28900	28900	28900	28900	28900	28900	28900
2864	CMU0976 A-III-vii-b : NON HODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA - DEVIC +RT - DAY 1; CARBOPLATIN 300MG/M2, DAYS 1-3; DEXAMETHASONE 40MG IV + ETOPOSIDE 100MG/M2 IV + IFOSFAMIDE 1.5MG/M2. REPEAT CHEMOTHERAPY EVERY 3 WEEKS FOR 3 CYCLES. RADIATION 50GY AND 3 COURSES OF DEVIC	MEDICAL ONCOLOGY	9600	9600	9600	9600	9600	9600	9600	9600
2865	CMU0976 A-III-vii-c : NON HODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA - VIPID - DAYS 1-3; ETOPOSIDE 100MG/M2 IV OVER 90 MINUTES + IFOSFAMIDE 1200MG/M2 IV OVER 1 HOUR + CISPLATIN 33MG/M2 IV OVER 1 HOUR + DEXAMETHASONE 40MG ORALLY OR IV. REPEAT CHEMOTHERAPY EVERY 3 WEEKS FOR 3 CYCLES	MEDICAL ONCOLOGY	7000	7000	7000	7000	7000	7000	7000	7000
2866	CMU0976 A-II-j : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CHLORAMBUCIL - DAYS 1-7; CHLORAMBUCIL 0.1MG/KG ORALLY DAILY OR 0.3MG/KG ORALLY DAILY. REPEAT EVERY 6 WEEKS.	MEDICAL ONCOLOGY	1100	1100	1100	1100	1100	1100	1100	1100
2867	CMU0976 A-II-k : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - FLUDARABINE - DAYS 1-5; FLUDARABINE 25MG/M2 IV DAILY. REPEAT EVERY 4 WEEKS FOR 5-6 CYCLES	MEDICAL ONCOLOGY	12700	12700	12700	12700	12700	12700	12700	12700
2868	CMU0976 A-II-l : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - FLUDARABINE + CYCLOPHOSPHAMIDE + RITUXIMAB (FCR) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 2-4; FLUDARABINE 25MG/M2/DAY IV +CYCLOPHOSPHAMIDE 250MG/M2/DAY IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES WITH	MEDICAL ONCOLOGY	27600	27600	27600	27600	27600	27600	27600	27600
2869	CMU0976 A-II-m : WALDENSTROM S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - ALEMTUZUMAB - ALEMTUZUMAB DOSES GRADUALLY ESCALATED OVER 1 WEEK (3, 10, AND 30 MG), FOLLOWED BY 36 ADDITIONAL TREATMENT-PHASE INFUSIONS AT 30-MG IV 3 TIMES WEEKLY FOR 12 WEEKS.	MEDICAL ONCOLOGY	2800	2800	2800	2800	2800	2800	2800	2800
2870	CMU0977 : MYELODYSPLASTIC SYNDROMES TREATMENT REGIMENS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2871	CMU0977 -i : SYMPTOMATICANEMIA WITH DEL(5Q) WITH OR WITHOUT OTHER CYTOGENETIC ABNORMALITIES	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2872	CMU0977 -i-a : SYMPTOMATIC ANEMIA WITH DEL(5Q) WITH OR WITHOUT OTHER CYTOGENETIC ABNORMALITIES - LENALIDOMIDE	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
2873	CMU0977 -ii : SYMPTOMATICANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2874	CMU0977 -ii-a-1 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - RHU-EPO WITH OR WITHOUT G-CSF	MEDICAL ONCOLOGY	26300	26300	26300	26300	26300	26300	26300	26300
2875	CMU0977 -ii-a-2 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - RHU-EPO (-) G-CSF	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
2876	CMU0977 -ii-b-1 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - DARBEPOETIN ALFA WITH OR WITHOUT G-CSF	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
2877	CMU0977 -ii-b-2 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - DARBEPOETIN ALFA (-) G-CSF	MEDICAL ONCOLOGY	9500	9500	9500	9500	9500	9500	9500	9500
2878	CMU0977 -iii : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2879	CMU0977 -iii-a-1 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST - DECITABINE (15MG/M2)	MEDICAL ONCOLOGY	16300	16300	16300	16300	16300	16300	16300	16300
2880	CMU0977 -iii-a-2 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST - DECITABINE (20MG/M2)	MEDICAL ONCOLOGY	17300	17300	17300	17300	17300	17300	17300	17300
2881	CMU0977 -iii-b : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST - LENALIDOMIDE	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
2882	CMU0978 : MULTIPLE MYELOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2883	CMU0978 -a : MULTIPLE MYELOMA - LENALIDOMIDE (28 DAYS) + DEXAMETHASONE	MEDICAL ONCOLOGY	7000	7000	7000	7000	7000	7000	7000	7000
2884	CMU0978 -b : MULTIPLE MYELOMA - LENALIDOMIDE (21 DAYS) + DEXAMETHASONE	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
2885	CMU0978 -c : MULTIPLE MYELOMA - LENALIDOMIDE	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
2886	CMU0978 -d : MULTIPLE MYELOMA - BENDAMUSTINE + LENALIDOMIDE + DEXAMETHASONE	MEDICAL ONCOLOGY	14300	14300	14300	14300	14300	14300	14300	14300
2887	CMU0978 -e : MULTIPLE MYELOMA - BENDAMUSTINE	MEDICAL ONCOLOGY	23100	23100	23100	23100	23100	23100	23100	23100
2888	CMU0978 -f : MULTIPLE MYELOMA - CYCLOPHOSPHAMIDE + LENALIDOMIDE + DEXAMETHASONE	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
2889	CMU0978 -g : MULTIPLE MYELOMA - DEXAMETHASONE + CYCLOPHOSPHAMIDE + ETOPOSIDE + CISPLATIN (DCEP)	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
2890	CMU0978 -h : MULTIPLE MYELOMA - DEXAMETHASONE + THALIDOMIDE + CISPLATIN + DOXORUBICIN + CYCLOPHOSPHAMIDE + ETOPOSIDE (DT-PACE)	MEDICAL ONCOLOGY	8100	8100	8100	8100	8100	8100	8100	8100
2891	CMU0978 -i : MULTIPLE MYELOMA - HIGH-DOSE CYCLOPHOSPHAMIDE	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
2892	CMU0978 -j : MULTIPLE MYELOMA - VAD / VAMP	MEDICAL ONCOLOGY	6400	6400	6400	6400	6400	6400	6400	6400
2893	CMU0978 -k : MULTIPLE MYELOMA - MELPHALAN	MEDICAL ONCOLOGY	4100	4100	4100	4100	4100	4100	4100	4100
2894	CMU0978 -l : MULTIPLE MYELOMA - MELPHALAN + PREDNISOLONE	MEDICAL ONCOLOGY	1200	1200	1200	1200	1200	1200	1200	1200
2895	CMU0978 -m : MULTIPLE MYELOMA - THALIDOMIDE + DEXAMETHASONE	MEDICAL ONCOLOGY	2500	2500	2500	2500	2500	2500	2500	2500
2896	CMU0978 -n : MULTIPLE MYELOMA - MELPHALAN / PREDNISOLONE/THALIDOMIDE(MPT)	MEDICAL ONCOLOGY	2400	2400	2400	2400	2400	2400	2400	2400
2897	CMU0978 -O : MULTIPLE MYELOMA - ZOLEDRONIC ACID	MEDICAL ONCOLOGY	2900	2900	2900	2900	2900	2900	2900	2900
2898	CMU0979 : ALL LYMPHOMA SALVAGE CHEMO (PACKAGE 953 TO BE UTILISED)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2899	CMU0980 : CHILDHOOD B CELL LYMPHOMA VARIABLE REGIMEN (PACKAGE 953 TO BE UTILISED)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
2942	CMU1010 : HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY	MEDICAL ONCOLOGY	100000	100000	100000	100000	100000	100000	100000	100000
2943	CMU1011 : HYPERTHERMIC INTRAPERITONEAL CATHETER INSERTION	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
2950	CMU1018 : CHEMOPORT - DEVICE WITH ACESSORIES AND MAINTENCE	MEDICAL ONCOLOGY	30000	30000	30000	30000	30000	30000	30000	30000
2954	CMU1020 : HEMATOLOGICAL AND ONCOLOGICAL EMERGENCIES ( SUPERIOR MEDIASTINAL SYNDROME, SUPERIOR VENA CAVA SYNDROME, HYPER LEUCOCYTOSIS, HYPERVISCOSITY DUE TO DYSPROTEINEMIA, VASO-OCCLUSIVE CRISIS)	MEDICAL ONCOLOGY	30000	30000	30000	30000	30000	30000	30000	30000
2955	CMU1021 : TUMOURLYSIS SYNDROME ( DRUGS AND MANAGEMENT WITHOUT DIALYSIS)	MEDICAL ONCOLOGY	20000	20000	20000	20000	20000	20000	20000	20000
2962	CMU1028 : INTRATHECAL CHEMOTHERAPY	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
3247	CMU1259 : Bone marrow aspiration of biopsy	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
3335	CMU1296-I : CT for CA Breast -Weekly Paclitaxel for Adjuvant Therapy Paclitaxel 80mg/m2 every week	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
3336	CMU1296-II : CT for CA Breast - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
3337	CMU1296-III : CT for CA Breast - Capecitabine for triple negative with residual disease after pre op taxane , alkylator, antracyclin. Capecitabine - 1000mg/m2 orally twice daily D1-D14 every 21 days	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400
3338	CMU1296-IV : CT for CA Breast - Carboplatin + Gemcitabine for her2 negative, unresectable or stage 4 -M1 disease. Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 2 D1 D8 Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 5-6 D1 only	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
3339	CMU1296-V : CT for CA Breast - Fulvestrant for ER-positive and or PR-positive, unresectable or stage -4-M1 disease. Fulvestrant 500 mg D1 D15 D28 then every 28 days. per dose13200 (39600 in cycle1 ) then 13200 per month - (per dose 45000 in cycle1 ) then 15000 per month	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
3340	CMU1296-VI : CT for CA Breast - Exemestane for ER-positive and or PR-positive, unresectable or stage -4-M1 disease. Exemestane 25 mg orally daily (q 3 monthsly)	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
3341	CMU1296-VII : CT for CA Breast - Lapatinib for her2 positive, unresectable or stage 4 -M1 disease. Lapatinib 500 mg BD orally , daily	MEDICAL ONCOLOGY	15050	15050	15050	15050	15050	15050	15050	15050
3342	CMU1297 : CT for Metastatic bone malignancy - Zoledronic Acid Zoledronic acid 4 mg IV Monthly	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
3343	CMU1298-I : CT for CA Ovary - Cisplatin + Irinotecan for Recurrent Platinum-Sensitive Epithelial cancer Cisplatin 60mg/m2 D1 Irinotecan 60 mg/m2 D1 D8 D15 every 28 days	MEDICAL ONCOLOGY	13050	13050	13050	13050	13050	13050	13050	13050
3344	CMU1298-II : CT for CA Ovary - Lipodox + Carboplatin Lipopdox 30 mg/m2 D1 Carboplatin AUC 5-6 D1 every 28 days	MEDICAL ONCOLOGY	17200	17200	17200	17200	17200	17200	17200	17200
3345	CMU1298-III : CT for CA Ovary - Etoposide for Recurrent Platinum-Resistant Epithelial Ovarian cancer Etoposide 50 mg/m2 OD D1-D21 every 28 days	MEDICAL ONCOLOGY	3400	3400	3400	3400	3400	3400	3400	3400
3346	CMU1298-IV : CT for CA Ovary - Irinotecan Recurrent Epithelial Ovarian cancer Irinotecan 60 -90 mg/m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	10950	10950	10950	10950	10950	10950	10950	10950
3347	CMU1298-IX : CT for CA Ovary - Letrozole Letrozole 2.5 mg orally daily (3 months)	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
3348	CMU1298-V : CT for CA Ovary - Lipodox for Recurrent Platinum-Resistant Epithelial Ovarian cancer Lipodox 40 mg/m2 IV every 28 days	MEDICAL ONCOLOGY	17950	17950	17950	17950	17950	17950	17950	17950
3349	CMU1298-VI : CT for CA Ovary - Carboplatin + Gemcitabine for Recurrent Platinum-Sensitive Epithelial Ovarian Cancer Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 2 D1 D8 Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 5-6 D1 only	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
3350	CMU1298-VII : CT for CA Ovary - Cyclophosphamide for Recurrent Epithelial Ovarian Cancer Cyclophosphamide 50 mg/m2 OD D1-D21 every 28 days	MEDICAL ONCOLOGY	2800	2800	2800	2800	2800	2800	2800	2800
3351	CMU1298-VIII : CT for CA Ovary - Tamoxifen Tamoxifem 20 mg orally daily (3 months)	MEDICAL ONCOLOGY	1200	1200	1200	1200	1200	1200	1200	1200
3352	CMU1298-X : CT for CA Ovary - Single agent Carboplatin Carboplatin AUC 5-6 D1 every 21 days ( maximum -6 cycle)	MEDICAL ONCOLOGY	7000	7000	7000	7000	7000	7000	7000	7000
3353	CMU1298-XI : CT for CA Ovary - Cisplatin Cisplatin 40 mg/m2 every week (maximum- 6 cycles)	MEDICAL ONCOLOGY	4100	4100	4100	4100	4100	4100	4100	4100
3354	CMU1299-I : CT for Germ Cell Tumor - Carboplatin (AUC 7) Carboplatin AUC 7 every 21 days	MEDICAL ONCOLOGY	7300	7300	7300	7300	7300	7300	7300	7300
3355	CMU1299-II : CT for Germ Cell Tumor - Etoposide + Cisplatin Cisplatin 20 mg/m2 IV D1-D5 Etoposide 100mg/m2 D1-D5 every 21 days	MEDICAL ONCOLOGY	10860	10860	10860	10860	10860	10860	10860	10860
3356	CMU1299-III : CT for Germ Cell Tumor - Gemcitabine + Oxaliplatin Gemcitabine 1000mg/m2 D1 D8 Oxaiplatin 130mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	17500	17500	17500	17500	17500	17500	17500	17500
3357	CMU1299-IV : CT for Germ Cell Tumor - Gemcitabine + Paclitaxel Gemcitabine 1000mg/m2 D1 D8 D15 Paclitaxel 100 mg/m2 D1 D8 D15 every 28 days	MEDICAL ONCOLOGY	17500	17500	17500	17500	17500	17500	17500	17500
3358	CMU1299-V : CT for Germ Cell Tumor - Paclitaxel + Ifosfamide + Cisplatin Paclitaxel 240 mg/m2 D1 Ifosfamide 1500mg/m2 D2-D5 Mesna 300 mg/m2 0h 4h 8h D2-D5 Cisplatin 25mg/m2 D2-D5 every 21 days	MEDICAL ONCOLOGY	24400	24400	24400	24400	24400	24400	24400	24400
3359	CMU1299-VI : CT for Germ Cell Tumor - Vinblastin + Ifosfamide + Cisplatin Vinblastine 0.11 mg/kg IV D1-D2 Mesna 240mg/m2 0h 4h 8h D1-D5 Ifosfamide 1200mg/m2 D1-D5 Cisplatin 20 mg/m2 D1-D5 every 21 days	MEDICAL ONCOLOGY	13600	13600	13600	13600	13600	13600	13600	13600
3360	CMU1300 : CT for Gestational Trophoblastic Neoplasia - Etoposide + Methotrexate + Dactinomycin + Cisplatin Etoposide 100mg/m2 IV D1 D2 D8 Dactinomycin 0.5 mg IV push D1 D2 Methotrexate 300 mg /m2 D1 Leucovorin 15 mg PO every 12 hrs for 4 doses Cisplatin 75mg/m2 D8 every 2 weeks	MEDICAL ONCOLOGY	12750	12750	12750	12750	12750	12750	12750	12750
3361	CMU1301 : CT for Cervical Cancer - Carboplatin + Paclitaxel (recurrent or metastatic) Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
3362	CMU1302-I : CT for Endometrial Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5 D1 every 21 days	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
3363	CMU1302-II : CT for Endometrial Cancer - Cisplatin + Doxorubicin Doxorubicin 60 mg/m2 D1 Cisplatin 50mg/m2 every 3 weeks	MEDICAL ONCOLOGY	4410	4410	4410	4410	4410	4410	4410	4410
3364	CMU1302-III : CT for Endometrial Cancer - Lipodox + Carboplatin Lipopdox 30 mg/m2 D1 Carboplatin AUC 5 D1 every 28 days	MEDICAL ONCOLOGY	17200	17200	17200	17200	17200	17200	17200	17200
3365	CMU1302-IV : CT for Endometrial Cancer - Carboplatin + Gemcitabine Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 2 D1 D8 Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 5-6 D1 only every 3 weeks	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
3366	CMU1302-V : CT for Endometrial Cancer - Anastrozole 1 mg orally daily (for 3 months)	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
3367	CMU1303 : CT for Vulvar Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5 D1 every 21 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
3368	CMU1304-I : CT for Ewing Sarcoma - Vincristine + Topotecan + Cyclophosphamide + Irinotecan + Temozolamide Vincristine 1.5mg/m2( day 1) Topotecan 1.5mg/m2 (day 1-5) Cyclophosphamide 250mg/m2 (days 1-5) Given every 3 weeks Irinotecan 10-50 mg/sqM days 1-5 and days 8-12 Temozolamide 100mg/m2 days 1-5 of each cycle every 3 weeks	MEDICAL ONCOLOGY	23160	23160	23160	23160	23160	23160	23160	23160
3369	CMU1304-II : CT for Ewing Sarcoma - VIE 4 cycles + VAC 6 cycles + VCD 4 cycles; VIE - Vincristine + Ifosfamide + Etoposide Vincristine 1.5mg/m2 (day 1, 8 and 15) Ifosfamide: 1800mg/m2 (days1-5) Etposide: 100mg/sq.m (days 1-5) Given every 3 weeks	MEDICAL ONCOLOGY	9900	9900	9900	9900	9900	9900	9900	9900
3370	CMU1304-III : CT for Ewing Sarcoma - Vincristine + Adriamycin + Cyclophosphamide Ifosfamide + Etoposide Ifosfamide: 1800mg/m2 (days1-5) Etposide: 100mg/sq.m (days 1-5) Given every 2-3 weekly Vincristine 1.5mg/m2 (day 1 and 8) Adriamyicn: 75mg/m2 (day 1) Cyclophosphamide 1200mg/m2 (day 1) Given 2-3 weekly	MEDICAL ONCOLOGY	12710	12710	12710	12710	12710	12710	12710	12710
3371	CMU1305-I : CT for Osteogenic Sarcoma - Doxorubicin + Cisplatin Cisplatin 100mg/m2 Doxorubicin 75mg/m2 given every 3 weeks	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
3372	CMU1305-II : CT for Osteogenic Sarcoma - Methotrexate + Doxorubicin + Cisplatin for Relapsed Osteogenic Sarcoma Cisplatin 120mg/sq.m Doxorubicin 75mg/m2 Methotrexate 8-12 gram/m2 Each cycle for 5 weeks	MEDICAL ONCOLOGY	27000	27000	27000	27000	27000	27000	27000	27000
3373	CMU1305-III : CT for Osteogenic Sarcoma - OGS - 12 Ifosfamide 1800 mg/m2 D1-D5 Mesna 600mg/m2 0h 3h 6h 9h D1-D5 Adriamycin 25mg/m2 D1- D3 Cisplatin 33 mg/m2 D1-D3 every 21 days	MEDICAL ONCOLOGY	29600	29600	29600	29600	29600	29600	29600	29600
3374	CMU1305-IV : CT for Osteogenic Sarcoma - OGS - 12 Ifosfamide 1800 mg/m2 D1-D5 Mesna 600mg/m2 0h 3h 6h 9h D1-D5 Cisplatin 33 mg/m2 D1-D3 every 21 days	MEDICAL ONCOLOGY	28600	28600	28600	28600	28600	28600	28600	28600
3375	CMU1306 : CT for Soft Tissue Sarcoma - Ifosfamide + Adriamycin Doxorubicin 30mg/m2 D1 D2 Ifosfamide 2000 to 3000mg/m2 Mesna 400 to 600 mg/m2 0h 4h 8h D1 - D3 Every 21 days	MEDICAL ONCOLOGY	13700	13700	13700	13700	13700	13700	13700	13700
3376	CMU1307-I : CT for Metastatic Melanoma - Dacarbazine + Cisplatin Dacarbazine 250mg/m2 D1-D5 Cisplatin 75 mg/m2 Every 21 days	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
3377	CMU1307-II : CT for Metastatic Melanoma - Temozolamide Temozolamide 200mg/m2 D1-D5 every 28 days	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
3378	CMU1307-III : CT for Metastatic Melanoma - Imatinib Tab Imatinib 400/800 mg daily	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
3379	CMU1308-I : CT for Anal Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
3380	CMU1308-II : CT for Anal Cancer - Cisplatin + Paclitaxel Paclitaxel 175 mg/m2 D1 Cisplatin 75mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	13300	13300	13300	13300	13300	13300	13300	13300
3381	CMU1309-I : CT for Colorectal Cancer - Capecitabine + Irinotecan Capecitabine 1000mg/m2 D1-D14 Irinotecan 200 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	12500	12500	12500	12500	12500	12500	12500	12500
3382	CMU1309-II : CT for Colorectal Cancer - 5FU + Leucovorin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Irinotecan 180mg/m2 85 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	9570	9570	9570	9570	9570	9570	9570	9570
3383	CMU1309-III : CT for Colorectal Cancer - 5FU + Leucovorin + Oxaliplatin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Irinotecan 180mg/m2 every 14 days	MEDICAL ONCOLOGY	18780	18780	18780	18780	18780	18780	18780	18780
3384	CMU1310 : CT for Esophageal Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
3385	CMU1311-I : CT for Esophageal / Stomach Cancer - Irinotecan Irinotecan 60- 90 mg/m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	10930	10930	10930	10930	10930	10930	10930	10930
3386	CMU1311-II : CT for Esophageal / Stomach Cancer - Docetaxel + Cisplatin + 5 FU Docetaxel 40mg/m2 D1 Cisplatin 40 mg/m2 D1 Leucovorin 400mg/m2 D1 5FU 1000mg/m2 D1 D2 every 14 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
3387	CMU1311-III : CT for Esophageal / Stomach Cancer - Docetaxel + Cisplatin + Capecitabine Docetaxel 40mg/m2 D1 Cisplatin 40 mg/m2 D1 Capecitabine 825mg/m2 twice daily every 14 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
3388	CMU1311-IV : CT for Esophageal / Stomach Cancer - Docetaxel + Oxaliplatin + 5 FU Docetaxel 50mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Leucovorin 400mg/m2 D1 5FU 1200mg/m2 D1 D2 every 14 days	MEDICAL ONCOLOGY	18500	18500	18500	18500	18500	18500	18500	18500
3389	CMU1311-V : CT for Esophageal / Stomach Cancer - Docetaxel + Oxaliplatin + Capecitabine Docetaxel 50mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Capecitabine 825 mg/m2 Twice daily every 14 days	MEDICAL ONCOLOGY	18500	18500	18500	18500	18500	18500	18500	18500
3390	CMU1311-VI : CT for Esophageal / Stomach Cancer - 5FU + Leucovorin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Irinotecan 180mg/m2 85 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	9570	9570	9570	9570	9570	9570	9570	9570
3391	CMU1311-VII : CT for Esophageal / Stomach Cancer - Paclitaxel Paclitaxel 80mg/m2 every week	MEDICAL ONCOLOGY	5990	5990	5990	5990	5990	5990	5990	5990
3392	CMU1312-I : CT for Hepatocellular Carcinoma - Doxorubicin (TACE) Doxorubicin 30-75 mg/m2 one course	MEDICAL ONCOLOGY	22500	22500	22500	22500	22500	22500	22500	22500
3393	CMU1312-II : CT for Hepatocellular Carcinoma - Lenvatinib 12 mg daily	MEDICAL ONCOLOGY	17000	17000	17000	17000	17000	17000	17000	17000
3394	CMU1313-I : CT for Panceratic Cancer - Gemcitabine + Nanopaclitaxel Gemcitabine 1000mg/m2 D1 D8 D16 Albumin bound Paclitaxel 125mg/m2 D1 D8 D15 every 28 days	MEDICAL ONCOLOGY	28380	28380	28380	28380	28380	28380	28380	28380
3395	CMU1313-II : CT for Panceratic Cancer - 5FU + Leucovorin + Oxaliplatin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Irinotecan 180mg/m2 every 14 days	MEDICAL ONCOLOGY	18880	18880	18880	18880	18880	18880	18880	18880
3396	CMU1313-III : CT for Panceratic Cancer - Capecitabine + Gemcitabine Gemcitabine 1000mg/m2 D1 D8 D15 Capecitabine 830mg/m2 twice daily D1-D21 every 28 days	MEDICAL ONCOLOGY	34130	34130	34130	34130	34130	34130	34130	34130
3397	CMU1314-I : CT for Gall Bladder Cancer / Cholangiocarcinoma - 5FU + Leucovorin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Irinotecan 180mg/m2 85 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	9620	9620	9620	9620	9620	9620	9620	9620
3398	CMU1314-II : CT for Gall Bladder Cancer / Cholangiocarcinoma - Gemcitabine Gemcitabine 300 mg/m2 D 1(weekly till RT ends)	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
3399	CMU1314-III : CT for Gall Bladder Cancer / Cholangiocarcinoma - Gemcitabine Gemcitabine 1000mg /m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	8980	8980	8980	8980	8980	8980	8980	8980
3400	CMU1314-IV : CT for Gall Bladder Cancer / Cholangiocarcinoma - Oxaliplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 Oxaliplatin 100 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	17400	17400	17400	17400	17400	17400	17400	17400
3401	CMU1314-V : CT for Gall Bladder Cancer / Cholangiocarcinoma - Capecitabine + Irinotecan Capecitabine 1000mg/m2 D1-D14 Irinotecan 200 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	12500	12500	12500	12500	12500	12500	12500	12500
3402	CMU1314-VI : CT for Gall Bladder Cancer / Cholangiocarcinoma - 5FU + Leucovorin + Oxaliplatin 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Oxaliplatin 85 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	13700	13700	13700	13700	13700	13700	13700	13700
3403	CMU1315 : CT for Gastointestinal stromal tumor - Sunitinib Sunitinb 37.5 mg once daily	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
3404	CMU1316 : CT for Mesothelioma - Gemcitabine + Cisplatin Gemcitabine 1000 mg/m2 D1 D8 Cisplatin 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	12150	12150	12150	12150	12150	12150	12150	12150
3405	CMU1317 : CT for Thymic Carcinoma - Cisplatin + Etoposide Etoposide 100mg/m2 D1 - D3 Cisplatin 75-100 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
3406	CMU1318-I : CT for CA Head & Neck - Carboplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
3407	CMU1318-II : CT for CA Head & Neck - Docetaxel Docetaxel 20mg/m2 every week	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
3408	CMU1318-III : CT for CA Head & Neck - Docetaxel Docetaxel 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	8500	8500	8500	8500	8500	8500	8500	8500
3409	CMU1318-IV : CT for CA Head & Neck - Etoposide + Carboplatin Etoposide 100mg/m2 D1 - D3 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	7690	7690	7690	7690	7690	7690	7690	7690
3410	CMU1318-IX : CT for CA Head & Neck - Paclitaxel Paclitaxel 80mg/m2 every week	MEDICAL ONCOLOGY	5970	5970	5970	5970	5970	5970	5970	5970
3411	CMU1318-V : CT for CA Head & Neck - Etoposide + Cisplatin Etoposide 100mg/m2 D1 - D3 Cisplatin 75-100 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	9270	9270	9270	9270	9270	9270	9270	9270
3412	CMU1318-VI : CT for CA Head & Neck - Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	9000	9000	9000	9000	9000	9000	9000	9000
3413	CMU1318-VII : CT for CA Head & Neck - Gemcitabine + Cisplatin Gemcitabine 1000 mg/m2 D1 D8 Cisplatin 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	12150	12150	12150	12150	12150	12150	12150	12150
3414	CMU1318-VIII : CT for CA Head & Neck - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 every 21 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
3415	CMU1318-X : CT for CA Head & Neck - Paclitaxel Paclitaxel 175mg/m2 every 21 days	MEDICAL ONCOLOGY	11800	11800	11800	11800	11800	11800	11800	11800
3416	CMU1318-XI : CT for CA Head & Neck - Carboplatin Carboplatin AUC 2 every week	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
3417	CMU1319 : CT for Renal Cell Cancer - Cabozantinib 60 mg od x 1 month every 4 weeks	MEDICAL ONCOLOGY	13000	13000	13000	13000	13000	13000	13000	13000
3418	CMU1320-I : CT for Ureter / Urethra - Cisplatin + Methotrexate + Vinblastin Methotrexate 30mg/m2 D1 D8 Vinblastine 4 mg/m2 D1 D8 Doxorubicin 30 mg/m2 D2 Cisplatin 100 mg/m2 D2 Leucovorin 15 mg PO D2 D9 every 21 days	MEDICAL ONCOLOGY	6750	6750	6750	6750	6750	6750	6750	6750
3419	CMU1320-II : CT for Ureter / Bladder / Urethra - Carboplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
3420	CMU1320-III : CT for Ureter / Urethra - Cisplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 Cisplatin 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	12150	12150	12150	12150	12150	12150	12150	12150
3421	CMU1320-IV : CT for Ureter / Urethra - Cisplatin + 5 FU 5 FU 1000mg/m2 D1-D4 Cisplatin 75mg/m2 D1 every 4 weeks	MEDICAL ONCOLOGY	8180	8180	8180	8180	8180	8180	8180	8180
3422	CMU1320-IX : CT for Ureter / Urethra - Methotrexate + Vinblastin + Doxorubicin + Cisplatin Methotrexate 30mg/m2 D1 Vinblastine 3 mg/m2 D2 Doxorubicin 30 mg/m2 D2 Cuisplatin 70 mg/m2 D2 every 14 days	MEDICAL ONCOLOGY	7540	7540	7540	7540	7540	7540	7540	7540
3423	CMU1320-V : CT for Ureter / Bladder / Urethra - Cisplatin + Paclitaxel Paclitaxel 175 mg /m2 D1 Cisplatin 75 mg /m2 D1 every 21 days	MEDICAL ONCOLOGY	13300	13300	13300	13300	13300	13300	13300	13300
3424	CMU1320-VI : CT for Ureter / Bladder / Urethra - Docetaxel Docetaxel 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	8500	8500	8500	8500	8500	8500	8500	8500
3425	CMU1320-VII : CT for Ureter / Bladder / Urethra - Gemcitabine + Paclitaxel Gemcitabine 2500 mg/m2 D1 Paclitaxel 150 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	15500	15500	15500	15500	15500	15500	15500	15500
3426	CMU1320-VIII : CT for Ureter / Bladder / Urethra - Gemcitabine Gemcitabine 1000mg /m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	9000	9000	9000	9000	9000	9000	9000	9000
3427	CMU1320-X : CT for Ureter / Bladder / Urethra - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
3428	CMU1320-XI : CT for Ureter / Urethra - Paclitaxel Paclitaxel 80 mg/m2 D1 every week	MEDICAL ONCOLOGY	6380	6380	6380	6380	6380	6380	6380	6380
3429	CMU1321-I : CT for CA Penis - Cisplatin + Paclitaxel Paclitaxel 175 mg/m2 D1 Cisplatin 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	13300	13300	13300	13300	13300	13300	13300	13300
3430	CMU1321-II : CT for CA Penis - Capecitabine Capecitabine 1000-1250 mg/m2 PO twice daily D1 -D14 every 21 days	MEDICAL ONCOLOGY	7300	7300	7300	7300	7300	7300	7300	7300
3431	CMU1321-III : CT for CA Penis - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
3432	CMU1321-IV : CT for CA Penis - Paclitaxel + Carboplatin Paclitaxel 80 mg/m2 D1 Carboplatin AUC 2 D1 every week	MEDICAL ONCOLOGY	7700	7700	7700	7700	7700	7700	7700	7700
3433	CMU1322-I : CT for CA Prostate - Docetaxel Docetaxel 60 mg/m2 D1 every 14 days	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
3434	CMU1322-II : CT for CA Prostate - Etoposide + Carboplatin Etoposide 100mg/m2 D1 - D3 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	7690	7690	7690	7690	7690	7690	7690	7690
3435	CMU1322-III : CT for CA Prostate - LHRH Agonist Leuprolide 22.5 ug every 3 months	MEDICAL ONCOLOGY	15300	15300	15300	15300	15300	15300	15300	15300
3436	CMU1322-IV : CT for CA Prostate - Mitoxantrone + Prednisolone Mitoxantrone 12mg/m2 every 3 weeks Prednsiolone 10 mg daily	MEDICAL ONCOLOGY	4200	4200	4200	4200	4200	4200	4200	4200
3437	CMU1322-V : CT for CA Prostate - Paclitaxel + Carboplatin Paclitaxel 80mg/m2 D1 Carboplatin AUC 2 D1 every week	MEDICAL ONCOLOGY	7700	7700	7700	7700	7700	7700	7700	7700
3438	CMU1322-VI : CT for CA Prostate - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
3439	CMU1322-VII : CT for CA Prostate - Docetaxel Docetaxel 20mg/m2 D1 every week	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
3440	CMU1322-VIII : CT for CA Prostate - Abiraterone 1000 mg + Prednisolone 10mg daily Once every month	MEDICAL ONCOLOGY	13000	13000	13000	13000	13000	13000	13000	13000
3441	CMU1323 : CT for B - Cell NHL - High Grade (Except Burkitt s & PCNSL) - Rituximab + Cyclophosphamide + Etoposide + Prednsiolone Rituximab 375mg/m2 Cyclophosphamide 750 mg/m2 Vincristine 1.4 mg/m2, on Day1 Etoposide 65mg/m2 Day 1 to 3 Prednisolone 100 mg Day 1-5 Total 6 cycles, repeat 21 days	MEDICAL ONCOLOGY	26200	26200	26200	26200	26200	26200	26200	26200
3442	CMU1324 : CT for High - Grade NHL - B Cell - Rituxmab + Dexamethasone + High Dose Cytarabine + Cisplatin Rituximab 375mg/m2 Day 1 Cytarabine 2g/m2 BD on day 2 Dexamethasone 40 mg Day 1 - 4 Cisplatin 75mg/m2 or Carboplatin AUC-5 on day 1 Cycle to be repeated every 21days	MEDICAL ONCOLOGY	34900	34900	34900	34900	34900	34900	34900	34900
3443	CMU1325 : CT for Relapsed B - Cell NHL - High Grade (Except Burkitts & PCNSL) - ICE - R Rituximab 375mg/m2 Ifosfamide 1.66g/m2 on day 1 - 3 Mesna 1.66g/m2 day 1 - 3 Carboplatin AUC 5 on day 1 Etoposide 100mg/m2 on day 1 - 3 Cycle every 21days for 6 cycles	MEDICAL ONCOLOGY	31900	31900	31900	31900	31900	31900	31900	31900
3444	CMU1326-I-A : CT for Burkitt s NHL - GMALL (German multicenter acute lymphoblastic leukemia)	MEDICAL ONCOLOGY	34500	34500	34500	34500	34500	34500	34500	34500
3445	CMU1326-I-B : CT for Burkitt s NHL - BFM Berlin- Frankfurt -Munster	MEDICAL ONCOLOGY	34500	34500	34500	34500	34500	34500	34500	34500
3446	CMU1326-II : CT for Chronic Lymphocytic Leukemia - Fludarabine + Cyclophosphamide Fludarabine 25mg/m2 D1-3 Cyclophosphamide 250 mg/m2 D1-3 every 28 days for 6 cycles	MEDICAL ONCOLOGY	18100	18100	18100	18100	18100	18100	18100	18100
3447	CMU1327-I : CT for Chronic Lymphocytic Leukemia - Lenalidomide lenalidomide-10-25 mg/day day 1 to 21 every 28 days	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
3448	CMU1327-II : CT for Peripheral T - Cell Lymphoma - SMILE Methotrexate 2gm/m2 D1 Ifosfamide 1500mg/m2 D2-4 Etoposide 100mg/m2 D2-4 L-asparginase 6000U/m2 D8,10,12,14,16,18,20 Dexamethasone 40mg D1-4 every 28 days	MEDICAL ONCOLOGY	19680	19680	19680	19680	19680	19680	19680	19680
3449	CMU1328-I : CT for NK - T Cell Lymphoma - GELOX Gemcitabine 1000mg/m2 D1 and D8 Oxaliplatin 130mg/m2 D1 L- asparginase 6000 U/m2 D1-7 Repeat every 21 days	MEDICAL ONCOLOGY	19300	19300	19300	19300	19300	19300	19300	19300
3450	CMU1328-II : CT for NK - T Cell Lymphoma - LVP L-asparginase 6000U/m2 D1-5 Vincristine 1.4mg/m2 D1 Prednisolone 100mg D1-5 Repeat every 21 days	MEDICAL ONCOLOGY	7950	7950	7950	7950	7950	7950	7950	7950
3451	CMU1329-I : CT for Hodgkin s Lymphoma - COPP Cyclophosphamide 650mg/m2 D1, 8 Vincristine 1.4mg/m2 D1, 8 Procarbazine 100 mg/m2 D1-14 Prednisolone 40mg/m2 D1-14 Every 28days. Total 6 - 8 cycles	MEDICAL ONCOLOGY	3830	3830	3830	3830	3830	3830	3830	3830
3452	CMU1329-II : CT for Hodgkin s Lymphoma - AEVD Adriamycin 25mg/m2 Vinblastine 6mg/m2 Dacarbazine 375 mg/m2 Day 1,15 Etoposide 65mg/m2 Day 1-3, 15-17 Every 28 days for 6 cycles	MEDICAL ONCOLOGY	10200	10200	10200	10200	10200	10200	10200	10200
3453	CMU1330A : CT for Relapsed Hodgkin Lymphoma - ICE Ifosfamide 1.5 mg/m2 D1-3 Carboplatin AUC5 D2 Etoposide 100mg/m2 D1-3 Every 3 weeks	MEDICAL ONCOLOGY	10530	10530	10530	10530	10530	10530	10530	10530
3454	CMU1330B : CT for Relapsed Hodgkin Lymphoma - MINE Ifosfamide 4 gm/m2 over 3days (D1-3) Mitoxantrone 8mg/m2 Etoposide 65mg/m2 D1-3 Every 3 weeks	MEDICAL ONCOLOGY	10530	10530	10530	10530	10530	10530	10530	10530
3455	CMU1330C : CT for Relapsed Hodgkin Lymphoma - PTCL - GDP Gemcitabine 1000mg/m2 D1 and D8 Dexamethasone 40mg D1-4 Cisplatin 75mg/m2 D1 or Cacrboplatin AUC-5 Every 3 weeks	MEDICAL ONCOLOGY	14750	14750	14750	14750	14750	14750	14750	14750
3456	CMU1331A : CT for Relapsed NHL & HL - DHAP Dexamethasone 40mg D1-4 Cisplatin 100mg/m2 or Carboplatin AUC-5D1 Cytarabine 2 gm/m2 BD D2 Repeat every 21 days	MEDICAL ONCOLOGY	12510	12510	12510	12510	12510	12510	12510	12510
3457	CMU1332A : CT for MM / Amyloidosis / POEMS - Lenalidomide + Dexamethasone Lenalidomide 25 mg daily Day1-21 Dexamethasone 40mg Day 1, 8, 15, 22 Every 28days	MEDICAL ONCOLOGY	5200	5200	5200	5200	5200	5200	5200	5200
3458	CMU1332B : CT for MM / Amyloidosis / POEMS - Pomalidomide + Dexamethasone Pomalidomide 4 mg daily Day 1-21 Dexamethasone 40mg Day 1, 8, 15, 22 Every 28 days	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
3459	CMU1333A : CT for MM / Amyloidosis - Cyclophosphamide + Thalidomide + Dexamethasone Cyclophosphamide 100mg D1-D14 Thalidomide 100-200 mg daily Day 1-28 Dexamethasone 40mg Day 1, 8, 15, 22 Every 28 days	MEDICAL ONCOLOGY	4080	4080	4080	4080	4080	4080	4080	4080
3460	CMU1333B : CT for MM / Amyloidosis - Melphalan + Thalidomide + Prednisolone Melphalan 9mg/m2 D1-D4 Thalidomide 100mg D1-28 Prednisolone 100mg Day1-4 Every 28days	MEDICAL ONCOLOGY	4100	4100	4100	4100	4100	4100	4100	4100
3461	CMU1333C : CT for MM / Amyloidosis - Bortezomib + Cyclophosphamide + Dexamethasone Cyclophosphamide - 300 mg/m2 day 1, 8, 15, 22 Dexamethasone 40mg Day 1, 8, 15, 22 Bortezomib 1.3 mg/m2 Day1, 8, 15, 22 Every 28 days	MEDICAL ONCOLOGY	14600	14600	14600	14600	14600	14600	14600	14600
3462	CMU1333D : CT for MM / Amyloidosis - Bortezomib + Dexamethasone Bortezomib 1.3 mg/m2 Day1, 8, 15, 22 Dexamethasone 40mg Day1, 8, 15, 22 Every 28 day	MEDICAL ONCOLOGY	13300	13300	13300	13300	13300	13300	13300	13300
3463	CMU1333E : CT for MM / Amyloidosis - Bortezomib + Melphalan + Prednsiolone Melphalan 9mg/m2 D1-D4 Prednisolone 100mg Day 1-4 Bortezomib 1.3 mg/m2 Day 1, 8, 15, 22 Every 28 days	MEDICAL ONCOLOGY	12600	12600	12600	12600	12600	12600	12600	12600
3464	CMU1333F : CT for MM / Amyloidosis - Bortezomib + Lenalidomide + Dexamethasone Lenalidomide 25 mg daily Day 1 - 21 Dexamethasone 40mg Day 1, 8, 15, 22 Bortezomib 1.3 mg/m2 Day 1, 8, 15, 22 Every 28 days	MEDICAL ONCOLOGY	17800	17800	17800	17800	17800	17800	17800	17800
3465	CMU1333G : CT for MM / Amyloidosis - Bortezomib + Thalidomide + Dexamethasone Thalidomide 100 mg daily Day 1 - 28 Dexamethasone 40 mg Day 1, 8, 15, 22 Bortezomib 1.3 mg/m2 Day 1, 8, 15, 22 Every 28 days	MEDICAL ONCOLOGY	15000	15000	15000	15000	15000	15000	15000	15000
3466	CMU1334B : CT for Chronic Myeloid Leukemia - Dasatinib 100 mg once a day	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
3467	CMU1335A : CT for Myeloproliferative Neoplasm - Hydroxurea Hydroxurea daily (Dose will be based on blood counts)	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
3468	CMU1336A : CT for Acute Myeloid Leukemia - Cytarabine 2 gm / M2 BD for 3 days Every 21 days for 3 cycles	MEDICAL ONCOLOGY	71250	71250	71250	71250	71250	71250	71250	71250
3469	CMU1336B : CT for Acute Myeloid Leukemia - Cytarabine 100 mg / M2 7 days Daunomycin 60 mg / M2 3 days ( this does not include antibiotics, antifungals, blood and platelets transfusion)	MEDICAL ONCOLOGY	105600	105600	105600	105600	105600	105600	105600	105600
3470	CMU1337A-I : CT for Acute Lymphoblastic Leukemia - Berlin- Frankfurt -Munster-90 - induction phase ( this does not include antibiotics, antifungals, blood and platelets transfusion)	MEDICAL ONCOLOGY	160000	160000	160000	160000	160000	160000	160000	160000
3471	CMU1337A-II : CT for Acute Lymphoblastic Leukemia - Berlin- Frankfurt -Munster-95 - induction phase ( this does not include antibiotics, antifungals, blood and platelets transfusion)	MEDICAL ONCOLOGY	160000	160000	160000	160000	160000	160000	160000	160000
3472	CMU1337A-III : CT for Acute Lymphoblastic Leukemia - Berlin- Frankfurt -Munster-2000 - induction phase ( this does not include antibiotics, antifungals, blood and platelets transfusion)	MEDICAL ONCOLOGY	160000	160000	160000	160000	160000	160000	160000	160000
3473	CMU1337A-IV : CT for Acute Lymphoblastic Leukemia - UKALL (United kingdom acute lymphoblastic leukaemia) - induction phase ( this does not include antibiotics, antifungals, blood and platelets transfusion)	MEDICAL ONCOLOGY	160000	160000	160000	160000	160000	160000	160000	160000
3474	CMU1337A-V : CT for Acute Lymphoblastic Leukemia - GMALL (German multicenter acute lymphoblastic leukemia) - induction phase ( this does not include antibiotics, antifungals, blood and platelets transfusion)	MEDICAL ONCOLOGY	160000	160000	160000	160000	160000	160000	160000	160000
3475	CMU1337B-I : CT for Acute Lymphoblastic Leukemia - BFM - Berlin- Frankfurt -Munster-90	MEDICAL ONCOLOGY	123750	123750	123750	123750	123750	123750	123750	123750
3476	CMU1337B-II : CT for Acute Lymphoblastic Leukemia - BFM-Berlin- Frankfurt -Munster-95	MEDICAL ONCOLOGY	123750	123750	123750	123750	123750	123750	123750	123750
3477	CMU1337B-III : CT for Acute Lymphoblastic Leukemia - BFM Berlin- Frankfurt -Munster-2000 - Continuation phase	MEDICAL ONCOLOGY	123750	123750	123750	123750	123750	123750	123750	123750
3478	CMU1337B-IV : CT for Acute Lymphoblastic Leukemia - UKALL (United kingdom acute lymphoblastic leukaemia) - Continuation phase	MEDICAL ONCOLOGY	123750	123750	123750	123750	123750	123750	123750	123750
3479	CMU1337B-V : CT for Acute Lymphoblastic Leukemia - GMALL (German multicenter acute lymphoblastic leukemia) - Continuation pahse	MEDICAL ONCOLOGY	123750	123750	123750	123750	123750	123750	123750	123750
3480	CMU1337C : CT for Acute Lymphoblastic Leukemia - 6 Mercaptopurine 50 mg / M2 daily Methotrexate 25 mg / M2 Weekly for 2 years	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
3481	CMU1338A-I : CT for Lymphoblastic Lymphoma / Acute Lymphoblastic Leukemia - Berlin- Frankfurt -Munster-90	MEDICAL ONCOLOGY	160000	160000	160000	160000	160000	160000	160000	160000
3482	CMU1338A-II : CT for Lymphoblastic Lymphoma / Acute Lymphoblastic Leukemia - Berlin- Frankfurt -Munster-95	MEDICAL ONCOLOGY	160000	160000	160000	160000	160000	160000	160000	160000
3483	CMU1338A-III : CT for Lymphoblastic Lymphoma / Acute Lymphoblastic Leukemia - Berlin- Frankfurt -Munster-2000	MEDICAL ONCOLOGY	160000	160000	160000	160000	160000	160000	160000	160000
3484	CMU1338A-IV : CT for Lymphoblastic Lymphoma / Acute Lymphoblastic Leukemia - UKALL (United kingdom acute lymphoblastic leukaemia)	MEDICAL ONCOLOGY	160000	160000	160000	160000	160000	160000	160000	160000
3485	CMU1338A-V : CT for Lymphoblastic Lymphoma / Acute Lymphoblastic Leukemia -GMALL (German multicenter acute lymphoblastic leukemia) - Induction Phase	MEDICAL ONCOLOGY	160000	160000	160000	160000	160000	160000	160000	160000
3486	CMU1338B-I : CT for Acute Lymphoblastic Lymphoma - BFM - Berlin- Frankfurt -Munster 90 - Continuation phase	MEDICAL ONCOLOGY	160900	160900	160900	160900	160900	160900	160900	160900
3487	CMU1338B-II : CT for Acute Lymphoblastic Lymphoma - BFM - Berlin- Frankfurt -Munster 95 - Continuation phase	MEDICAL ONCOLOGY	160900	160900	160900	160900	160900	160900	160900	160900
3488	CMU1338B-III : CT for Acute Lymphoblastic Lymphoma - BFM - Berlin- Frankfurt -Munster 2000 - Continuation phase	MEDICAL ONCOLOGY	160900	160900	160900	160900	160900	160900	160900	160900
3489	CMU1338B-IV : CT for Acute Lymphoblastic Lymphoma - UKALL (United kingdom acute lymphoblastic leukaemia) - Continuation phase	MEDICAL ONCOLOGY	160900	160900	160900	160900	160900	160900	160900	160900
3490	CMU1338B-V : CT for Acute Lymphoblastic Lymphoma - GMALL (German multicenter acute lymphoblastic leukemia) - Continuation phase	MEDICAL ONCOLOGY	160900	160900	160900	160900	160900	160900	160900	160900
3491	CMU1338C : CT for Lymphoblastic Lymphoma - 6 Mercaptopurine 50 mg/M2 daily and Methotrexate 25 mg/M2 Weekly for 2 Years	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
3492	CMU1339A : CT for Acute Promyelocytic Leukemia (High Risk) - Arsenic trioxide ATRA Daunomycin or Idarubcin Cytarabine - multiagent - vary in each protocol	MEDICAL ONCOLOGY	72000	72000	72000	72000	72000	72000	72000	72000
3493	CMU1339B : CT for Acute Promyelocytic Leukemia (High Risk) - Arsenic trioxide ATRA Daunomycin or Idarubcin Cytarabine - multiagent - vary on protocol	MEDICAL ONCOLOGY	96750	96750	96750	96750	96750	96750	96750	96750
3494	CMU1339C : CT for Acute Promyelocytic Leukemia (High Risk) - 6 MP 50 mg / day daily Methotrexate 15 mg Weekly ATRA 45 mg / M2 for 14 days Every three months for 18 Months	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
3495	CMU1340A : CT for Acute Promyelocytic Leukemia (Low Risk) - ATO: Arsenic trioxide 0.15 mg / kg day 1-Day 5, day 8-12, day 15-19, day 22-26 every 56 days for 4 cycles ATRA : All trans retinoic acid 45 mg / M2 day 1-Day 14 and Day 29-43 every 56 days for 4 cycles - (per 56 day cycle)	MEDICAL ONCOLOGY	55000	55000	55000	55000	55000	55000	55000	55000
3496	CMU1340B : CT for Acute Promyelocytic Leukemia (Low Risk) - ATO - Arsenic trioxide - 0.15 mg / kg day 1-45 or 60 ATRA - All trans retinoic acid 45 mg / M2 - day 1-45 or 60	MEDICAL ONCOLOGY	81000	81000	81000	81000	81000	81000	81000	81000
3497	CMU1341A : Granulocyte Colony Stimulating Factor Use - 5 microgram / kg / day (max 300 microgram per day) for 7 days or PEG - GCSF 6mg one single dose per chemotherapy cycle	MEDICAL ONCOLOGY	4500	4500	4500	4500	4500	4500	4500	4500
3498	CMU1342A : CT for Langerhans Cell Histiocytosis - Langerhans Cell Histiocytosis (Histiocytosis Protocol - Induction)	MEDICAL ONCOLOGY	25280	25280	25280	25280	25280	25280	25280	25280
3499	CMU1342B : CT for Langerhans Cell Histiocytosis - Langerhans Cell Histiocytosis (Histiocytosis Protocol - Maintenance)	MEDICAL ONCOLOGY	28880	28880	28880	28880	28880	28880	28880	28880
3500	CMU1343A : CT for Low Grade Glioma - Vincristine + Carboplatin Vincristine 1.5mg/m2 (day 1, 8 and 15 for first 4 cycles and then only day 1 from cycle 5 to 17) Carboplatin 550mg/m2 every 3 weeks (all cycles)	MEDICAL ONCOLOGY	5850	5850	5850	5850	5850	5850	5850	5850
3501	CMU1343B : CT for Low Grade Glioma - Vinblastin Vinblastine 6 mg/m2 every week	MEDICAL ONCOLOGY	3340	3340	3340	3340	3340	3340	3340	3340
3502	CMU1344A : CT for Neuroblastoma - Cabroplatin + Etoposide + Cyclophosphamide + Doxorubicin Carboplatin 600mg/m2 Etoposide 100mg/m2 (days 1-5) Cyclophosphamide Doxorubicin	MEDICAL ONCOLOGY	8590	8590	8590	8590	8590	8590	8590	8590
3503	CMU1344C : CT for Neuroblastoma - 13-cis retinoic acid 160mg/m2 per day for 2 weeks Each cycle given 4 weekly	MEDICAL ONCOLOGY	2030	2030	2030	2030	2030	2030	2030	2030
3504	CMU1345B : CT for Rhabdomyosarcoma - Vincristine + Ifosfamide + Etoposide Vincristine 1.5mg/m2 (days 1, 8 and 15) Ifosfamide 1.8gm/m2 (days 1-5) Etoposide 100mg/m2 (days 1-5) Each cycle every 3 weeks	MEDICAL ONCOLOGY	16200	16200	16200	16200	16200	16200	16200	16200
3505	CMU1346A : CT for Relapse Rhabdomyosarcoma - Vincristine + Topotecan + Cyclophosphamide and Vincristine + Adriamycin + Cyclophosphamide Vincristine 1.5mg/m2 (day 1) Topotecan 1.5mg/m2 (day 1-5) Cyclophosphamide 250mg/m2 (days 1-5) 3 - weekly Vincristine 1.5mg/m2 Adriamyicn 60mg/m2 Cyclophosphamide 600mg/m2 (all Day 1) Every 3 weeks. Cycles given in couplets	MEDICAL ONCOLOGY	12420	12420	12420	12420	12420	12420	12420	12420
3506	CMU1347A : CT for Pediatric Acute Lymphoblastic Leukemia - Consolidation (Phase II, CNS Therapy Reinduction)	MEDICAL ONCOLOGY	239650	239650	239650	239650	239650	239650	239650	239650
3507	CMU1347B-I : CT for Pediatric Acute Lymphoblastic Leukemia - ICICLE	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
3508	CMU1347B-II : CT for Pediatric Acute Lymphoblastic Leukemia - BFM	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
3509	CMU1347B-III : CT for Pediatric Acute Lymphoblastic Leukemia KLALL	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
3510	CMU1347B-IV : CT for Pediatric Acute Lymphoblastic Leukemia - MCP - Mitroxantrone,Chlorambucil,Prednisolone - 841	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
3511	CMU1347C : CT for Pediatric Acute Lymphoblastic Leukemia - 6 - Mercaptopurine 75mg/m2 daily Methotrexate 20mg/m2 weekly Vincristine 1.5mg/m2 monthly Intrathecal methotrexate 12 mg 3 monthly	MEDICAL ONCOLOGY	2670	2670	2670	2670	2670	2670	2670	2670
3512	CMU1347D : CT for Ph+ve Pediatric Acute Lymphoblastic Leukemia for adult and paediatric - Dasatinib + chemo (to be used only with ALL therapy)	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
3513	CMU1348A : CT for Pediatric Lymphoblastic Lymphoma - Consolidation (Phase II, CNS Therapy Reinduction)	MEDICAL ONCOLOGY	239650	239650	239650	239650	239650	239650	239650	239650
3514	CMU1348B-I : CT for Pediatric Lymphoblastic Lymphoma - ICICLE	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
3515	CMU1348B-II : CT for Pediatric Lymphoblastic Lymphoma -BFM	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
3516	CMU1348B-III : CT for Pediatric Lymphoblastic Lymphoma - KLALL	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
3517	CMU1348B-IV : CT for Pediatric Lymphoblastic Lymphoma - MCP - Mitroxantrone,Chlorambucil,Prednisolone - 841	MEDICAL ONCOLOGY	87000	87000	87000	87000	87000	87000	87000	87000
3518	CMU1348C : CT for Pediatric Lymphoblastic Lymphoma - 6 - Mercaptopurine 75mg/m2 daily Methotrexate 20mg/m2 weekly Vincristine 1.5mg/m2 monthly Intrathecal methotrexate 12 mg 3 monthly	MEDICAL ONCOLOGY	2670	2670	2670	2670	2670	2670	2670	2670
3519	CMU1349B : CT for Pediatric Acute Myeloid Leukemia - Cytrabine 200mg/m2/day days 1-10 and Daunorubicin 50mg/m2 days 1, 3 and 5 Etposide 100mg/m2 days 1-5	MEDICAL ONCOLOGY	105240	105240	105240	105240	105240	105240	105240	105240
3520	CMU1350A : CT for Pediatric Acute Promyelocytic Leukemia - Consolidation	MEDICAL ONCOLOGY	58800	58800	58800	58800	58800	58800	58800	58800
3521	CMU1350B : CT for Pediatric Acute Promyelocytic Leukemia - Induction	MEDICAL ONCOLOGY	129400	129400	129400	129400	129400	129400	129400	129400
3522	CMU1350C : CT for Pediatric Acute Promyelocytic Leukemia - Maintenance (18 months total cost)	MEDICAL ONCOLOGY	39300	39300	39300	39300	39300	39300	39300	39300
3523	CMU1351A : CT for Pediatric Hodgkins Lymphoma - COPDAC - Cyclophosphamide, Vincristine sulfate,Prednisone,Dacarbazine	MEDICAL ONCOLOGY	9450	9450	9450	9450	9450	9450	9450	9450
3524	CMU1351B : CT for Pediatric Hodgkins Lymphoma - OPEA - Oncovin,Etoposide,Prednisone,doxorubicin hydrochloride	MEDICAL ONCOLOGY	13000	13000	13000	13000	13000	13000	13000	13000
3525	CMU1352A : CT for Pediatric Hodgkins Lymphoma Relapse - ICE - ifosfamide, carboplatin, etoposide	MEDICAL ONCOLOGY	14000	14000	14000	14000	14000	14000	14000	14000
3526	CMU1352B : CT for Pediatric Hodgkins Lymphoma Relapse - DECA - Dexamethasone, Etoposide, Cytarabine, Cisplatin	MEDICAL ONCOLOGY	14000	14000	14000	14000	14000	14000	14000	14000
3527	CMU1352C : CT for Pediatric Hodgkins Lymphoma Relapse - IGVD	MEDICAL ONCOLOGY	34000	34000	34000	34000	34000	34000	34000	34000
3528	CMU1353A : CT for Pediatric Non Hodgkins Lymphoma - LMB (Lymphoma malign B) 89 - 96 - Consolidation (second month)	MEDICAL ONCOLOGY	42570	42570	42570	42570	42570	42570	42570	42570
3529	CMU1353B : CT for Pediatric Non Hodgkins Lymphoma - LMB (Lymphoma malign B) 89 - 96 - Consolidation (first month)	MEDICAL ONCOLOGY	42420	42420	42420	42420	42420	42420	42420	42420
3530	CMU1353C : CT for Pediatric Non Hodgkins Lymphoma - LMB (Lymphoma malign B) 89 - 96 - Maintenance	MEDICAL ONCOLOGY	65780	65780	65780	65780	65780	65780	65780	65780
3531	CMU1353D : CT for Pediatric Non Hodgkins Lymphoma - MCP - Mitroxantrone,Chlorambucil,Prednisolone - 842	MEDICAL ONCOLOGY	98700	98700	98700	98700	98700	98700	98700	98700
3532	CMU1354A : Pediatric - Germ Cell Tumor / JEB	MEDICAL ONCOLOGY	10650	10650	10650	10650	10650	10650	10650	10650
3533	CMU1355A : CT for Pediatric Hepatoblastoma - Carboplatin + Cisplatin + Doxorubicin	MEDICAL ONCOLOGY	5590	5590	5590	5590	5590	5590	5590	5590
3534	CMU1355B : CT for Pediatric Hepatoblastoma - Cisplatin	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
3535	CMU1356A : CT for CA Lung - Docetaxel Docetaxel 75 mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	8500	8500	8500	8500	8500	8500	8500	8500
3536	CMU1356B : CT for CA Lung - Erlotinib Erlotinib 150 mg once daily	MEDICAL ONCOLOGY	4500	4500	4500	4500	4500	4500	4500	4500
3537	CMU1356C : CT for CA Lung - Gefitnib Gefitinib 250 mg once daily	MEDICAL ONCOLOGY	2500	2500	2500	2500	2500	2500	2500	2500
3538	CMU1356F : CT for CA Lung - Topotecan Topotecan 1.5 mg/m2 D1-D5 every 21 days	MEDICAL ONCOLOGY	24600	24600	24600	24600	24600	24600	24600	24600
3539	CMU1356G : CT for CA Lung - Docetaxel Docetaxel 20 mg/m2 D1 every week	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
3540	CMU1356J : CT for CA Lung - Gemcitabine Gemcitabine 1000mg /m2 D1 D8 every 21 days	MEDICAL ONCOLOGY	8980	8980	8980	8980	8980	8980	8980	8980
3541	CMU1356K : CT for CA Lung - Gemcitabine + Carboplatin Gemcitabine 1000 mg/m2 D1 D8 Carboplatin AUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	13900	13900	13900	13900	13900	13900	13900	13900
3542	CMU1356M : CT for CA Lung - Paclitaxel Paclitaxel 80mg/m2 every week	MEDICAL ONCOLOGY	5990	5990	5990	5990	5990	5990	5990	5990
3543	CMU1356N : CT for CA Lung - Paclitaxel Paclitaxel 175mg/m2 every 21 days	MEDICAL ONCOLOGY	11800	11800	11800	11800	11800	11800	11800	11800
3544	CMU1356P : CT for CA Lung - Paclitaxel + Cisplatin Paclitaxel 175 mg/m2 D1 Cisplatin 75mg/m2 D1 every 21 days	MEDICAL ONCOLOGY	13300	13300	13300	13300	13300	13300	13300	13300
3545	CMU1356S : CT for CA Lung - Vinorelbine + Carboplatin Vinorelbine 25mg/m2 D1 D8 CarboplatinAUC 5-6 D1 every 21 days	MEDICAL ONCOLOGY	17000	17000	17000	17000	17000	17000	17000	17000
3546	CMU1357A : CT for CA Cervix - Carboplatin Carboplatin AUC 2 every week	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
3547	CMU1358A : CT for primary CNS lymphoma - De-Angelis/MTR	MEDICAL ONCOLOGY	36000	36000	36000	36000	36000	36000	36000	36000
3548	CMU1359A : GCT Testis - SA Carboplatin AUC 7 once every 3 weeks	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
3549	CMU1360A : CT for GCT of bone - Denosumab Denosumab 120 mg s/c D1, 8, 15 then every 28 days - 19800 per dose. Max 6 dose	MEDICAL ONCOLOGY	18000	18000	18000	18000	18000	18000	18000	18000
3550	CMU1361A : GEP NET Neuroendocrine carcinoma - Temozolamide 150mg/m2 D9-14 + Capecitabine 1gm/me D1-14 every 28 days	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
3551	CMU1361B : GEP NET high grade Neuroendocrine carcinoma - Carboplatin AUC 5 + Etoposide 100mg/m2 D1-D3 every 21 days	MEDICAL ONCOLOGY	13400	13400	13400	13400	13400	13400	13400	13400
3685	CMU1424A : Central lines in cancer patients for drug therapy -Silicon catheters in advanced cancer patients- Long term central lines	MEDICAL ONCOLOGY	10000	0	0	0	0	0	0	0
4235	CMU1804A : HIGH GRADE LYMPHOMAS - R - CODOX - M ALTERNATED WITH R - IVAC - R - CODOX - M (ORIGINAL OR MODIFIED) - DAY 1 - CYCLOPHOSPHAMIDE + DOXORUBICIN - IV, DAYS 2 - 5 - CYCLOPHOSPHAMIDE IV, DAYS 1, 3 - CYTARABINE IT, DAYS 1, 8; VINCRISTINE IV, DAY 10; MTX IV 1 HOUR, THEN INFUSION FOR 23 HOURS, DAY 11; LEUCOVORIN IV - 6TH HOURLY; DAY 13 - G - CSF SC DAILY, DAY 15; MTX - IT DAY 16 - LEUCOVORIN ORAL G, +/ - DAY 1; RITUXIMAB IV. REPEAT FOR 4 CYCLES ALTERNATE BETWEEN CODOX - M AND IVAC	MEDICAL ONCOLOGY	39800	39800	39800	39800	39800	39800	39800	39800
4236	CMU1804B : HIGH GRADE LYMPHOMAS - R - CODOX - M ALTERNATED WITH R - IVAC - R - IVAC (IFOSFAMIDE + CYTARABINE + ETOPOSIDE) AND IT MTX +/ - RITUXIMAB - DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES. DAYS 1 - 5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, + MESNA 360MG/M2, DAY 5; MTX 12MG IT DAY 6; LEUCOVORIN 15MG ORAL - MTX, DAY 7; G - CSF 5uG/KG SC DAILY UNTIL GRANULOCYTE COUNT >/=1 X 109/L, + DAY 1; RITUXIMAB 375 MG/M2 IV. REPEAT FOR 4 CYCLES ALTERNATE BETWEEN CODOX - M AND IVAC.	MEDICAL ONCOLOGY	37400	37400	37400	37400	37400	37400	37400	37400
4237	CMU1804C : HIGH GRADE LYMPHOMAS - R - MA - RIITUXIMAB, METHOTREXATE, CYTARABINE - DAY 1 - RITUXIMAB 375 MG/M2, METHOTREXATE 1 G/M2, IV INFUSION OVER 24 HRS, CALCIUM FOLINATE (36 HOURS AFTER INITIATION OF METHOTEXATE), DAY 2 METHOTREXATE 12 MG INTRATHECAL, DAYS 3 & 4 CYTARABINE 3 G/M2, IV INFUSION (AT 24, 36, 48 AND 60 HOURS AFTER COMPLETION OF IV METHOTREXATE), DAY 5 G - CSF, DAY 7 CYTARABINE 100 MG INTRATHECAL	MEDICAL ONCOLOGY	37300	37300	37300	37300	37300	37300	37300	37300
4238	CMU1804D : HIGH GRADE LYMPHOMAS / DIFFUSE LARGE CELL LYMPHOMA - EPOCH - R (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 1&2) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1 - 4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1 - 5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G - CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL	MEDICAL ONCOLOGY	28100	28100	28100	28100	28100	28100	28100	28100
4239	CMU1804E : CT FOR HIGH - GRADE NON - HODGKIN LYMPHOMA - CYCLOPHOSPHAMIDE + VINCRISTINE + PREDNISONE + RITUXIMAB (RGCVP) - DAY 1;RITUXIMAB 375MG/M2 IV, CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5 - 10 MINUTES, GEMCITABINE 750 MG/M2IV, DAYS 1 - 5; PREDNISONE 40MG/M2 ORALLY DAILY, DAY 8 - GEMCITABINE 750 MG/M2IV. REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES	MEDICAL ONCOLOGY	24340	24340	24340	24340	24340	24340	24340	24340
4240	CMU1805A : CT FOR CA PROSTATE - DAY 1 - DEGARELIX 240MG - CYCLE 1, REPEAT CYCLE EVERY 4 WEEKS.	MEDICAL ONCOLOGY	26000	26000	26000	26000	26000	26000	26000	26000
4241	CMU1805A : CT FOR RELAPSED NHL & HL - R - DHAP - RITUXIMAB 375 MG/M2, DEXAMETHASONE 40MG D1 - 4, CISPLATIN 100MG/M2 OR CARBOPLATIN AUC - 5 D, CYTARABINE 2 GM/M2 BD D2, REPEAT EVERY 21 DAYS	MEDICAL ONCOLOGY	32400	32400	32400	32400	32400	32400	32400	32400
4242	CMU1805B : CT FOR CA PROSTATE - DAY 1 - DEGARELIX 80MG - SUBSEQUENT CYCLES, REPEAT CYCLE EVERY 4 WEEKS.	MEDICAL ONCOLOGY	11000	11000	11000	11000	11000	11000	11000	11000
4243	CMU1805B : CT FOR RELAPSED NHL & HL - R - DHAOX - RITUXIMAB 375 MG/M2, DEXAMETHASONE 40MG D1 - 4, OXALIPLATIN 130MG/M2, CYTARABINE 2 GM/M2 BD D2, REPEAT EVERY 21 DAYS	MEDICAL ONCOLOGY	34080	34080	34080	34080	34080	34080	34080	34080
4244	CMU1806A : CT FOR ENDOMETRIAL CANCER - DOXORUBICIN, CISPLATIN, PACLITAXEL - DAY 1 - DOXORUBICIN 45MG/M2, DAY 1 - CISPLATIN 50MG/M2 IV, DAY 2 - PACLITAXEL 160MG/M2. REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES.	MEDICAL ONCOLOGY	13300	13300	13300	13300	13300	13300	13300	13300
4245	CMU1806B : CT FOR ENDOMETRIAL CANCER - ALBUMIN BOUND PACLITAXEL - DAY 1 - ALBUMIN - BOUND PACLITAXEL 100 - 125MG/M2 IV, WEEKLY. CYCLED 3 WEEKS ON 1 WEEK OFF.	MEDICAL ONCOLOGY	9000	9000	9000	9000	9000	9000	9000	9000
4246	CMU1806C : CT FOR ENDOMETRIAL CANCER - CARCINOSARCOMA - CISPLATIN, IFOSFAMIDE - DAYS 1 - 4 -  IFOSFAMIDE 1,500MG/M2 IV, MESNA 300MG/M2 IV OVER 15 MINUTES THREE TIMES DAILY, BEFORE IFOSFAMIDE, 4 AND 8 HOURS AFTER IFOSFAMIDE, CISPLATIN 20MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES.	MEDICAL ONCOLOGY	14400	14400	14400	14400	14400	14400	14400	14400
4247	CMU1807A : CT FOR LUNG CANCER - NSCLC - ADVANCED OR METASTATIC DISEASE - EGFR EXON 19 DELETION / L858R / EGFR S768I / L861Q AND / OR G719X MUTATIONS OR PROGRESSIVE DISEASE (T790M) - AFATINIB - DAYS 1 - 28: AFATINIB 40MG ORALLY ONCE DAILY. REPEAT CYCLE EVERY 4 WEEKS	MEDICAL ONCOLOGY	7000	7000	7000	7000	7000	7000	7000	7000
4248	CMU1807B : CT FOR LUNG CANCER – NSCLC - ADVANCED OR METASTATIC DISEASE - ALK / ROS1 REARRANGEMENT POSITIVE - CERITINIB - DAYS 1-28 - CERITINIB 450MG ORALLY ONCE DAILY. REPEAT CYCLE EVERY 4 WEEKS.	MEDICAL ONCOLOGY	9500	9500	9500	9500	9500	9500	9500	9500
4249	CMU1808A : CT FOR NET – OCTREOTIDE - MONTHLY	MEDICAL ONCOLOGY	22000	22000	22000	22000	22000	22000	22000	22000
4250	CMU1809A : CT FOR CHRONIC LYMPHOCYTIC LEUKEMIA – IBRUTINIB WITH RITUXIMAB - IBRUTINIB - DAYS 1-28 - IBRUTINIB 420MG ORALLY ONCE DAILY. REPEAT CYCLE EVERY 4 WEEKS.	MEDICAL ONCOLOGY	21700	21700	21700	21700	21700	21700	21700	21700
4251	CMU1809B : CT FOR CHRONIC LYMPHOCYTIC LEUKEMIA – IBRUTINIB WITH RITUXIMAB – RITUXIMAB (CYCLE 3 - 6 OF IBRUTINIB) – DAY 1 - RITUXIMAB 375MG/M2 IV – INCLUSIVE OF ALL 4 DOSES. REPEAT CYCLE EVERY 4 WEEKS. IBRUTINIB TO BE CONTINUED	MEDICAL ONCOLOGY	27000	27000	27000	27000	27000	27000	27000	27000
4252	CMU1809C : CT FOR CHRONIC LYMPHOCYTIC LEUKEMIA – IBRUTINIB WITH RITUXIMAB – RITUXIMAB (CYCLE 2 OF IBRUTINIB) – DAY 1,8,15, 22 – RITUXIMAB 375MG/M2 IV INCLUSIVE OF ALL 4 DOSES. REPEAT CYCLE EVERY 4 WEEKS – CYCLES 2 TO 6	MEDICAL ONCOLOGY	85300	85300	85300	85300	85300	85300	85300	85300
4253	CMU1810A : CT MULTIPLE MYELOMA - BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE - DAYS 1,4,8,11: BORTEZOMIB 1.3MG/M2 SUBCUTANEOUS, DAYS 1-14: LENALIDOMIDE 25MG ORALLY ONCE DAILY, DAYS 1-2,4-5,8-9,11-12: DEXAMETHASONE 20MG ORALLY ONCE DAILY OR DAYS 1,8,15: DEXAMETHASONE 40MG ORALLY ONCE DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES.	MEDICAL ONCOLOGY	33300	33300	33300	33300	33300	33300	33300	33300
4254	CMU1810B : CT MULTIPLE MYELOMA - BORTEZOMIB - DAY 1: BORTEZOMIB 1.3MG/M2 SUBCUTANEOUS. REPEAT CYCLE EVERY 2 WEEKS FOR UP TO 2 YEARS.	MEDICAL ONCOLOGY	7500	7500	7500	7500	7500	7500	7500	7500
4255	CMU1810C : CT MULTIPLE MYELOMA - BORTEZOMIB - DAYS 1,8,15,22: BORTEZOMIB 1.6MG/M2 SUBCUTANEOUS. REPEAT CYCLE EVERY 5 WEEKS FOR UP TO 6 MONTHS.	MEDICAL ONCOLOGY	28500	28500	28500	28500	28500	28500	28500	28500
4256	CMU1810D : CT MULTIPLE MYELOMA - BORTEZOMIB + THALIDOMIDE + DEXAMETHASONE - DAYS 1,4,8,11: BORTEZOMIB 1.3MG/M2 SUBCUTANEOUS, DAYS 1-21: THALIDOMIDE 50-200MG ORALLY ONCE DAILY, DAYS 1-2,4-5,8-9,11-12: DEXAMETHASONE 20MG ORALLY ONCE DAILY OR DAYS 1-4,9-12: DEXAMETHASONE 40MG ORALLY ONCE DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES.	MEDICAL ONCOLOGY	33300	33300	33300	33300	33300	33300	33300	33300
4257	CMU1810E : CT MULTIPLE MYELOMA - POMALIDOMIDE + BORTEZOMIB + DEXAMETHASONE - DAYS 1,4,8,11: BORTEZOMIB 1.3MG/M2 SUBCUTANEOUS, DAYS 1-14: POMALIDOMIDE 4MG ORALLY ONCE DAILY, DAYS 1-2,4-5,8-9,11-12: DEXAMETHASONE 10 OR 20MG ORALLY ONCE DAILY REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES (CYCLES 1-8)	MEDICAL ONCOLOGY	39400	39400	39400	39400	39400	39400	39400	39400
4258	CMU1810F : CT MULTIPLE MYELOMA - POMALIDOMIDE + BORTEZOMIB + DEXAMETHASONE - DAYS 1, 8 - BORTEZOMIB 1.3MG/M2 SUBCUTANEOUS, DAYS 1-14: POMALIDOMIDE 4MG ORALLY ONCE DAILY, DAYS 1-2,8-9 : DEXAMETHASONE 10 OR 20MG ORALLY ONCE DAILY REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES (CYCLES 9 AND BEYOND)	MEDICAL ONCOLOGY	24800	24800	24800	24800	24800	24800	24800	24800
4259	CMU1810G : CT MULTIPLE MYELOMA - POMALIDOMIDE + CYCLOPHOSPHAMIDE + DEXAMETHASONE - DAYS 1,8,15: CYCLOPHOSPHAMIDE 400MG ORALLY ONCE DAILY, DAYS 1-21: POMALIDOMIDE 4MG ORALLY ONCE DAILY, DAYS 1,8,15,22: DEXAMETHASONE 40MG ORALLY ONCE DAILY. REPEAT CYCLE EVERY 4 WEEKS.	MEDICAL ONCOLOGY	7400	7400	7400	7400	7400	7400	7400	7400